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CHAPTER I 
 
INTRODUCTION 
 
The plasma membrane of eukaryotes has evolved to be important in its function as a 
barrier to the outside world.  It creates an interface between the interior of the cell and 
the external environment, and protects the cell against pathogens. Within organisms, the 
plasma membrane functions as a site of cell signaling some of which is due to the 
asymmetric nature of its composition.  Normally, within the membrane bilayer, 
phosphatidylserine (PS) and phosphatidylethanolamine (PE) are sequestered to the 
cytosolic leaflet.  Ablation of plasma membrane asymmetry and exposure of these 
phospholipids can serve as a signal for various biological and regulatory mechanisms, 
such as platelet activation, apoptosis, and recruitment of macrophages.   
 
Maintenance of the membrane asymmetry of phospholipids in the plasma membrane is 
of vital importance.  A class of proteins called the type-IV P-type ATPases or flippases 
maintains this asymmetry.  These proteins function by flipping phospholipids from one 
side of the membrane bilayer to the other side in an energy-dependent manner.  
Furthermore, these flippases play vital roles in vesicle-mediated protein transport 
(Sebastian, Baldridge, Xu, & Graham, 2012).  This introductory chapter will seek to 
introduce flippases, their family of proteins, trace the origins of their discovery, 
understand the important roles they play within a cell and in organisms, how they work, 
and how they’re regulated. 
 2 
The Family of P-type ATPases 
 
P-type ATPases are a large family of membrane proteins that pump heavy metal ions, 
cations, and phospholipids across a membrane bilayer against their concentration 
gradient using the energy of ATP hydrolysis.  According to the Axelsen and Palmgren 
nomenclature, they are divided into five groups based on their phylogenetic 
relationships (sequence alignments) (Axelsen & Palmgren, 1998; Kuhlbrandt, 2004).  
Type I (or P1) ATPases are heavy metal pumps (ex. K+ ATPase, Cu+2 ATPase), while 
Type II (or P2) ATPases are cation transporters (ex. sarcoplasmic reticulum Ca+2 ATPase 
(SERCA), Na+/K+ ATPase).  Type III (or P3) ATPases include the proton pumps (ex. H+ 
ATPase, Mg+ ATPase) and Type V (or P5) ATPases have unknown substrate specificity.  
Meanwhile, Type IV (or P4) ATPases (ex. Drs2p, ATP8A1) flip phospholipids across the 
membrane bilayer, are called flippases, and are of primary interest to the work 
presented in this thesis (Kuhlbrandt, 2004).  Figure 1-1 shows the phylogenetic 
relationships between the P4-ATPases found in yeast (Saccharomyces cerevisiae), plants 
(Arabidopsis thaliana), worms (Caenorhabditis elegans), and humans (Homo sapiens).  
 
Structure and Function 
 
Several of the P-type ATPases have had crystal structures reported, including P1-, P2- 
and the P3-ATPases (Gourdon et al., 2011; Morth et al., 2007; Pedersen, Buch-Pedersen, 
Morth, Palmgren, & Nissen, 2007).  From these structures, it has become evident that the 
P-type ATPases have high levels of similarity in their structure and domain organization  
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Figure 1-1. Phylogenetic tree showing the relationship between the P4-ATPases of yeast (S. 
cerevisiae), worms (C. elegans), plants (A. thaliana) and humans (H. sapiens). Image from 
(Sebastian et al., 2012). 
 
(Fig. 1-3). The P-type ATPases have four structural domains – the actuator (A) domain, 
the phosphorylation (P) domain, the nucleotide binding (N) domain and the 
transmembrane (TM) domain (Fig. 1-2A). The A domain is formed by the N-terminal tail 
and the cytosolic loop between transmembrane segments 2 and 3.  There is a large 
cytosolic loop between TM 4 and 5, which forms both the P and N domains (Toyoshima, 
2009; Toyoshima, Nakasako, Nomura, & Ogawa, 2000).  Most P-type ATPases, especially 
the P4-ATPases (based on homology modeling) have 10 transmembrane segments. 
Additionally, several of these proteins have long N- and C-terminal extensions that can 
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form additional regulatory R-domains (Au, 1987; Hwang, Harper, Liang, & Sze, 2000; P. 
James et al., 1988; Palmgren, Larsson, & Sommarin, 1990; Palmgren, Sommarin, Serrano, 
& Larsson, 1991; Portillo, de Larrinoa, & Serrano, 1989; Rasi-Caldogno, Carnelli, & De 
Michelis, 1992, 1993, 1995).  The influence of an R-domain (the C-terminal tail) on Drs2p 
will be the focus of Chapter 2 of this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. Structure of P4-ATPase (A) and association with Cdc50 family members (B). 
Image from ((Sebastian et al., 2012). 
 
SERCA was the first of the ATPases to be crystallized (Fig. 1-3) and structures have been 
reported in nine different conformations representing most, if not all, of the 
A 
B 
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conformations of the protein during its catalytic reaction cycle (Toyoshima & Mizutani, 
2004; Toyoshima et al., 2000; Toyoshima & Nomura, 2002; Toyoshima, Nomura, & Tsuda, 
2004).  This has led to a clearer understanding of the reaction cycle in which these 
proteins are involved. During their catalytic cycle, the P-type ATPases form an aspartyl-
phosphate intermediate, which has led to their being called “P-type”.  The catalytic cycle 
is called the Post-Albers cycle, after Robert Post and R. Wayne Albers, who were the first 
to describe this mechanism (Albers, Fahn, & Koval, 1963; Charnock & Post, 1963; Post, 
Hegyvary, & Kume, 1972; Post & Jolly, 1957; Post & Sen, 1965; Post, Sen, & Rosenthal, 
1965). Although Post and Albers initially described the mechanism of action of the 
Na+/K+ ATPase, this description has since been extended to other P-type ATPases as 
well.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3. Sequence of Drs2p threaded onto crystal structure of SERCA1p. Drs2p is a yeast 
P4-ATPase, and SERCA1p is a cation pump of the P2-ATPase family. A, P, N, TM indicate 
the different structural domains of the protein. Image from Zhou, et al. (Book chapter, Wiley). 
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Figure 1-4. Model of the Post-Albers cycle. This image shows the taking up and release of 3 Na+ 
ions to the lumen and the taking up and release of 2 K+ ions to the cytosol. The different steps of 
the cycle, and ATP hydrolysis are also indicated. Image from http://aups.org.au/Proceedings/42/19-28/. 
 
 
The pump cycles between two main conformations, E1 and E2, that are controlled by 
substrate and nucleotide binding, along with the addition and release of a phosphate 
group (Fig. 1-4).  In the E1-ATP step, three Na+ ions, from the cytosol, bind a high 
affinity site within the transmembrane domain of the protein (specifically, a binding 
pocket surrounded by TM segments 4, 5, 6, 7, and 9).  The interaction of the Na+ ions 
with this site induces the N domain, which interacts with a molecule of Mg+2-ATP, to 
undergo a conformational change that brings the γ-phosphate to closer proximity with 
the phosphorylation site in the P-domain.  This allows transfer of the γ-phosphate, from 
the ATP to the conserved aspartate residue (Asp369).  At this point of the cycle, i.e. E1P-
ADP, the substrate binding sites (within the transmembrane domain) are oriented so 
that they are not accessible from either side of the membrane.  Furthermore, the Na+ ions 
are in an occluded state. Then, the A domain rotates to bring the TGES motif, located 
within the actuator domain, closer to the phosphorylated aspartate.  At the same time, 
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ADP is released.  This step produces the E2P conformation, and also involves the 
opening of the membrane domain to the extracellular (or lumenal) side of the membrane 
and the loss of the high affinity Na+ binding sites.  At this point, the three Na+ ions are 
quickly released, against their concentration gradient, and 2 K+ ions quickly take their 
place within the open substrate binding site that has now acquired high affinity for K+. 
The aspartyl phosphate residue is hydrolyzed by the TGES motif, access from either side 
of the membrane to the substrate binding site is obstructed, and this moves the ATPase 
from the E2-P to the E2 state. Finally, re-orientation of the A and N domains, as well as 
dissociation of the Mg+2 and an inorganic phosphate molecule, resets the protein back to 
the E1 state. Subsequently, the K+ ions are released to the cytosol (against the gradient) 
because the substrate binding site is now open and reorients into the Na+-binding 
conformation (Toyoshima, 2009). 
 
While the other members of the P-type ATPase family have conserved binding pockets 
that can easily translocate small ions, the major question remained – how can P4-
ATPases translocate large phospholipid molecules? Recent work, from the Graham lab, 
has posited new insight into the mechanism by which P4-ATPases are able to translocate 
phospholipids during their catalytic cycle. Rather than using the canonical substrate-
binding site defined for cation pumps, the P4-ATPases have evolved the use of a new 
translocation pathway using the first four TM segments. In addition to identifying the 
residues, within TM4, responsible for substrate specificity, a novel two-gate mechanism 
for phospholipid flip was proposed (Baldridge & Graham, 2012; Baldridge & Graham, 
2013). Over 20 residues have been identified as sites that aid in the translocation of the 
phospholipid at the two gates. This mechanism suggests that the binding of the 
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phospholipid (from the exofacial leaflet), at the entry gate, likely occurs during the 
transition of the protein from E1-P to E2-P.  The phospholipid is then loaded into the exit 
gate at E2-P. Dephosphorylation, and transition back to the E1 conformation would eject 
the phospholipid into the cytosolic leaflet (Baldridge & Graham, 2013). 
 
Dnf1p and Drs2p are both yeast flippases that cycle between the trans-Golgi network 
(TGN), plasma membrane and early endosomes.  Drs2p is usually found in the TGN and 
early endosomes while Dnf1p has primarily plasma membrane and early endosomal 
localization.  While they are quite similar in overall structure, cellular localization and 
mechanism of function, they differ in their phospholipid (substrate) preferences.  Dnf1p 
preferentially flips PC while Drs2p preferentially flips PS.  To identify residues that 
would confer substrate specificity for each of these P4-ATPases, several Dnf1p chimeras 
were created with sections of the Drs2p protein swapped into the Dnf1p structure 
(Baldridge & Graham, 2012).  Swapping TM segments 3 and 4 from Drs2p into Dnf1p 
conferred PS substrate preference to Dnf1p.  Further analysis of these segments revealed 
that a single mutation, Tyr618 to Phe (in TM4) is sufficient to confer a change in 
substrate preference in Dnf1p.  The complementary mutation (Phe511 to Tyr) in TM4 of 
Drs2p also altered the substrate specificity of Drs2p from PS to PC (Baldridge & Graham, 
2012).   
 
Moreover, through additional genetic screens and directed mutagenesis experiments, 
many residues that further contribute to substrate preference and specificity were 
identified. It was discovered that these residues group at two interfacial regions that 
flank TM segments 1-4. These data suggest there are two regions of importance that 
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determine substrate specificity and allow for the flip of a bulky phospholipid substrate 
during the catalytic cycle of the protein; these are called the entry and exit gates.  The 
phospholipid is initially selected at the entry gate and is transferred to the exit gate to 
allow the head group to exit to the opposing leaflet (Baldridge & Graham, 2013).  
 
The Family of P4-ATPases and the Cdc50 family of proteins 
 
The first P4-ATPase sequence to be published was Drs2p (from yeast).  From sequence 
comparisons, performed at that time, it was thought to be a Ca+2 ATPase (Ripmaster, 
Vaughn, & Woolford, 1993).  Soon afterwards, the sequence for bovine ATPase II 
(ATP8A1) was published and found be almost 50% identical to the sequence of Drs2p 
(Tang, Halleck, Schlegel, & Williamson, 1996).  As a result, Drs2p and ATP8A1 were 
recognized as the founding members of a new family of P-type ATPases (Axelsen & 
Palmgren, 1998).  While they are not found in prokaryotes, the P4-ATPases have several 
members in each of the sequenced eukaryotic genomes.  Yeast have five P4-ATPases.  
They are Drs2p (Defect in Ribosome Synthesis), Dnf1p, Dnf2p and Dnf3p (Drs2p Neo1p 
Family ATPases), and Neo1p (Neomycin resistance).  Meanwhile, C. elegans has six, 
designated TAT-1 through TAT-6 (for Transbilayer Amphipath Transporter).  Mammals 
have at least 14 (ATP8A1 to ATP11C, also see Fig. 1-1 and 1-2).  Many of these proteins 
(considered the α subunit) associate with a β subunit (Bryde et al., 2010; B. Chen et al., 
2010; Furuta, Fujimura-Kamada, Saito, Yamamoto, & Tanaka, 2007; Lopez-Marques et al., 
2010; Paulusma et al., 2008; Perez-Victoria, Sanchez-Canete, Castanys, & Gamarro, 2006; 
Poulsen et al., 2008; Saito et al., 2004; Takatsu et al., 2011; van der Velden et al., 2010).  
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Much work has shown that P4-ATPases require co-chaperones for proper exit from the 
endoplasmic reticulum (ER) (Saito et al., 2004). These co-chaperones, members of the 
Cdc50p family of proteins (Cdc50p, Lem3p, and Crf1p), are considered to be β subunits 
to P4-ATPases. In yeast, there are three members of this family – Cdc50p (which 
associates with Drs2p), Lem3p/Ros3p (which associates with Dnf1p and Dnf2p), and 
Crf1p (which associates with Dnf3p). Both mammalian and worm P4-ATPases also have 
3 CDC50 members – CDC50A, CDC50B, and CDC50C in mammals, W03G11.2, 
R08C7.2a (CHAT-1), and F20C5.4 in C. elegans (Fig. 1-2). There may be several reasons 
why there are so few β subunits compared to the α subunits.  The first is likely 
functional redundancy; i.e. several α subunits can share a single β subunit.  Another 
reason is that some P4-ATPases (like Neo1p in yeast) do not have a β subunit associated 
with it (Bryde et al., 2010; S. Chen et al., 2006; Paulusma et al., 2008; Poulsen et al., 2008; 
Saito et al., 2004; Takatsu et al., 2011; van der Velden et al., 2010). 	  
The β subunits for the yeast P4-ATPases were initially discovered in genetic screens 
looking at defects in phospholipid translocation and membrane asymmetry (Radji, Kim, 
Togan, Yoshikawa, & Shirahige, 2001).  More recently, these findings have been 
extended to C. elegans. A forward genetic screen, based on the loss of PS asymmetry, 
uncovered mutations in both CHAT-1 and TAT-1, which are Cdc50p and Drs2p 
homologs respectively (B. Chen et al., 2010).  Furthermore, parallels have been drawn 
between the Drs2p-Cdc50p complexes and the Na+/K+ and H+/K+ ATPases, which, also 
possesses β (and in some cases γ) subunits (Geering, 2001; Kuhlbrandt, 2004).   
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The CDC50 family of proteins has two transmembrane segments, as well as a large 
glycosylated extracellular domain (Fig. 1-2). The essential interaction between the P4-
ATPases and their co-chaperones was discovered by the Tanaka lab; they showed that 
absence of the β subunit, Cdc50p, caused ER accumulation of Drs2p. Similarly, the 
deletion of Lem3p, caused ER accumulation of Dnf1p and Dnf2p.  This interaction is also 
reciprocal - deletion of Drs2p caused Cdc50p accumulation in the ER. In addition to co-
localizing with their respective α subunits, co-immunoprecipitation experiments have 
shown that the Cdc50p chaperones physically interact with the P4-ATPases.  The Tanaka 
group also observed similar phenotypes in mutants of the P4-ATPases and mutants of 
Cdc50 family proteins (S. Chen et al., 2006; Furuta et al., 2007; Saito et al., 2004). This 
suggests functionally essential interactions exist between the α and β subunits. 
Conditional mutants of Cdc50p have also been identified.  These mutants maintain their 
ability to bind Drs2p, but lose function in vivo at non-permissive temperatures.  From 
these experiments, it was discovered that, when Cdc50p mutants lose activity, the 
Cdc50p-Drs2p heterodimer is functionally defective (Takahashi, Fujimura-Kamada, 
Kondo, & Tanaka, 2011). This implies that Cdc50 proteins play important roles in the 
catalytic cycles of P4-ATPases. 
 
When the yeast P4-ATPase, Drs2p, was purified and reconstituted into liposomes, it was 
discovered that there was a sub-stoichiometric amount of Cdc50p present in these 
samples (Zhou & Graham, 2009).  An argument was made that the low levels of flippase 
activity detected in these preparations was due to the small amounts of Cdc50p. The 
assessment was that higher levels of Drs2p-Cdc50p complexes within a sample would 
generate higher levels of activity because it is thought that Cdc50p plays a major role in 
 12 
Drs2p activity. When the Molday lab used a dual affinity approach to purify ATP8A2 
complexed with CDC50A (using monoclonal antibodies which recognized each of these 
proteins), they obtained samples that had a robust ATPase and flippase activity – 
especially when compared to the values obtained for Drs2p (Coleman & Molday, 2011).  
However, since they didn’t assay the ATP8A2 monomer (in the absence of CDC50A), it 
is still uncertain how much of a role CDC50A plays in the activity of the P4-ATPase.  
 
While recent evidence from plants and human P4-ATPase experiments suggest that the 
β subunit is not essential for substrate specificity or proper localization of the flippase, it 
has been shown that, in both yeast and human complexes, β subunits prefer to bind the 
E2-P form of the P4-ATPases. Furthermore, the Molday group, created chimeras 
between CDC50A and CDC50B which enabled them to map regions (both the TM and 
exocytoplasmic domains) on CDC50A that were: (a) critical for association with ATP8A2 
and, (b) essential for creating a functional complex. They also discovered that the N-
terminal cytosolic segment of CDC50A is important in the reaction cycle of the P4-
ATPase (Coleman & Molday, 2011). As more evidence is being uncovered, it is obvious 
that the Cdc50 family of proteins plays important roles in the activity of P4-ATPases.  
However, the extent to which these proteins influence flippase activity and play 
regulatory roles, especially interactions with other proteins during vesicular trafficking, 
is still open for discussion.   
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Impact of P4-ATPases on Physiology 
 
While P4-ATPases are essential for yeast cell viability (Hua, Fatheddin, & Graham, 2002), 
there are also several biological processes and disorders that have been linked to P4–
type ATPases. On an organ and organismal level, this protein class plays a major role in 
promoting and maintaining optimal health. For example, mutations in human ATP8B1 
(or FIC1) cause progressive familial intrahepatic cholestasis (PFIC) or benign recurrent 
intrahepatic cholestasis (BRIC) (Bull et al., 1998; Folmer, Elferink, & Paulusma, 2009). 
These severe diseases cause liver failure due to defects in bile secretion, and patients 
often need liver transplants to stay alive.  The liver cells lose phospholipid asymmetry 
and canalicular membranes become more sensitive to bile salts. The loss of resistance 
enhances the extraction of cholesterol from the cells, which eventually leads to 
cholestasis.  This is one example of a disease directly attributed to a defect in P4-ATPase 
expression or function. Meanwhile, several other diseases states and defects are linked 
to mutations in P4-ATPases. For example, deficiencies in Atp8b1 are associated with 
progressive hearing loss due to cochlear hair cell degeneration (Stapelbroek et al., 2009). 
 
As mentioned, P4-ATPases are responsible for creating and maintaining membrane 
asymmetry – especially at the plasma membrane.  Exposure of PS (which is normally 
sequestered in the cytosolic leaflet of the plasma membrane) to the extracellular leaflet is 
critical as a signaling mechanism in apoptosis and blood clotting reactions (Zwaal, 
Comfurius, & Bevers, 2005). Phagocytes recognize exposed PS and proceed to engulf 
and kill the cell. At an organismal level, experiments demonstrating this were performed 
in C. elegans (Darland-Ransom et al., 2008). When the ATP8A1 ortholog, TAT-1, is 
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ablated, PS is exposed to the cell surface and these cells are removed by mechanisms 
dependent on proteins responsible for the recognition and engulfment of PS-exposing 
cells.  Mutations in ATP8A2, which has high expression levels in the brain, retina, and 
testes, have been implicated in axonal degeneration (and thus, neurodegenerative 
diseases) in mice (Cacciagli et al., 2010; Coleman, Kwok, & Molday, 2009). These 
observations have also been made in human patients. 
 
P4-ATPases are also linked to B-cell development (Atp11c) (Siggs et al., 2011; Yabas et al., 
2011), neuronal growth and maturation (Atp8a2) (Q. Xu et al., 2012), hippocampal-
dependent learning (Atp8a1) (Levano et al., 2012), cell migration (Atp8a1) (Kato et al., 
2013), and spermatogenesis (Atp8b5/FetA) (P. Xu et al., 2009). In mice, mutations in 
Atp10a (also known as Atp10c) are implicated in obesity and type II diabetes phenotype 
(M. Dhar et al., 2000). Atp10a-deficient mice also display hyperinsulinemia and are 
insulin-resistant (M. S. Dhar et al., 2004).  Recently, ATP10D has been linked to lipid 
metabolism deficiencies, and this association has been extended to suggest risks for 
myocardial infarction (Flamant et al., 2003; Hicks et al., 2009). In C. elegans, tat-2 through 
tat-4 become essential for worm reproduction during periods of sterol starvation 
(Lyssenko, Miteva, Gilroy, Hanna-Rose, & Schlegel, 2008). 
 
In plants, MgPDE1 and MgAPT2, which are P4-ATPases of the rice blast fungus, 
M.grisea, are required for its pathogenicity, especially root infectivity by the fungus 
(Balhadere & Talbot, 2001). Knockdown of Arabidopsis thaliana ALA1 is associated with 
cold resistance of the plant and these plants are much smaller than wild-type plants 
(Gomes, Jakobsen, Axelsen, Geisler, & Palmgren, 2000).  Mutations in ALA3 are 
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responsible for malformation of roots, pollen tubes and trichome patterning.  Basically, 
trafficking defects cause the root cells to be unable to secrete the appropriate proteins 
and establish proper border cells to successfully interact with the soil environment.  
 
The mechanism underlying the correlation between these biological phenomena and P4–
ATPases is yet to be elucidated, but the impact of this class of proteins on life is 
unquestionable. Physiologically, defects in P4-ATPases can cause many disease 
conditions.  But, the two main functions of the P4-ATPases, at a cellular level, include 
their role in the creation and establishment of membrane asymmetry as well as their 
influence in vesicle-mediated protein trafficking.  These topics will be further explored 
in the following sections. 
 
Function of P4-ATPases in Cells – Membrane Asymmetry and Membrane Curvature 
 
The plasma membrane, Golgi, and endosomal membranes of eukaryotic cells are 
asymmetric structures composed of different phospholipids on each of its two 
membrane monolayers.  Phosphatidylserine (PS), and phosphatidylethanolamine (PE) 
are mostly sequestered to the cytosolic or inner membrane, while phosphatidylcholine 
(PC) and sphingolipids are sequestered to the extracellular or lumenal (outer) membrane.  
The unique feature of this asymmetry is that each of the two membrane surfaces provide 
differing environments, both chemical and electric (net charge), which allow for varying 
protein functions at the membrane.  The plasma membrane is the site of important cell-
cell interactions, and the site of interactions for soluble signaling proteins with the 
membrane surfaces.  Many important signaling cascades are initiated at the plasma 
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membrane.  Disruption of plasma membrane asymmetry, as previously described, is a 
hallmark of physiological process such as apoptosis and blood clotting. There is also 
evidence that controlled loss of plasma membrane asymmetry plays a role in cellular 
process such as host-pathogen interactions and cytokinesis (Emoto et al., 1996; Mercer & 
Helenius, 2008; Zwaal & Schroit, 1997). 
 
Phospholipids are amphiphilic molecules with a hydrophilic head group and 
hydrophobic tails.  Due to this chemical structure, they are able to freely diffuse within a 
membrane bilayer, but very rarely flip-flop spontaneously between membrane leaflets.  
The reason is that the energy needed for the hydrophilic head group to traverse the 
hydrophobic environment that exists between the membrane leaflets is great.  Therefore, 
this is a phenomenon that occurs rarely (Kornberg & McConnell, 1971). Normal 
maintenance of the asymmetry of phospholipids in the plasma membrane is extremely 
important.  So the question remains – how is membrane asymmetry, present in most 
eukaryotic membranes, created and maintained? 
 
At the ER, the site of phospholipid synthesis, the lipid bilayer is symmetric, due to the 
presence of a scramblase – an energy-independent protein that allows for non-specific 
bidirectional movement of lipids.  Recent work has identified one of the scramblases 
involved in phospholipid scrambling (and PS exposure) at the plasma membrane. This 
protein, called TMEM16F, was identified in a mouse B-cell line as displaying Ca+2-
dependent scramblase activity (Suzuki, Umeda, Sims, & Nagata, 2010). Mutations in this 
scramblase were identified in patients with Scott’s syndrome (a rare bleeding disorder 
where there is a lack of scramblase activity) (Castoldi, Collins, Williamson, & Bevers, 
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2011; Suzuki et al., 2010).  When TMEM16F was reconstituted and assayed for activity, it 
was found that, as a result of a Ca+2 influx, scramblase activity was initiated.  
Furthermore, two other proteins from the TMEM16 family, also purified and 
reconstituted, failed to show such scramblase activity (Malvezzi et al., 2013).  Meanwhile, 
in genetic studies, TMEM16C, TMEM16D, TMEM16G, and TMEM16J were also 
implicated in having phospholipid scramblase activity, while the other TMEM16 family 
members were identified as Cl– channels (Suzuki et al., 2013).  Thus, scramblases are one 
protein class that mediates phospholipid transfer, however they are not involved in the 
creation of membrane asymmetry.   
 
Floppases and flippases are the other two protein classes involved in the creation of 
membrane asymmetry. The difference is that these proteins mediate energy-dependent, 
unidirectional movement of phospholipids. While floppases “flop” lipids from the 
cytosolic to the extracellular (or lumenal) leaflet, flippases (the P4-ATPases) “flip” lipids 
from the extracellular to the cytosolic leaflet. The class of proteins responsible for 
floppase activity is the ABC transporters, and they are found both in prokaryotic and 
eukaryotic membranes (Juliano & Ling, 1976). In eukaryotes, ABCA1, ABCA2, ABCB4, 
and ABCG1 are all capable of flopping PC and cholesterol across the membrane, while 
ABCG5 and ABCG8 displays substrate specificity for sterol movement. Another class of 
ABC transporters are involved in multi-drug resistance and bile secretion (MDR 
proteins) (Doerrler & Raetz, 2002; Dong, Yang, & McHaourab, 2005). MsbA is an ABC 
transporter (closely related to the MDR family) and found in E.coli. It is responsible for 
translocating lipidA moieties of lipopolysaccharides from the cytosolic to the 
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periplasmic membrane (Dean & Annilo, 2005).  Overall, the ABC transporters are 
capable of translocating a wider range of substrates compared to the P4-ATPases.  
 
Flippases, meanwhile, have more specific substrate specificities and move PS and PE 
unidirectionally towards the cytosolic leaflet (Alder-Baerens, Lisman, Luong, Pomorski, 
& Holthuis, 2006; Gomes et al., 2000; Natarajan, Wang, Hua, & Graham, 2004; Pomorski 
et al., 2003; Tang et al., 1996).  Initially, it was unclear if flippases played a direct role in 
the translocation of phospholipids at membranes.  Deletion of DRS2 caused defects in PS 
translocation (Tang et al., 1996), although later reports suggested this influence was 
minimal (Marx et al., 1999; Siegmund et al., 1998). Furthermore, discovery of trafficking 
deficiencies in these mutants also suggested that P4-ATPases had indirect roles in 
phospholipid translocation.  Subsequent work showing that inactivation of Drs2p causes 
an ablation in flippase activity in purified Golgi membranes (Natarajan et al., 2009; 
Natarajan et al., 2004), as well as genetic studies demonstrating a function for Dnf1p and 
Dnf2p in flippase activity (towards NBD-labeled PC and PE) at the plasma membrane 
(Pomorski et al., 2003), cemented the idea that these proteins were likely flipping 
phospholipids.  Plasma membrane flippase activity, meanwhile, was also demonstrated 
in several plant (ALA1, ALA2, and ALA3), and mammalian (FetA, Atp8b1) ATPases 
(Poulsen et al., 2008; P. Xu et al., 2009). 
 
Another mechanism for concentrating PS in the cytosolic leaflet of the plasma membrane 
is by direct transfer of PS, from its site of synthesis (at the ER), to the PM. New evidence 
has been presented for the role of oxysterol-binding proteins (OSBP’s) in this lipid 
translocation of PS.  In yeast, Osh6 and Osh7 (oxysterol-binding protein homologs) have 
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been discovered to have specificity for PS and participate, in vivo, in transporting PS 
from the ER to the plasma membrane, as well as maintaining PS homeostasis.  This is 
some of the first evidence of non-vesicular transport of a phospholipid. Additionally, 
ORP5 and ORP10 (human OSBPs) have been identified as sharing a similar preference 
for PS (Maeda et al., 2013). Because of the role of PS sequestration as a hallmark 
membrane asymmetry (the loss of which serves as an important signaling mechanism), 
this discovery opens new avenues of research into several disease states and associated 
therapies, including cancer and metabolic diseases. 
 
The first evidence that a protein was responsible for translocating phospholipids 
between the two leaflets of a membrane bilayer and that this action was responsible for 
the asymmetric composition of membranes came with the discovery of the 
aminophospholipid translocase (APLT) by Seigneuret and Devaux (Seigneuret & 
Devaux, 1984).  When different phospholipids were added exogenously, to human red 
blood cells, it was observed that PS and PE were preferentially translocated to the 
cytosolic leaflet of the red blood cell, which resulted in shape changes to the cell (Fig. 1-
5). For instance, when spin-labeled PC was added to the extracellular membrane, there 
was an increase in the surface area of the extracellular membrane (echinocyte shape) and 
the membrane appears swollen.  However, when a spin-labeled PS was added to the 
extracellular membrane, the red blood cells went from the normal discocyte shape to the 
echinocyte shape (due to addition of exogenous phospholipid to the outer leaflet) and 
the quickly to a crenated stomatocyte shape (Fig. 1-5) (Daleke & Huestis, 1985; 
Seigneuret & Devaux, 1984).  This second change was due to the flipping of PS, by the 
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Figure 1-5. Red blood cell membranes change shape in response to exogenously added 
phospholipids and phospholipid translocation. The left panel (c) shows echinocyte shape (after 
addition of exogenous phospholipids). The center panel (f) shows discocyte shape of a normal 
red blood cell. The right panel (i) shows crenated stomatocyte shape which occurs when the 
exogenously added phospholipid is translocated across the membrane bilayer. Image from Daleke 
& Huestis, 1989. 
 
APLT, to the cytosolic leaflet. There is a concurrent increase in the surface area of the 
cytosolic leaflet, while the extracellular leaflet bends inward to maintain the association 
between the membrane bilayers.  Thus, it seems that the change in cell shapes correlates 
with the differences in the number of phospholipids between the two leaflets of a 
membrane bilayer. 
 
This idea – that, when there is an increase in the phospholipid number of one layer of a 
tightly coupled membrane bilayer, it expands and the other layer contracts to maintain 
this coupling – is called the Bilayer Couple Hypothesis (Sheetz & Singer, 1974), and was 
first conceived by Sheetz and Singer in 1974.  It serves as the foundation upon which 
most of the hypotheses that address the role of proteins and their role in the creation of 
membrane curvature has been built.  One example relevant to this hypothesis is the 
influence of phosphatidic acid translocation across liposome membranes (driven by a 
pH gradient), which induces curvature as predicted by the hypothesis (Eastman, Hope, 
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& Cullis, 1991).  Shape changes in red blood cells (see section on APLT discovery by 
Seigneuret and Devaux) induced by additional phospholipid being added to the 
extracellular leaflet and then flipped to the cytosolic leaflet is another example. 
 
There are several hypotheses on how membrane curvature is formed and captured by 
proteins in order to bud transport vesicles from the plasma membrane or organelles.  
The textbook view of vesicle budding suggests that the assembly of clathrin triskelia and 
associated adaptor proteins onto a membrane causes localized curvature of the 
membrane due to the intrinsic curved structure of the polyhedral clathrin coat and its 
ability to self-assemble into baskets (Kirchhausen, 2000a, 2000b). Clathrin-coated vesicles 
have been shown to form from protein-free liposomes, in vitro (Takei et al., 1998).  
However, calculations on the energy required for membrane deformation versus the 
energy used by clathrin to self-assemble into polyhedral baskets suggests that this 
clathrin may be insufficient for driving the dynamic levels of membrane curvature 
needed for vesicle formation in cells (Nossal, 2001).  Other labs have argued for the 
“Brownian ratchet” mechanism which claims that since biological membranes are 
extremely fluid structures, momentary curvature is created due to natural fluid 
fluctuations in the membrane (Hinrichsen, Meyerholz, Groos, & Ungewickell, 2006).  
Various proteins, including clathrin subunits, are able to sense and capture this 
curvature and, as a result, recruit the proteins necessary to build a functional vesicle.   
 
Proteins that possess specialized domains (such as BAR-domains, ENTH- and ANTH-
domains, and ALPS domains) have also been implicated in sensing, capturing, or 
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causing membrane curvature (Ford et al., 2002; Graham & Kozlov, 2010; Itoh & De 
Camilli, 2006; Ren, Vajjhala, Lee, Winsor, & Munn, 2006).  It has also been hypothesized 
that proteins with amphipathic helices, such as Arf, or lysolipids, can generate positive 
membrane curvature by inserting their helix (or acyl chain) into the outer leaflet of the 
membrane bilayer. There has been much work done in artificial membranes to show that 
cytosolic proteins, such as Arf, COPI, and epsins, are capable of tubulating membranes 
(Beck et al., 2011; Beck et al., 2008).  However, it has been argued that these effects are a 
result of protein-protein crowding (Stachowiak et al., 2012). Furthermore, the quantity of 
protein added to the membranes in these experiments is not representative of the 
protein levels found normally in a cell.  Also, the rate of membrane curvature formation 
by these proteins is not typical in cells.  Finally, lipid-modifying enzymes, 
lysophospholipid acyltransferases (LPATs), sphingomyelinase, and dynamin are other 
proteins implicated in the creation of membrane curvature (Graham & Kozlov, 2010).  
 
P4-ATPases, due to their ability to translocate phospholipids between membrane leaflets, 
and their association with protein trafficking defects, are yet another group of proteins 
deemed to have a function in membrane curvature formation.  The favored model for 
how flippases contribute to membrane asymmetry and vesicle budding is based on the 
bilayer couple hypothesis by Sheetz and Singer.  This hypothesis states that the 
expansion of one leaflet relative to the other will cause membrane bending because the 
two leaflets are physically coupled to each other (Sheetz & Singer, 1974).  
 
 23 
In addition to the creation and maintenance of membrane asymmetry, flippases also 
play important roles in vesicle-mediated protein transport.  More specifically, it is 
hypothesized that flippases are involved in the creation of transport vesicles.  How is 
this achieved? The ability of flippases to flip phospholipids creates asymmetry in the 
membrane composition.  Additionally, this unidirectional flip, from the cytosolic leaflet 
to the extracellular or lumenal leaflet, creates an imbalance in the number of 
phospholipids in each membrane. As the number of phospholipids in the cytosolic 
leaflet increases, the surface area of that leaflet increases and positive membrane 
curvature is attained (Fig. 1-6) (Graham & Kozlov, 2010).  The decrease in the number of 
phospholipids in the lumenal leaflet, coupled with the close association between the two 
membrane layers, results in membrane invagination towards the cytosolic side.  The 
resulting positive membrane curvature, bending into the cytosol, is then captured by 
coat proteins, adaptor proteins and other factors responsible for the formation of a 
mature transport vesicle.  Flippase activity by P4-ATPases should, as a result, induce 
positive membrane curvature (bending of the membrane towards the cytosol).  However, 
we have no direct evidence that the flippase activity of P4-ATPases causes membrane 
bending. Drs2p, we hypothesize, causes flipping of phospholipids from one leaflet to the 
other, expands the outer leaflet causing membrane bending since the two leaflets are 
coupled. This curvature is captured by curvature-sensing proteins that are able to recruit 
AP-1 and clathrin onto the membrane (Graham & Kozlov, 2010).  In Chapter 3 of this 
thesis, I outline experiments and assays designed and developed to test the role of Drs2p 
on membrane curvature and its influence in vesicle budding. 
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Figure 1-6. Potential mechanism by which Drs2p creates membrane curvature and works to 
create transport vesicles.  Image from (Graham & Kozlov, 2010). 
 
 
Function of P4-ATPases in Cells – Vesicle-Mediated Protein Transport* 
* This section has been modified from the BBA Review:  (Sebastian et al., 2012).  
 
P4-ATPases were first linked to protein trafficking when Drs2p, and its chaperone, 
Cdc50p, were discovered to genetically interact with Arf (C. Y. Chen & Graham, 1998; C. 
Y. Chen, Ingram, Rosal, & Graham, 1999; S. Chen et al., 2006; Sakane, Yamamoto, & 
Tanaka, 2006). Arf (ADP-ribosylation factor) is a small G-protein that cycles between 
GTP- and GDP-bound form through the action of several guanine nucleotide exchange 
factors (ArfGEFs) and GTPase activating proteins (ArfGAPs). In the GTP-bound form, 
Arf mediates the binding of adaptor proteins and coat proteins, such as COPI and 
clathrin, to sites of vesicle formation (Bonifacino & Glick, 2004). The synthetic lethal 
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interaction between Drs2p and Cdc50p with Arf suggested that these proteins were 
important players in vesicle budding pathways. drs2Δ is also synthetically lethal with 
clathrin temperature-sensitive alleles, but not COPI or COPII mutations, which 
implicated Drs2p in clathrin-mediated protein trafficking pathways (C. Y. Chen et al., 
1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-7. Drs2p trafficking pathways and players.  Image from (Sebastian et al., 2012). 
 
Drs2p primarily localizes to the trans-Golgi network (TGN) and this is one of the sites 
from which clathrin-coated vesicles bud. The phenotypes exhibited by drs2Δ cells are 
similar to the defects observed in cells deficient in clathrin. Both mutants accumulate 
enlarged Golgi cisternae and late Golgi enzymes involved in proteolytically processing 
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pro-α-factor are mislocalized in both drs2Δ and clathrin mutants. Furthermore, the drs2Δ 
cells are markedly deficient in clathrin-coated vesicles (CCVs) that can be purified from 
these cells (C. Y. Chen et al., 1999). The screen for mutants defective in ribosome 
synthesis that first identified DRS2 may seem at odds with the roles described here in 
protein trafficking and membrane asymmetry. However, many mutants that exhibit 
defects in vesicle-mediated protein transport create membrane stress, which is sensed by 
the cell integrity pathway to down regulate ribosome production and attenuate 
translation (Deloche, de la Cruz, Kressler, Doere, & Linder, 2004; Li, Moir, Sethy-Coraci, 
Warner, & Willis, 2000). The defect in ribosome synthesis only appears after shifting 
drs2Δ cells to cold temperatures (below 20 °C) for a few hours (Ripmaster et al., 1993), 
while most of the Golgi defects are observed at any temperature (C. Y. Chen et al., 1999; 
Muthusamy, Raychaudhuri, et al., 2009). The localization of Drs2p to the TGN and 
observation that temperature-sensitive for function alleles of DRS2 (drs2–12 or drs2–31) 
cause a loss of vesicle formation within 30 minutes of temperature shift imply a direct 
role for Drs2p in vesicle budding (Gall et al., 2002). 
 
There are many co-factors involved in the formation, budding and uncoating of clathrin-
coated vesicles (Kirchhausen, 2000a). Most notably, adaptor proteins are essential in 
cargo selection and organizing the coat at sites of vesicle formation. In yeast, AP-1 
(adaptor protein-1), a heterotetrameric complex composed of γ, β1, μ1, and σ1 adaptin 
subunits, is recruited by Arf and functions at the TGN and early endosomes (Fig. 1-7). 
Another set of adaptor proteins, Gga1 and Gga2 (Golgi-localized, Gamma-ear containing, 
Arf-binding) bud clathrin-coated vesicles from the TGN that are targeted to the late 
endosome. The AP-3 tetrameric adaptor (composed of δ, β3, μ3 and σ3 adaptin subunits) 
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also appears to bud from the TGN in an Arf-dependent, but clathrin independent 
manner (Muthusamy, Natarajan, Zhou, & Graham, 2009). After a clathrin-coated vesicle 
buds, the yeast auxilin (Swa2) and Hsp70 (Ssa proteins) are required for clathrin 
disassembly and uncoating (Fig. 1-7) (Gall et al., 2000; Xiao, Kim, & Graham, 2006).  
 
Drs2p and Cdc50p are required for bi-directional transport between the TGN and the 
early endosome in pathways mediated by AP-1/clathrin and an F-box protein called 
Rcy1p (Fig. 1-7) (Furuta et al., 2007; Hua et al., 2002; Liu, Surendhran, Nothwehr, & 
Graham, 2008). The phenotypes associated with loss of Drs2p or AP-1 function within 
cells are very similar. For example, chitin synthase III (Chs3p) is thought to cycle 
between the TGN and early endosome and is exported to the plasma membrane at 
certain times in the cell cycle (Valdivia, Baggott, Chuang, & Schekman, 2002). Mutation 
of exomer subunit genes, such as CHS6, prevents transport of Chs3p to the plasma 
membrane. But, when chs6Δ is combined with either drs2Δ or AP-1 subunit mutations, 
Golgi-endosomal trafficking is disrupted and Chs3p redirects to the plasma membrane 
and late endosome or vacuole (Liu et al., 2008; Valdivia et al., 2002). These results 
suggest that Drs2p, AP-1 and clathrin mediate both anterograde and retrograde 
transport of this cargo between the TGN and early endosome (Liu et al., 2008).  
 
Drs2p also appears to cycle between the TGN and early endosomes (Fig. 1-7). 
Occasionally, some Drs2p molecules find their way to the plasma membrane, but 
multiple endocytosis signals ensure a quick return to the early endosome and TGN 
system (Liu, Hua, Nepute, & Graham, 2007). When AP-1 is disrupted, wholesale re-
routing of Drs2p to the plasma membrane is observed and Drs2p can be held at this 
 28 
location with an endocytosis block. However, upon lifting the endocytosis block, Drs2p 
recycles through the endocytic pathway back to the TGN in the absence of AP-1 (Liu et 
al., 2008). The role of AP-1, it seems, is to traffic Drs2p and Chs3p from the TGN to the 
early endosome, but unlike Chs3p, Drs2p does not need AP-1 for the return trip. 
Because Drs2p is required to support Chs3p trafficking in AP-1 pathways, it seemed 
possible that the flippase activity may be required to support Drs2p's own transport by 
AP-1. In fact, inactivation of Drs2p activity (by shifting a GFP-tagged temperature 
sensitive form of Drs2p to the nonpermissive temperature) caused re-routing of Drs2p to 
the plasma membrane, comparably to what was observed by inactivation of AP-1 (Liu et 
al., 2008).  
 
Figure 1-8. Enzymatically active Drs2p is required for the budding of AP-1/clathrin-coated 
vesicles. Image from Liu, et al., 2008. 
 
These observations support the idea that the formation of AP-1/clathrin-coated vesicles 
requires Drs2p flippase activity. Remarkably, however, the Arf-dependent recruitment 
of AP-1 and clathrin to the TGN is not perturbed in drs2Δ cells (Fig. 1-8) (Liu et al., 2008). 
Moreover, the enlarged Golgi cisternae that accumulate in drs2Δ cells lack budding 
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profiles or highly curved tubular elements (C. Y. Chen et al., 1999; Gall et al., 2002), even 
though the coat proteins are present on the membrane. Thus, a simple model that Drs2p 
facilitates coat recruitment to drive vesicle budding is incorrect. It seems more likely that 
Drs2p imparts curvature to the membrane by pumping phospholipid to the cytosolic 
leaflet, thereby producing a surface that the clathrin coat can more easily deform 
(Graham, 2004). 
 
Drs2p and Cdc50p are also critical for directing cargo from the early endosome back to 
the TGN in the "Rcy1p pathway" (Fig. 1-7) (Furuta et al., 2007; Hua et al., 2002). The F-
box protein Rcy1p can form a Skp1-cullin-F-box (SCF-Rcy1) complex (Kus, Caldon, 
Andorn-Broza, & Edwards, 2004) and Rcy1p is required for the early endosome to TGN 
trafficking of Snc1p, an exocytic SNARE protein that cycles between the early endosome, 
TGN and plasma membrane (Galan et al., 2001; Lewis, Nichols, Prescianotto-Baschong, 
Riezman, & Pelham, 2000). The SCF Rcy1p complex is an effector of the Rab proteins 
Ypt31p and Ypt32p, and is proposed to ubiquitinate Snc1p to generate a signal for 
recycling out of the endosome (S. H. Chen, Shah, & Segev, 2011). Trafficking of Snc1p is 
unaffected by AP-1 disruption (Liu et al., 2008) and there is some indication that COPI 
might influence the Rcy1p pathway, although the vesicle coat acting in this pathway is 
unclear (Robinson et al., 2006). The sorting nexin complex Snx4/41/42p and the ArfGAP 
Gcs1p are also linked to this recycling pathway (Hettema, Lewis, Black, & Pelham, 2003; 
Sakane et al., 2006). The drs2Δ and cdc50Δ mutations disrupt retrograde trafficking of 
Snc1p from the early endosome to the TGN comparably to the rcy1Δ mutation. In 
addition, Cdc50p accumulates in the early endosomes of Rcy1p mutants and so Drs2p–
Cdc50p also appears to travel the Rcy1p pathway back to the TGN (Furuta et al., 2007). 
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In fact, growth defects associated with rcy1Δ can be suppressed by overexpression of 
Drs2p/Cdc50p and Snc1p, implying that these proteins are the critical cargos in the 
Rcy1p pathway (Furuta et al., 2007). While Rcy1p interacts with Drs2p–Cdc50p (Furuta 
et al., 2007), it is not known if Rcy1p ubiquitinates this flippase to facilitate retrieval or 
acts by another mechanism.  
 
The C. elegans tat-1 and chat-1 mutants (potentially orthologous to Drs2p–Cdc50p) also 
show a strong defect in cargo recycling through endosomes (B. Chen et al., 2010; Ruaud 
et al., 2009), indicating that this function in protein trafficking is well-conserved through 
evolution. TAT-1 and CHAT-1 co-localize within intestinal cells to the plasma 
membrane (apical and basolateral) along with early/recycling endosomes. In fact, 
CHAT-1 decorates tubules on recycling endosomes that require RAB-10 for formation, 
and these tubules are exaggerated in an rme-1 mutant (Eps15 homology domain (EHD) 
protein required for tubule scission) (B. Chen et al., 2010). Intestinal cells of the tat-1 or 
chat-1 mutants accumulate large vacuolated structures bearing markers for late 
endosomes and lysosomes (B. Chen et al., 2010; Ruaud et al., 2009). In addition, several 
markers for the early and late endosomes, recycling endosomes and late Golgi show 
aberrant co-localization to aggregated vesicles. A number of proteins that normally 
recycle from the early endocytic pathway back to the plasma membrane, including 
human transferrin receptor, human IL-2 receptor α-chain and glucose transporter 1 
(GLUT-1), are all trapped in abnormal endosomal intermediates in the mutants (B. Chen 
et al., 2010). Moreover, the recycling endosome tubular extensions appear to be 
completely lost in the tat-1 and chat-1 mutants (B. Chen et al., 2010). These data suggest 
that TAT-1 and CHAT-1 help drive the tubular membrane extensions from recycling 
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endosomes that enrich cargo for delivery back to the plasma membrane. 
 
In addition to bidirectional transport between the TGN and early endosome, and 
recycling from endosomes back to the plasma membrane, P4-ATPases may also 
contribute to budding of exocytic vesicles from the TGN (Gall et al., 2002). Budding 
yeast produce at least two classes of exocytic vesicles distinguished by density and cargo 
(Harsay & Bretscher, 1995). Inactivation of either Drs2p or clathrin prevents formation of 
the denser class that accumulates when actin assembly is perturbed (Gall et al., 2002). It 
remains unclear if these Drs2p-dependent exocytic vesicles actually bud from the TGN 
or an early endosome, and it is possible that they are analogous to the tubular carriers 
produced by recycling endosomes in C. elegans.  
 
However, phenotypes exhibited by A. thaliana ala3 mutants suggest a defect in forming 
exocytic secretory vesicles directly from the TGN (Poulsen et al., 2008). The peripheral 
columnella cells in the root tip of wild-type plants display TGN cisternae with large, 
bulbous extensions filled with electron translucent slime polysaccharide. Secretory 
vesicles containing the slime polysaccharide derived from the Golgi are easily detected 
in the cytoplasm prior to their fusion to the plasma membrane. In contrast, the ala3 
columella cells have a complete absence of the distended TGN cisternae and a marked 
deficiency of secretory vesicles in the cytoplasm (Poulsen et al., 2008). ALA3 also plays a 
critical role in trichome formation on leaves, which is a wonderful model for directional 
membrane growth and complex cell patterning (Zhang & Oppenheimer, 2009). The 
trichome branch elongation defect in ala3 plants may result from defects in membrane 
trafficking and/or regulation of the actin cytoskeleton. This is reminiscent of the 
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polarized growth defects reported for lem3Δ mutants in budding yeast (Saito et al., 2007), 
and the loss of microvilli from the apical membrane of Caco-2 cells deficient for Atp8b1 
(Verhulst et al., 2010).  
 
Thus far, only Atp8b5 has been shown to have a role in protein trafficking in 
mammalian cells (P. Xu et al., 2009). RNA interference of Atp8b5 in murine 
mastocytoma P815 cells causes the distension of Golgi cisternae and abrogates 
constitutive secretion. Interestingly, these secretory pathway defects are only observed 
at lower temperatures (33°C), perhaps because other P4-ATPases can compensate for the 
Atp8b5 deficiency at 37°C (P. Xu et al., 2009). Alternatively, it is possible that Golgi 
membranes in Atp8b5 deficient cells are more sensitive to changes in membrane fluidity 
associated with reduced temperature.  
 
In the budding yeast system, there is clear evidence for both overlapping and non-
overlapping functions for the P4-ATPases (Hua et al., 2002). The defects in bidirectional 
transport between the TGN and endosomes and exocytosis are observed in drs2Δ single 
mutants, in spite of the presence of four other P4-ATPases in these cells.  Dnf1p is also 
unable to replace the function of Drs2p in AP-1/clathrin-coated vesicle formation or the 
formation of Snc1 retrograde vesicles. Thus, Neo1p and the Dnf P4-ATPases cannot 
replace the critical function of Drs2p in these pathways. However, growth and protein 
trafficking defects associated with drs2Δ become more severe as additional DNF genes 
are knocked out. For example, neither a drs2Δ nor a dnf1Δ single mutant displays a defect 
in the AP-3-dependent transport of cargo to the vacuole. However, the drs2Δ dnf1Δ 
double mutant exhibits a substantial defect in sorting AP-3 cargo (Hua et al., 2002). Thus, 
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it appears that Drs2p and Dnf1p are interchangeable in this pathway.  Furthermore, 
Dnf1-N550S, a mutant form of Dnf1p that preferentially translocates PS, has been shown 
to replace Drs2p in transport between the TGN and early endosomes.  It is also able to 
recruit the downstream effector, Gcs1p (an Arf-GAP) to sites of increasing membrane 
curvature and anionic charge.  This anionic charge is often imparted to the membrane 
due to the translocation of phosphatidylserine to the cytosolic leaflet (P. Xu, Baldridge, 
Chi, Burd, & Graham, 2013).  Neo1p and Dnf1p may also compensate for loss of Drs2p 
in delivering cargo from the Golgi to the late endosome, which is a GGA-dependent 
pathway (Hua & Graham, 2003; Singer-Kruger et al., 2008; Wicky, Schwarz, & Singer-
Kruger, 2004). In addition, the dnf1Δ dnf2Δ cells show a cold-sensitive endocytosis defect 
that is exacerbated by addition of drs2Δ (Pomorski et al., 2003). While cells are viable until 
all four DRS2 DNF genes are knocked out, the single neo1Δ mutation is lethal (Hua et al., 
2002). Thus, Neo1p has an essential role that cannot be replaced by Drs2p or Dnf 
proteins.  
 
Neo1p appears to localize to both Golgi and endosomes and has been implicated in the 
COPI-dependent retrograde transport of cargo from the Golgi to the ER (Hua & Graham, 
2003; Singer-Kruger et al., 2008; Wicky et al., 2004). For example, the Rer1p protein 
rapidly cycles between the ER and Golgi, but COPI inactivation causes mislocalization 
of Rer1p to downstream compartments (Sato, Sato, & Nakano, 2001). Similarly, Neo1p 
inactivation causes the same Rer1p mislocalization phenotype (Hua & Graham, 2003). 
Additionally, Neo1p has been implicated in GGA dependent trafficking of cargo from 
the TGN to the late endosome. GGA is recruited to the TGN membrane by associations 
with both Arf and the Arf-like protein Arl1p, which forms a complex with Mon2 (a large 
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scaffold protein) and Neo1p (Singer-Kruger et al., 2008). In C. elegans, TAT-5 has been 
implicated in the budding of extracellular vesicles.  Loss of TAT-5 causes loss of PE 
asymmetry which then leads to wide-scale shedding of these vesicles.  Worm embryos, 
then, have defects in cell adhesion and morphogenesis (Wehman, Poggioli, 
Schweinsberg, Grant, & Nance, 2011). 
 
Regulation of P4-ATPases 
 
Thus, the role of flippases in a cell is an important one.  And, as such, it is closely 
regulated by a variety of mechanisms in the cell. Flippase protein kinases (FPK) are a 
class of proteins that were discovered, in a genetic screen, as positive regulators of 
Dnf1p and Dnf2p (Nakano, Yamamoto, Kishimoto, Noji, & Tanaka, 2008).  In addition to 
directly phosphorylating the P4-ATPase, a double mutant of these proteins (fpk1Δ fpk2Δ) 
has similar phenotypic defects as dnf1Δ dnf2Δ – they have defects in their flippase 
activity (as measured by inability to translocate fluorescent derivatives of the Dnf 
substrates, PC or PE), and have protein trafficking defects (similar to a loss of Dnf1p-
Lem3p or Dnf2p-Lem3p phenotype) (Nakano et al., 2008). Additional work has 
identified other protein kinases, such as Ypk1p, that play a role in regulating Fpk 
activity at the membrane, and it is the organization of and changes to the membrane 
composition that tightly regulates the influence of these kinases, and the resulting 
activity of the flippase (Roelants, Baltz, Trott, Fereres, & Thorner, 2010). 
 
An oxysterol-binding protein, called Kes1p, is involved in down-regulating Drs2p 
function 
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2009).  Meanwhile, Drs2p is also able to downregulate Kes1p function (Muthusamy, 
Raychaudhuri, et al., 2009).  Oxysterol-binding proteins bind and remove sterols from 
the membrane.  A hypothesis as to the way Drs2p is able to regulate the activity of 
Kes1p is that Drs2p can change the membrane structure which then inhibits the ability 
of Kes1p from extracting sterols from the membrane (Muthusamy, Raychaudhuri, et al., 
2009). Recent work (described on pages 18 and 19 of this chapter) has also indicated that 
Kes1p can extract PI4P from the membrane.  Kes1p has been shown to stimulate a PI4P 
phosphatase (Alfaro et al., 2011), and lowering the levels of PI4P on the membrane 
hinders Drs2p flippase activity as PI4P has recently been shown to be a direct regulator 
of Drs2p activity (Fig. 1-6 and 1-7) (Zhou, Sebastian, & Graham, 2013). 
	  
Drs2p is strongly influenced by the phosphotidylinositol 4-phosphate (PI4P) produced 
by Pik1p (phosphatidylinositol 4-kinase) (Sciorra et al., 2005).  The C-terminal tail of 
Drs2p possesses a basic patch of amino acid residues, which have been mapped to 
preferentially bind phosphoinositides (in the case of Drs2p, PI4P) (Natarajan et al., 2009). 
When PI4P production is abolished, by the deletion by its respective phosphatase or 
inactivation of Pik1p, in isolated TGN membranes, the activity of Drs2p is considerably 
diminished (Natarajan et al., 2009). Additionally, the C-tail of Drs2p possesses residues 
(which overlap the PI4P binding region) that have a preference for binding an ArfGEF.  
A stimulation of Drs2p flippase activity is detectable, in isolated Golgi membranes, 
when incubated with an ArfGEF (Natarajan et al., 2009).  
 
New work from the lab of Fang-Jen Lee has also implicated Arl1 as an additional 
regulator of Drs2p.  The Lee group shows that Drs2p, ArfGEF and Arl1p come together 
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to form a stable ternary complex, and the formation of this complex stimulates the 
flippase activity of Drs2p (Tsai, Hsu, Liu, Chen, & Lee, 2013). Their findings, and its 
relationship to the regulation of flippases are discussed in greater detail on pages 59 and 
60 of this thesis (Chapter II).  
 
In the secretory pathway, as Figure 1-7 indicates, Kes1p, Pik1p and Sac1p primarily 
function to regulate the activity of Drs2p at the TGN. Arf-GEF exerts its influence at both 
the TGN and early endosomes 
 
As previously mentioned, the family of P-type ATPases have four structural domains in 
common – the actuator, phosphorylation, nucleotide-binding, and transmembrane 
domains.  Additionally, some P-type ATPases possess regulatory domains (R domains) 
contained within the N-terminal or C-terminal sequence of the protein (Au, 1987; 
Hwang et al., 2000; P. James et al., 1988; Palmgren et al., 1990; Palmgren et al., 1991; 
Portillo et al., 1989; Rasi-Caldogno et al., 1992, 1993, 1995). The C-terminal tail of Drs2p 
has been implicated as an R domain and, as described above, regions have been mapped 
where effectors, such as PI4P and ArfGEF are able to interact. The role that the C-
terminal tail of Drs2p plays, in regulating flippase activity, will be explored further in 
Chapter 2 of this thesis.  
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CHAPTER II 
 
AUTO-INHIBITION OF DRS2P, A YEAST PHOSPHOLIPID FLIPPASE, BY ITS 
CARBOXYL-TERMINAL TAIL* 
*This chapter was previously published as: Zhou, X., Sebastian, T. T., & Graham, T. R. (2013). 
Auto-inhibition of Drs2p, a yeast phospholipid flippase, by its carboxyl-terminal tail. J Biol 
Chem, 288 
 
Abstract 
 
Drs2p, a yeast type IV P-type ATPase (P4-ATPase), or flippase, couples ATP hydrolysis 
to phosphatidylserine (PS) translocation and the establishment of membrane asymmetry. 
A previous study has shown that affinity-purified Drs2p, possessing an N-terminal 
tandem affinity purification tag (TAPN-Drs2), retains ATPase and translocase activity, 
but Drs2p purified using a C-terminal tag (Drs2-TAPC) was inactive (Zhou & Graham, 
2009). In this study, we show that the ATPase activity of N-terminally purified Drs2p 
associates primarily with a proteolyzed form of Drs2p lacking the C-terminal cytosolic 
tail.  Truncation of most of the Drs2p C-terminal tail sequence activates its ATPase 
activity by approximately 4-fold. These observations are consistent with the hypothesis 
that the C-terminal tail of Drs2p is auto-inhibitory to Drs2p activity. 
Phosphatidylinositol-4-phosphate (PI(4)P) has been shown to positively regulate Drs2p 
activity in isolated Golgi membranes through interaction with the C-terminal tail 
(Natarajan et al., 2009). In proteoliposomes reconstituted with purified, N-terminally 
TAP-tagged Drs2p, both ATPase activity and flippase activity were significantly higher 
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in the presence of PI(4)P. In contrast, PI(4)P had no significant effect on the activity of a 
truncated form of Drs2p, which lacked the C-terminal tail. This work provides the first 
direct evidence, in a purified system, that a phospholipid flippase is subject to auto-
inhibition by its C-terminal tail, which can be relieved by a phosphoinositide to 
stimulate flippase activity. 
 
Introduction 
 
P-type ATPases are a large family of membrane pumps that transport various substrates, 
such as ions, against their chemical gradients across membranes. They are divided into 5 
subfamilies (P1- to P5-ATPases) and further into smaller subgroups based on sequence 
homology and substrate specificity (Axelsen & Palmgren, 1998; Kuhlbrandt, 2004). The 
P4-ATPases translocate specific phospholipid molecules from the extracellular leaflet of 
the plasma membrane, or lumenal leaflet of internal organelles, to the cytosolic leaflet.  
This activity is crucial for both the establishment of plasma membrane asymmetry, and 
vesicle-mediated protein transport in the secretory and endocytic pathways (Sebastian, 
Baldridge, Xu, & Graham, 2012). The overall architecture of P-type ATPases is 
exemplified by the crystal structures of several P-type ATPases. They possess three 
cytosolic domains (A: actuator; N: nucleotide binding; P: phosphorylation) and a multi-
span transmembrane domain (Toyoshima, 2009; Toyoshima et al., 2000). In addition to 
these common structural features, some P-type ATPases have an additional regulatory 
cytosolic domain, called an R domain, within the N- or C-terminal cytosolic tail of the 
protein (Au, 1987; Hwang et al., 2000; P. James et al., 1988; Palmgren et al., 1990; 
Palmgren et al., 1991; Portillo et al., 1989; Rasi-Caldogno et al., 1992, 1993, 1995). Some 
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members of the P-type ATPase family also have additional beta subunits associated with 
them.  There is evidence that these subunits, in varying degrees, aid in regulation, 
folding and/or proper localization of the P-type ATPase (Geering, 2001; Kuhlbrandt, 
2004; Sebastian et al., 2012).   
 
The R domain serves as an auto-inhibitory element that limits the activity of the P-type 
ATPase. Removal of the R domain, by limited proteolysis or genetic engineering, 
activates the protein. Various regulatory activities can relieve the auto-inhibition caused 
by this R domain. For example, the P2B-ATPase subgroup, comprising the plasma 
membrane Ca2+ pumps, contains an R domain in the C-terminal tail (in animals) (Au, 
1987; Carafoli, 1994; P. James et al., 1988), or in the N-terminal tail (in plants) (Hwang et 
al., 2000; Rasi-Caldogno et al., 1992, 1993, 1995; Sze, Liang, Hwang, Curran, & Harper, 
2000). When calmodulin interacts with this R domain, it displaces the auto-inhibitory tail 
and activates the protein for Ca2+ transport. Phosphorylation of serine or threonine 
residues within the R domain of P2B-ATPases has also been found to regulate ATPase 
activity by disrupting calmodulin binding and resulting in protein activation (in 
animals), or inactivation (in plants) (Carafoli, 1994; Caroni & Carafoli, 1981; P. H. James, 
Pruschy, Vorherr, Penniston, & Carafoli, 1989; Sze et al., 2000). The P3A-ATPase family, 
which is comprised of plasma membrane proton pumps from plants and fungi, also 
possesses a C-terminal R domain and utilizes a similar activation mechanism, which 
includes phosphorylation and binding of regulatory proteins to the R domain (Fuglsang 
et al., 1999; Maudoux et al., 2000; Olsson, Svennelid, Ek, Sommarin, & Larsson, 1998; 
Palmgren, 2001; Palmgren et al., 1990; Palmgren et al., 1991; Piotrowski, Morsomme, 
Boutry, & Oecking, 1998; Portillo, 2000; Portillo et al., 1989). Evidence for the role of the 
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N-terminus in regulating P-type ATPase function has also been shown (Cornelius, 
Mahmmoud, Meischke, & Cramb, 2005; Ekberg, Palmgren, Veierskov, & Buch-Pedersen, 
2010). 
 
Drs2p is a P4-ATPase from the budding yeast Saccharomyces cerevisiae. At steady state, 
Drs2p is localized primarily to the trans-Golgi network (TGN), and is involved in 
multiple protein trafficking pathways between the TGN, plasma membrane and 
endosomes (Sebastian et al., 2012). Drs2p is structurally similar to the other P-type 
ATPases with A, N, and P cytosolic domains and 10 transmembrane segments 
(Sebastian et al., 2012).  Drs2p associates with a beta subunit, Cdc50p, which is its co-
chaperone and a member of the Cdc50p family of proteins. Cdc50p is essential for 
proper localization of Drs2p within the cell (S. Chen et al., 2006; Furuta et al., 2007; Saito 
et al., 2004).  Drs2p catalyzes a phosphatidylserine (PS) flippase activity detected in 
isolated TGN membranes (Natarajan et al., 2004) and post-Golgi secretory vesicles 
(Alder-Baerens et al., 2006), as well as in proteoliposomes reconstituted with purified 
Drs2p (Zhou & Graham, 2009). Interestingly, like P2B- and P3A-ATPases, Drs2p appears 
also to have an R domain within its C-terminal tail. Features identified in the Drs2p R 
domain include a motif that binds Gea2p (an Arf guanine nucleotide exchange factor) 
(Chantalat et al., 2004) and a region that binds phosphatidylinositol-4-phosphate (PI(4)P) 
(Natarajan et al., 2009). Drs2p flippase activity was virtually abolished in TGN 
membranes isolated from yeast cells deficient in Gea2p and PI(4)P production, and 
addition of Gea2p and PI(4)P to these TGN membranes restored flippase activity 
(Natarajan et al., 2009). Additional evidence from the Lenoir lab sheds light on the role 
that PI(4)P plays in Drs2p regulation. It was found that, in crude membranes, PS 
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inhibited the dephosphorylation of the Drs2p/Cdc50p complex. It was only in the 
presence of PI(4)P, that PS was able to accelerate the dephosphorylation step associated 
with substrate transport (Jacquot et al., 2012). These results suggested that Drs2p is auto-
inhibited by its C-terminal tail in the absence of Gea2p and PI(4)P, both of which are 
positive regulators that stimulate Drs2p activity by binding to its C-terminal R domain. 
In this study, we present evidence that directly supports this hypothesis. 
 
Experimental Procedures 
 
Reagents. IgG Sepharose 6 Fast Flow, calmodulin Sepharose 4B, and ATP (>99% purity) 
were from GE Healthcare.  ATPγS was from Sigma and Ni-NTA agarose was from 
Qiagen. AcTEV protease and SimplyBlue SafeStain (Coomassie G-250) were from 
Invitrogen. Bio-Beads SM-2 was from Bio-Rad, and Triton X-100, polyoxyethylene (9) 
dodecyl ether (C12E9), and polyoxyethylene (8) dodecyl ether (C12E8) were from Anatrace. 
Phospholipids and fluorescent derivatives were from Avanti Polar Lipids and were: 
DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine), DOPS (1,2-dioleoyl-sn-glycero-3-
phospho-L-serine), PI(4)P (L-α-phosphatidylinositol-4-phosphate from porcine brain), 
NBD-PC (1-palmitoyl-2-[6-(NBD-amino)hexanoyl]-sn-glycero-3-phosphocholine), C6 
NBD-PS (1-palmitoyl-2-[6-(NBD-amino)hexanoyl]-sn-glycero-3-phosphoserine), and C12 
NBD-PS (1-palmitoyl-2-[12-(NBD-amino)dodecanoyl]-sn-glycero-3-phosphoserine). 
Lipids were dissolved in chloroform except PI(4)P, which was dissolved in 
chloroform/methanol/water (20:9:1, vol:vol:vol), and stored at -20°C.  Antibodies used 
in this study were rabbit primary antibodies against Drs2p, and an Alexa Fluor 680-
labeled goat secondary antibody against rabbit IgG (Invitrogen). 
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Media and strains. Yeast cells were grown in standard rich medium (1% yeast extract/2% 
peptone/2% dextrose) or synthetic minimal media containing required supplements 
(Sherman, 1991), and nutrients were doubled in cell cultures for protein purification 
purposes. 
 
The yeast strains used were XZY63b (MATα his3 leu2 ura3 lys2 atp2Δ::URA3 PGPD::CDC50 
pRS425-PGPD::TAPN::DRS2), XZY51 (MATα his3 leu2 ura3 lys2 atp2Δ::URA3 PGPD::CDC50 
pRS425-PGPD::DRS2:TAPC), XZY85 (MATα his3 leu2 ura3 lys2 atp2Δ::URA3 PGPD::CDC50 
pRS425-PGPD::TAPN::DRS2::TAPC), XZY94 (MATα his3 leu2 ura3 lys2 PGPD::CDC50 pRS425-
PGPD::DRS2::(TEV)::TAPC2), XZY95 (MATα his3 leu2 ura3 lys2 PGPD::CDC50 pRS425-
PGPD::DRS2(TEV)CT121::(TEV)::TAPC2), XZY96 (MATα his3 leu2 ura3 lys2 PGPD::CDC50 
pRS425-PGPD::DRS2(TEV)CT121::TAPC2), and XZY60m (MATα his3 leu2 ura3 lys2 
atp2Δ::URA3 PGPD::TAPN::DRS2 PGPD::CDC50), where TAPN encodes the protein A-TEV 
protease cleavage site-His10 tag, TAPC encodes the calmodulin binding peptide (CBP)-
TEV protease cleavage site-protein A tag, (TEV) encodes the TEV protease cleavage site, 
TAPC2 encodes the protein A-His10 tag, and DRS2(TEV)CT121 encodes a modified Drs2 
protein that has the TEV protease cleavage site inserted in its C-terminal tail at the 
position that is 121-residue away from the C-terminal end of wild-type Drs2p. 
 
Protein purification. TAP-tagged Drs2p was affinity purified using a TAP procedure 
described previously with some modifications (Zhou & Graham, 2009). Briefly, yeast 
cells were cultured to 3-6 OD600/ml in minimal media or 5-10 OD600/ml in rich media at 
30°C, harvested and lysed using an EmulsiFlex-C3 High Pressure Homogenizer 
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(Avestin). The cell lysate was centrifuged at 15,000 x g for 12 min, and 20% of Triton X-
100, C12E9, or C12E8 was added to the supernatant to a final concentration of 1% to 
solubilize Drs2p. TAP-tagged Drs2p was then purified using an IgG column plus either 
a Ni2+ column (for TAPN and TAPC2) or a calmodulin column (for TAPC). In experiments 
where Drs2p was first purified using the TAPN tag and then different Drs2p populations 
were separated using the TAPC tag, the procedure was a combination of the TAPN 
purification plus the second affinity step (the calmodulin column) of the TAPC 
purification. Experiments where proteins were purified for the purposes of performing 
flippase assays were performed using C12E8 exclusively. 
 
Purified Drs2p samples (except samples to be used in flippase assays) were centrifuged 
in Microcon YM-100 filter (Millipore) at 13,000 x g for 15 min at 4°C to near dryness, and 
resuspended in desired amount of storage buffer (40mM Tris-HCl, pH 7.5, 150mM NaCl, 
40% glycerol, 0.1% Triton X-100) to store at -20°C. Recovery of Drs2p was determined 
using Odyssey Infrared Imaging System (LI-COR) to quantify SimplyBlue-stained bands 
relative to a BSA standard curve.  Recombinant Sec7 domain of Gea2p was purified as 
previously described (Natarajan et al., 2009).  
 
Proteoliposome formation. Purified Drs2p was reconstituted into proteoliposomes as 
previously described with some modifications (Zhou & Graham, 2009). Briefly, 0.5mL of 
single-step affinity purified Drs2p using Ni-NTA column was mixed with 2mg of lipid 
mixture solubilized in 0.5mL of 1% C12E9 for 30 min at 4°C. After addition of 200mg of 
extensively washed SM-2 beads, and 12-15 h of incubation on an end-over-end rotator at 
4°C, the supernatant containing proteoliposomes was carefully removed, stored at 4°C.  
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We found that proteoliposomes formed with Drs2p purified in C12E9 were often too 
“leaky” to use in flippase assays. Membrane seal was significantly improved when 
reconstitutions were performed using C12E8 solubilized protein. Therefore, the following 
changes were made during proteoliposome formation. 2mg of lipids were solubilized in 
a 0.5mL volume that contains 1.5% C12E8 and incubated for 30 min at 4°C. 150mg of 
extensively washed SM2 Bio-beads were then added to this solution and it was 
incubated for 6 h on an end-over-end rotator at 4°C. After this, another 300mg of SM-2 
beads were added and the sample was incubated for a further 12-15 h with end-over-
end rotation. The supernatant containing proteoliposomes was carefully removed and 
stored at 4°C. 
 
Flotation of proteoliposomes. 200μl of the proteoliposome sample was first incubated with 
10mM dithionite, for 5 min at 4°C, to pre-quench the fluorescence in the outer leaflet of 
the proteoliposomes. The sample was, then, mixed with 200μl of 80% glycerol and 
placed at the bottom of a bipartite glycerol step gradient. 600μl of 10% glycerol was laid 
on the top. The samples were centrifuged in a TLS-55 rotor (Beckman Coulter) at 
50,000rpm for 6 h at 4°C, and 200μl, each, of the top two fractions were collected by 
pipetting. These fractions contain pure Drs2p proteoliposomes. 
 
ATPase Assay. Purified Drs2p was assayed for ATPase activity in ATPase buffer (50mM 
Tris-HCl, pH 7.5, 100 mM NaCl, 50 mM KCl, 1 mM NaN3, 0.1% Triton X-100, 4 mM Na+-
ATP, pH 7.5, 10 mM MgCl2) at 37°C for 1 h. For ATPase assays using proteoliposomes, 
detergent was omitted from ATPase buffer. Released phosphate was measured 
colorimetrically using modified protocols previously described (Carter & Karl, 1982; 
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Paterson et al., 2006; Zimmerman & Daleke, 1993). Briefly, the volume of the sample was 
brought to 275μl with deionized water, and the ATPase reaction was stopped by 
addition of 150μl of molybdate solution (2 M HCl/50 mM Na2MoO4) and 75μl of 
malachite green solution (0.042% malachite green in 1% polyvinyl alcohol solution). The 
sample was mixed for 2 min before addition of 500μl of citric acid (7%), and the optical 
density at 660 nm was read at 30 min after addition of the citric acid solution. The 
amount of released phosphate was determined by a phosphate standard curve 
constructed in the same ATPase buffer. 
 
Flippase Assay. Floated proteoliposomes were assayed for flippase activity using 
previously published methods (McIntyre & Sleight, 1991; Zhou & Graham, 2009).  
Briefly, 40μL of floated, Drs2p-containing, proteoliposomes were incubated, at 37°C, 
with 5mM MgCl2 and either 5mM ATP or 5mM ATPγS in a flippase buffer (40 mM Tris-
HCl, pH 7.5, 200mM NaCl). At time 0 min and 40 min, 20μL samples were removed and 
mixed with 1mL of flippase buffer in a cuvette. Baseline fluorescence readings, were 
taken for 30 s, on an AB2 fluorometer (SLM Instruments, Inc.) at λex = 460nm, and λem = 
534nm.  10μL of 1M dithionite (dissolved in 1M Tris, pH 9.4) was then added to the 
sample and fluorescence was recorded for 120 s. Finally, the fluorescence was 
completely quenched by addition of 50μL of 10% Triton X-100 and background 
fluorescence was recorded for 30 s. The percentage of NBD-phospholipid in the outer 
bilayer of each of the proteoliposome samples (both ATP and the ATPγS control, at time 
t = 0 min and 40 min) was calculated using previously described formulae (Zhou & 
Graham, 2009). To calculate the percentage of NBD-phospholipid flipped, the values for 
an ATPγS control were subtracted from the respective ATP activated sample. 
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Western blotting. Western blotting was performed as previously described (C. Y. Chen et 
al., 1999). The primary antibody used was rabbit anti-Drs2p (1:2000). The secondary, 
Alexa Fluor 680-labeled goat anti-rabbit IgG antibody (Invitrogen) was used at 1:2000. 
Western blots were imaged with Odyssey Infrared Imaging System (LI-COR). 
 
Results 
 
Drs2p retains ATPase activity after purification by the N-terminal TAPN tag, but not the C-
terminal TAPC tag. In a previous study, both TAPN-Drs2p and Drs2p-TAPC were 
expressed from chromosome-integrated expression cassettes and affinity purified to 
comparable yields and purities (Zhou & Graham, 2009). Although both TAP-tagged 
Drs2p forms appeared to be functional in vivo, only TAPN-Drs2p retained ATPase 
activity after purification, whereas purified Drs2p-TAPC was inactive. Interestingly, 
purified Drs2p-TAPC did not seem to be aggregated or denatured, suggesting that the 
differing activities between the two Drs2p proteins may have a biologically relevant 
cause (Zhou & Graham, 2009). 
 
To further address this issue and to more easily manipulate Drs2p, the expression 
cassettes for Drs2p were transferred to a multicopy plasmid (pRS425) to produce 
constructs (I) and (II), while the β-subunit Cdc50p was overexpressed using the strong 
GPD promoter integrated into the endogenous chromosomal locus (Fig. 2-1A, B). Both 
TAPN-Drs2p and Drs2p-TAPC were successfully expressed and purified using this 
plasmid system (Fig. 2-1B, C), and they still showed differential levels of ATPase activity, 
as previously observed (Fig. 2-1D). Cdc50p was recovered at low, substoichiometric 
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levels in these preparations and was not visible in the coomassie stained gel. The band 
migrating just above the 28kDa marker is the TEV protease used to elute the tagged 
proteins from an IgG column. 
 
  
 
 
 
 
 
 
 
 
Figure 2-1. TAPN-Drs2p has ATPase activity.  (A) Tagged DRS2 was expressed from a 2⎧ 
plasmid, and CDC50 was from the chromosome.  (B) Schematic of TAPN-Drs2p (I) and 
Drs2p-TAPC (II) was modeled on the crystal structure of SERCA1 in the nucleotide-free 
E12Ca+2 conformation (7). The cytosolic domains are facing upward.  (C) purified TAPN-
Drs2p (I) and Drs2p-TAPC (II) were subjected to SDS-PAGE, and the gel was stained with 
SimplyBlue.  (D) ATPase activity of purified TAPN-Drs2p and Drs2p-TAPC preparations. 
Samples were assayed with or without orthovanadate, and the orthovanadate controls were 
subtracted from the experimental value to obtain the nmol of orthovanadate released. ProA: 
protein A. 
 
ATPase activity is associated with a faster-mobility form of Drs2p in purified samples. The 
major molecular difference between purified TAPN-Drs2p and Drs2p-TAPC is different 
tag appendages (His10 vs. calmodulin binding peptide (CBP)) to different positions of 
Drs2p (N- vs. C-terminus) (Fig. 2-1B).  
To test if different tags at the termini caused varying levels of ATPase activity of 
purified Drs2p, a dual TAP-tagged construct of Drs2p (TAPN-Drs2p-TAPC (III)) was 
 48 
expressed (Fig. 2-2A). Cdc50p was, again, overexpressed using a strong GPD promoter. 
Purification of TAPN-Drs2p-TAPC, using either the TAPN tag or the TAPC tag, yielded 
purified protein levels that were comparable to the previous experiments (Fig. 2-2B). 
Theoretically, both preparations should contain Drs2p of the same molecular 
composition (His10-Drs2p-CBP), which indeed appeared as a single major band on 
Coomassie-stained gels for both preparations (Fig. 2-2B). Surprisingly, however, ATPase 
activity was only detected in samples of TAPN-Drs2p-TAPC purified using the TAPN tag, 
but not the TAPC tag (Fig. 2-2C), indicating some difference between these two 
preparations. Western blots revealed a minor Drs2p band with faster mobility in TAPN-
Drs2p-TAPC samples purified with TAPN tag, but not with TAPC (Fig. 2-2D), suggesting 
a possible link between this faster-mobility band and ATPase activity. 
 
It was possible that the faster-mobility band of Drs2p was a C-terminally cleaved form 
of Drs2p, which had lost some C-terminal sequences along with the TAPC tag during 
purification. This form would not be recovered during purifications using the TAPC-tag 
because the tag was lost. To explore this idea, and better determine the relationship 
between ATPase activity and the faster migrating (or cleaved) Drs2p, TAPN-Drs2p-TAPC 
purified by TAPN ((III)N) was further applied to a calmodulin column. Consistently, the 
unbound fraction was enriched with the faster-mobility form of Drs2p (Fig. 2-3A, “U”), 
whereas the bound fraction was almost devoid of this minor band (Fig. 2-3A, “B”). 
Furthermore, ATPase activity was significantly higher in the unbound fraction (U) and 
much lower in the bound fraction (B) (Fig. 2-3B). The simplest explanation for these data 
is that a C-terminally cleaved, faster migrating Drs2p is primarily responsible for the 
ATPase activity observed in N-terminally purified Drs2p samples. 
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Figure 2-2. Differential activity of TAPN-Drs2-TAPC purified with either the N-terminal or C-
terminal tag.  (A) Schematic of TAPN-Drs2p-TAPC modeled on the SERCA1 crystal structure.  
(B) Purified TAPN-Drs2p-TAPC samples from strain XZY85 (atp2Δ) using the TAPN tag (lane 
1, (III)N) or TAPC tag (lane 2, (III)C) were subject to SDS-PAGE and the gel was stained with 
SimplyBlue.  (C) ATPase activity of purified TAPN-Drs2p-TAPC preparations.  (D) Samples 
from (B) were electrotransferred to polyvinylidene difluoride (PVDF) membrane for western 
blotting using Drs2 antibodies. The upper arrowhead indicates the intact TAPN-Drs2p-TAPC 
form and the lower arrowhead indicates a minor band with faster mobility. Another faint 
band migrated below the two arrowheads, but was unlikely to contribute significantly to the 
ATPase activity. ProA: protein A. 
 
Removal of Drs2p C-terminal tail stimulates Drs2p ATPase activity. To directly test if 
proteolytic cleavage within the C-terminal tail could stimulate Drs2p activity, the 
expression cassette was modified so that the C-terminal tail of Drs2p was either retained 
or removed during purification (Fig. 2-4A, B). To do so, Drs2p was first tagged at C- 
terminus by the TAPC2 tag, which lacks the TEV protease cleavage site. Then, the TEV 
site was inserted immediately after the C-terminus of Drs2p (Drs2p(TEV)-TAPC2, (IV)), or 
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Figure 2-3. Drs2p ATPase activity associates with the faster mobility form. (A) Purified 
TAPN-Drs2p-TAPC before separation (lane III (N)), the unbound fraction from the 
calmodulin column (lane U), and the bound and eluted fraction (lane B) were subjected to 
SDS-PAGE and western blotting with anti-Drs2p. The upper arrowhead indicates the intact 
TAPN-Drs2p-TAPC form and the lower arrowhead indicates the faster mobility form. (B) 
ATPase activity was assayed with purified TAPN-Drs2p-TAPC before separation and the two 
fractions after separation.  
 
within the C-terminus of Drs2p (Drs2p(TEV)CT121-TAPC2, (VI)), close to the C-terminal 
end of transmembrane segment 10. Cleavage, at the latter TEV site, removes 121 
residues from the predicted 137 amino acid long C-terminal tail of Drs2p. An 
intermediate construct that contains both TEV sites was also constructed for analysis 
(Drs2p(TEV)CT121(TEV)-TAPC2, (V)). After purification using TAPC2 and final release by 
TEV cleavage, Drs2p was found to migrate at expected sizes with either full-length or 
almost no C-terminal tail (Fig. 2-4B). TEV cleavage within the tail was inefficient, as 
indicated by the doublet in the samples for (V) and the low recovery of the faster 
migrating form of Drs2p in both the (V) and (VI) preparations.   
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Figure 2-4. Proteolytic removal of the C-terminal tail stimulates Drs2p activity.  (A) 
Schematic of three forms of Drs2p with TEV cleavage sites at different locations in the C-
terminal tail. (IV) has a TEV cleavage site between the tail and the TAPC tag, (V) has two 
TEV cleavage sites – the first is between transmembrane segment 10 and the C-terminal tail, 
and the second is between the C-terminal tail and the TAPC tag, and (VI) has a TEV cleavage 
site between transmembrane segment 10 and the C-terminal tail.  (B) These three variants 
were purified and the samples were applied to an SDS-PAGE gel and stained with 
SimplyBlue. Because of the poor recovery of (VI), the TEV protease near the 28kDa marker is 
overrepresented in this sample.  (C) ATPase activity of (IV), (V) and (VI). 
 
Unlike Drs2p-TAPC (Fig. 2-1D, (II)), purified Drs2p(TEV)-TAPC2 (IV) displayed low, basal 
ATPase activity (Fig. 2-4C, (IV)), indicating that the CBP moiety of TAPC inhibited Drs2p. 
More importantly, Drs2p(TEV)CT121-TAPC2 (VI), which has lost the majority of its C-
terminal tail, exhibited an approximately 3.5-fold higher specific activity than that of 
Drs2p with an intact C-terminal tail (Fig. 2-4C, (IV) vs. (VI)). Consistently, the 
 52 
Drs2p(TEV)CT121(TEV)-TAPC2 (V) preparation, containing a mixture of intact and CT121-
cleaved forms, showed an intermediate ATPase specific activity (Fig. 2-4C, (V)). We 
conclude that the C-terminal tail of Drs2p contains an auto-inhibitory domain, and 
removal of the C-terminal tail activates Drs2p. 
 
To investigate whether the faster migrating (clipped) form of Drs2p was detectable in 
vivo, whole cell extracts were prepared and a Western blot was performed (Fig. 2-5). A 
wild-type strain was grown under a variety of conditions (low or high temperature, rich 
or minimal media) to determine if cleavage events would occur physiologically. Drs2p 
mobility was also examined in a strain lacking three other P4-ATPases (dnf1,2,3Δ), which 
along with DRS2 constitutes an essential group of genes with overlapping function.  We 
thought that deleting three of the four members of this group might cause the cells to 
express a more active form of Drs2p (possibly a cleaved form). However, in all 
conditions tested, Drs2p migrated slightly slower than the 160kDa marker. We could not 
detect a form that migrated slightly faster than the 160kDa marker at the same position 
of purified tail-less Drs2p, even after overexposing the blot (Fig. 2-5). A minor band was 
detected that migrated at ~130kDa (asterisk in Fig. 2-5), which could represent a 
proteolyzed form although the functional significance of this form is uncertain. While 
we cannot rule out the possibility that Drs2p activity can be activated physiologically by 
proteolytic cleavage, we suspect this cleavage event only occurs after the cells are lysed. 
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Figure 
2-5. The proteolyzed form of Drs2p is not readily detected in cells. A Western blot was 
performed with whole cell extracts (1 A600 of cells) from wild-type strain (BY4742) grown in 
minimal media at 30°C, rich media at 15°C, rich media at 30°C, and rich media at 37°C.  
dnf1,2,3Δ and drs2Δ whole cell extracts were also blotted, as well as aliquots (in increasing 
concentrations) of purified tail-less Drs2p (Fig. 4, (VI)). A band that migrates faster than the 
tail-less form of Drs2p is marked with an asterisk. The membrane was blotted with α-Drs2p. 
WT: wild-type. 
 
PS stimulates and PI(4)P activates Drs2p activity.  Following observations made previously, 
we decided to determine the effect that increasing levels of PS had on the ATPase 
activity of Drs2p. Phosphatidylserine is the preferred substrate of ATPase II/ATP8a1, 
which has 67% amino acid sequence similarity to Drs2p (Tang et al., 1996). PS strongly 
stimulates the ATPase activity of Atp8a1 and Atp8a2 in detergent micelles or when 
reconstituted into phospholipid bilayers (Coleman et al., 2009; Ding et al., 2000; Paterson 
et al., 2006). In contrast, when assayed in detergent micelles, the ATPase activity of 
Drs2p is weakly stimulated by PS (by ~20%) (Zhou & Graham, 2009). However, TAPN-
Drs2 displayed approximately 3-fold higher specific activity when reconstituted into PC 
liposomes containing 20% PS compared to PC liposomes (Fig. 2-6A).  Both basal and 
substrate stimulated activities were inhibited by vanadate as expected.  Thus, substrate 
seems to stimulate Drs2p ATPase activity more effectively when presented in a 
phospholipid bilayer.  
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Figure 2-6. Phosphatidylserine and Phosphatidylinositol-4-phosphate stimulates ATPase 
activity of Drs2p. (A) Purified TAPN-Drs2p was reconstituted into proteoliposomes 
containing either 100 mol% DOPC, 99 mol% DOPC with 1 mol% DOPS, or 80 mol% DOPC 
with 20 mol% DOPS.  These proteoliposomes were assayed for ATPase activity either in the 
presence or absence of 100μM orthovanadate.  (B) TAPN-Drs2p was reconstituted into 
proteoliposomes comprised of a DOPC backbone with 1 mol% DOPS in the presence or 
absence of 1 mol% PI(4)P.  For each of these proteoliposome samples, ATPase activity was 
measured in the presence or absence of Gea2p (Sec7 domain) at a ratio of ~1:20 mol:mol 
Drs2p:Gea2p. The proteoliposomes were incubated with Gea2p for 15 min on ice before 
assaying for activity. DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPS, 1,2-dioleoyl-
sn-glycero-3-phospho-L-serine. 
 
Natarajan and colleagues have demonstrated that, in isolated Golgi membranes, Drs2p 
flippase activity is positively regulated by PI(4)P and Gea2p (Sec7 domain), both of 
which were shown to bind the C-terminal tail of Drs2p (Natarajan et al., 2009). These 
observations suggest that PI(4)P and Gea2p regulate Drs2p activity by directly binding 
its C-terminal tail. Alternatively, they may act indirectly through other factors that were 
present in the membrane samples. To distinguish these two possibilities, we tested 
whether PI(4)P and/or Gea2p could stimulate the ATPase activity of purified Drs2p 
reconstituted in proteoliposomes (also containing 2.5% C6 NBD-PS). PI(4)P was added 
at 1 mol% during proteoliposome formation and Gea2p (recombinant Sec7 domain at a 
Drs2p:Gea2p ratio of ~ 1:20, mol:mol) was added directly to proteoliposomes containing 
TAPN-Drs2p. However, while addition of PI(4)P enhanced the ATPase activity of Drs2p, 
Gea2p had no effect on overall ATPase activity (Fig. 2-6B). Furthermore, the presence of 
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both PI(4)P and Gea2p, did not improve the ATPase activity over the levels observed by 
PI(4)P alone. These data suggest that PI(4)P is directly influencing Drs2p activity, while 
the Gea2p Sec7 domain alone is insufficient for Drs2 activation (see Discussion).  
 
To further examine the influence of PI(4)P on Drs2p activity, TAPN-Drs2p was 
reconstituted into POPC proteoliposomes containing NBD-PS and 0%, 1%, 2.5% or 5% 
PI(4)P.  Stimulation of ATPase activity was observed at all concentrations of PI(4)P with 
a peak at 2.5% (Fig. 2-7A). Phospholipid translocase activity was also measured in 
proteoliposomes containing TAPN-Drs2p using a dithionite quenching assay to monitor 
ATP-dependent translocation of NBD-PS from the inner leaflet to the outer leaflet.  In 
this case, the amount of NBD-PS flipped by TAPN-Drs2p also increased with increasing 
concentrations of PI(4)P (Fig. 2-7B). Proteoliposomes containing 5% PI(4)P did not form 
a tight seal to dithionite and were, therefore, not assayed.  While PI(4)P appeared to 
stimulate TAPN-Drs2p flippase activity, there was substantial variability between 
replicates leading to a large standard deviation for each data set. 
 
We hypothesized that the variability in translocase activity with TAPN-Drs2p likely 
arose from differing extents of C-terminal tail proteolysis in each preparation of enzyme. 
For instance, the proteoliposomes may have either the full-length form of TAPN-Drs2p, 
the clipped form or a mixture of the two forms, which could lead to variability in the 
activity observed. One of the Drs2p preparations used in the assays shown in Figure 2-
7A and 2-7B clearly displayed the full-length and clipped forms (Fig 2-7A, inset).  
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Figure 2-7. PI(4)P directly stimulates Drs2p ATPase and NBD-PS flippase activity. TAPN-
Drs2p (I) was reconstituted into proteoliposomes comprised of a DOPC backbone with 
2.5mol% C12 NBD-PS and the indicated amount of PI(4)P. (A) ATPase activity of TAPN-
Drs2p (I) after subtracting the orthovanadate controls.  A coomassie stained sample of 
purified TAPN-Drs2p shows a faster migrating band, which is possibly the proteolyzed form 
of Drs2p (inset). (B) Drs2p proteoliposomes were assayed for NBD-PS flippase activity.  The 
data are averages from 14 experiments +/- s.d.  (C) Drs2p(TEV)-TAPC2 (Fig. 4 (IV)) was 
purified and reconstituted into proteoliposomes containing DOPC, 2.5mol% C12 NBD-PS 
and 2.5mol% PI(4)P, PI(3)P, PI(5)P or PI(4,5)P2.  The sample marked “-” contains no 
phosphoinositide. (D) Drs2p(TEV)-TAPC2 (IV) was purified, reconstituted and assayed for 
ATPase activity and (E) NBD-PS flippase activity (n=3 independent experiments).  (F) 
Drs2p(TEV)CT121-TAPC2 (Fig. 4, (VI)) was purified, reconstituted and assayed for NBD-PS 
flippase activity (n=3 independent experiments). * p<0.05, ** p<0.01, *** p<0.0001. 
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To overcome this limitation, Drs2p(TEV)-TAPC2 (Fig. 2-4, (IV)), which yields a full-length 
form of Drs2p with an intact C-terminal tail, was purified and reconstituted into 
proteoliposomes in the presence or absence of 2.5mol% PI(4)P.  The ATPase activity of 
the full-length Drs2p was stimulated almost 6-fold in the presence of PI(4)P (Fig. 2-7D). 
The NBD-PS flippase activity was similarly enhanced by PI(4)P (Fig. 2-7E).  Accordingly, 
the variation in flippase activity that was observed with TAPN-Drs2p was no longer 
observed with the full-length form of Drs2p. Furthermore, Drs2p(TEV)CT121-TAPC2 (Fig. 
2-4, (VI)) was purified and reconstituted into proteoliposomes. These samples, when 
assayed for flippase activity, were found to be slightly more active in the absence of 
PI(4)P, as they were in proteoliposomes that contained 2.5% PI(4)P (Fig. 2-7F). Thus, tail-
less Drs2 is no longer responsive to PI(4)P and these data are consistent with the 
proposed model that PI(4)P activates Drs2p through direct interaction with the Drs2p C-
terminal tail.  
 
To determine if the C-terminal tail of Drs2p has a preference for a specific 
phosphoinositide, we purified the full-length Drs2p (Fig. 2-4, (IV)) and reconstituted it 
into PC/PS proteoliposomes containing different phosphoinositides. The 
proteoliposomes contained either no phosphoinositides, or 2.5mol% of PI(4)P, PI(3)P, 
PI(5)P or PI(4,5)P2. PI(4)P significantly stimulated the flippase activity of Drs2p 
compared to the other phosphoinositides (Fig. 2-7C). Thus, PI(4)P preferentially interacts 
with the C-terminal tail of Drs2p to stimulate Drs2p activity. 
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Discussion 
 
A model for Drs2p C-terminal tail auto-inhibition and regulation. When this study and 
published data are taken together, a model for the regulation of Drs2p can be proposed. 
Drs2p has a C-terminal cytosolic tail predicted to be 137 amino acids long. The tail likely 
contains an auto-inhibitory domain (an R domain) that keeps Drs2p activity at a low, 
basal level within membranes that lack PI(4)P (e.g. the ER and early Golgi). Upon arrival 
in the TGN, Drs2p would be activated by the high levels of PI(4)P in this compartment. 
We show that the TAPN-Drs2p samples, purified with the N-terminal tag, and which 
contain a faster-migrating, clipped form of Drs2p, has a higher level of ATPase activity 
when compared to preparations of Drs2p-TAPC, which lacks the cleaved form of Drs2p. 
Thus, it appears that a cleavage event within the C-terminal tail of Drs2p enhances 
activity of TAPN-Drs2p. A Western blot of whole cell extracts of wild-type strains 
(grown under various conditions) and mutant strains did not show substantial cleavage 
of Drs2p. The cleavage event observed in the purified protein samples most likely occurs 
after cell lysis and there is no indication that proteolysis is a physiologically relevant 
mechanism for activating Drs2p. 
 
Furthermore, when Drs2p is purified with the full-length tail intact, the ATPase activity 
levels of Drs2p are quite low – but still detectable (Fig. 2-4C, (IV)). Reconstituted full-
length Drs2p also has low levels of flippase activity (Fig. 2-7D, 0% PI(4)P).  However, 
once the tail is cleaved off during purification using an engineered TEV site, we observe 
a significant increase in Drs2p specific activity (Fig. 2-4C, (VI)). Therefore, removal of the 
C-terminal tail stimulates activity. As in the case of the other P-type ATPases, the R 
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domain (as described in the introduction) had the ability to self-regulate the activity of 
the P-type ATPase.  Relieving the interaction between the R domain and the P-type 
ATPase stimulated the activity of the protein (Carafoli, 1994; Palmgren, 2001; Portillo, 
2000; Sze et al., 2000). This study, similarly, provides direct evidence for a role of the C-
terminal tail (and an R domain) in regulating the activity of Drs2p. 
 
The role of effectors in regulating the activity of Drs2p. In purified TGN membranes, it has 
been shown that the addition of Gea2p (Sec7 domain) stimulates the phospholipid 
translocase activity of Drs2p (Natarajan et al., 2009). Furthermore, the addition of both 
PI(4)P and Gea2p to the samples, stimulated the flippase activity of Drs2p to greater 
levels than either of them did individually. In this study, we attempted to recapitulate 
these observations in the reconstituted system. And, while addition of PI(4)P to Drs2p-
proteoliposomes activated the P4-ATPase (Fig. 2-6B, Fig. 2-7), the Gea2p Sec7 domain 
had little effect on the specific activity of Drs2p, even when added in concert with PI(4)P 
(Fig. 2-6B).  
 
During the course of our studies, work published recently from the lab of Fang-Jen Lee 
provides a likely explanation for these observations (Tsai, Hsu, Liu, Chen, & Lee, 2013). 
Arl1p (Arf-like protein 1) is a member of the small GTP-binding protein family that 
cycles, like Arf, between active GTP-bound and inactive GDP-bound forms. Like Drs2p, 
Arl1p also localizes to the TGN in yeast (Peyroche, Courbeyrette, Rambourg, & Jackson, 
2001; Peyroche, Paris, & Jackson, 1996). The Lee group was able to show that all three 
proteins – Drs2p, Gea2p, and Arl1p – form a stable ternary complex through direct 
interactions with each other. This complex is important for stimulating the flippase 
 60 
activity of Drs2p at the Golgi. Furthermore, Arl1p function at the Golgi also requires this 
complex. To our reconstituted system, we added the recombinantly purified Sec7 
domain of Gea2p. However, it is the N-terminal portion of Gea2p (upstream of the Sec7 
domain) that is responsible for interacting with Arl1p (Tsai et al.). Additionally, Arl1p 
was absent from our reconstituted reactions. However, in purified Golgi membranes, it 
is likely that Arl1p-GTP co-purifies with the membrane (Natarajan et al., 2009). As a 
result, in the presence of Gea2p, the activity of Drs2p was stimulated. Our data imply 
that the interaction of Gea2p Sec7 domain is insufficient to activate Drs2p when Arl1p-
GTP is absent. More work will be needed to determine the temporal and spatial 
organization of these various effectors and regulators during the formation of transport 
vesicles at the Golgi. 
 
While a previous study was able to show that PI(4)P stimulates the flippase activity of 
Drs2p in purified Golgi membranes (Natarajan et al., 2009), this study provides the first 
evidence, in a reconstituted system, that PI(4)P directly regulates the activity of Drs2p. 
When the full-length form of Drs2p (Fig. 2-4, (IV)), is reconstituted, PI(4)P is able to 
stimulate a 6-fold increase in the ATPase and flippase activities (Fig. 2-7D, 2-7E). In 
contrast, tail-less Drs2p (Fig. 2-4, (VI)) does not display a difference in lipid translocase 
activity when reconstituted in the presence or absence of PI(4)P (Fig. 2-7F).  
 
The step at which PI(4)P exerts its influence seems to be the dephosphorylation step of 
the Drs2p catalytic cycle (Jacquot et al., 2012). P4-ATPases do not require the presence of 
substrate for phosphorylation (E1 to E2-P), although for the mammalian orthologs of 
Drs2p, ATP8A1 and ATP8A2, the PS substrate potently stimulates dephosphorylation 
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(E2-P to E1) (Coleman, Vestergaard, Molday, Vilsen, & Andersen, 2012; Ding et al., 2000). 
In contrast, PS slows down the ability of Drs2p to undergo dephosphorylation, whereas 
addition of PI(4)P to the reaction strongly accelerates this step. Addition of PI(4)P in the 
absence of PS, meanwhile, only had a small effect on dephosphorylation (Jacquot et al., 
2012). So, the major role that PI(4)P plays is at the dephosphorylation step – the point at 
which the phospholipid substrate has been loaded into the flippase, presumably at a site 
we described as the exit gate formed from residues in the first four transmembrane 
segments (Baldridge & Graham, 2012; Baldridge & Graham, 2013; Baldridge, Xu, & 
Graham, 2013). Displacement of the C-terminal R domain by interaction with PI(4)P 
would then allow dephosphorylation and ejection of substrate into the cytosolic leaflet. 
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CHAPTER III 
 
INFLUENCE OF Drs2p FLIPPASE ACTIVITY ON MEMBRANE MORPHOLOGY 
 
Introduction 
 
 
As described in Chapter I, we hypothesized that the flippase activity of Drs2p plays a 
part in bending the membrane during transport vesicle formation.  The reason is that the 
flipping of phospholipids across membrane leaflets causes an increase in the number of 
phospholipids on one leaflet compared to the other. This increase in phospholipid 
number results in the expansion of the surface area of the leaflet. In response to this 
expansion, the other leaflet contracts because both leaflets are coupled. In this chapter, I 
outline experiments and assays designed to determine what role is played by Drs2p in 
the creation of membrane curvature.  
 
The initial strategy was to purify TGN membranes containing either a wild-type copy of 
Drs2p or a temperature sensitive form of Drs2p, and determine if activating Drs2p 
flippase activity with the addition of ATP induces any morphological change in the 
isolated membranes.  The second approach was to purify Drs2p, reconstitute this protein 
in giant unilamellar vesicles (GUVs) and test whether activation of Drs2p would induce 
shape changes in the membrane.  
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Influence of Drs2p Activity on the Morphology of Purified Golgi Membranes 
 
Our lab has been able to show that, in the absence of Drs2p, there is no AP-1/CCV 
function even though the coat is recruited to the TGN. We believe that Drs2p contributes 
to membrane curvature based on the bilayer-couple hypothesis proposed by Sheetz and 
Singer (Sheetz & Singer, 1974). Drs2p, we hypothesize, catalyzes flipping of 
phospholipids from one leaflet to the other, expands the outer leaflet causing membrane 
bending since the two leaflets are coupled. This curvature is captured by curvature-
sensing proteins that are able to recruit AP-1 and clathrin onto the membrane (Graham 
& Kozlov, 2010). In this section, I put forth experiments to test the role of Drs2p on 
membrane curvature and its influence in vesicle budding using purified Golgi 
membranes.  
 
Results and Discussion 
 
A former graduate student, Zhaolin Hua, created yeast strains that are deficient in four 
of the five yeast P4–ATPases (Natarajan et al., 2004). These four flippases, Drs2p, Dnf1p, 
Dnf2p and Dnf3p, form a group of essential genes since deletion of this group of genes is 
fatal to the cell (Hua et al., 2002). The strains created were kept alive with either a wild–
type or temperature–sensitive copy of DRS2 on a plasmid (DRS2 or drs2-ts). These 
strains are designated ZHY409 (drs2Δ dnf1Δ dnf2Δ dnf3Δ pRS313 DRS2) and ZHY410–3A 
(drs2Δ dnf1Δ dnf2Δ dnf3Δ pRS313 drs2–31). The advantage of using these strains, for my 
experiments, is that drs2-ts can be inactivated by temperature shift of purified Golgi 
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membranes (Natarajan et al., 2004). Thus, we can determine if any ATP-induced changes 
in membrane morphology is due to Drs2p activity.  
 
To purify trans-Golgi membranes, fractions were prepared by differential centrifugation 
and sucrose gradient fractionation as described in Natarajan and Graham (Natarajan & 
Graham, 2006). The sucrose gradient fractionation step allows for the separation of early 
Golgi membranes (cis–Golgi) from the late Golgi membranes (trans–Golgi network). The 
various fractions containing these membranes are distinguished by the amount of Kex2p 
activity present. Kex2p is normally found on the late Golgi membranes and Drs2p co–
fractionates with this protein.  High values for Kex2p activity in the colorimetric Kex2 
assay allows the determination of fractions concentrated in TGN membranes (Natarajan 
& Graham, 2006). The Bicinchoninic Acid Assay Kit (BCA Kit: a colorimetric assay) was 
used to determine the concentration of protein present in the TGN membrane 
preparations. 
 
The strains ZHY409 (DRS2) and ZHY410–3A (drs2-ts) were grown in 2L of YPD at 27°C 
(permissive temperature) to an OD600 value of approximately 0.4–0.45 OD600/mL. Half of 
each of the cultures (1L) were then shifted for one hour to 37°C which is a non–
permissive temperature for the drs2-ts strain. This shift should abrogate Drs2p protein 
function in the drs2-ts cells. The other half of the culture was maintained at 27°C for an 
hour. The cells were then harvested and the Golgi membranes were isolated as 
described.  Late Golgi membrane fractions were identified using the Kex2 Assay and 
these membranes were used for further study. 
 65 
The morphology of purified late Golgi membranes was first studied by using negative 
stain EM (Fig. 3-1 A and B).  The population of membranes were very heterogenous in 
size and the average diameter of the membranes ranged from 65 – 100nm, with 
membranes as large as 500nm, and as small as 30nm. This observation held true for 
Golgi membranes from both DRS2 and drs2-ts, harvested from cells grown at 27°C (Fig. 
3-1A), as well as from cells shifted to 37°C (Fig. 3-1B). Most of these are assumed to be 
Golgi membranes although some may be small transport vesicles or early endosomal 
membranes. The average diameters of the membranes is presented in Fig. 3-1C. The 
protein composition of the Golgi membrane preps was compared to whole cell lysates of 
each of the strains by running them on SDS–PAGE and immunoblotting (Fig. 3-1D). 
Analysis of the membranes by Western blot showed that they were enriched for Drs2p 
compared to the whole cell extract samples. There was no obvious difference in the 
amounts of Drs2p detected in Golgi membranes from either of the two strains tested and 
at either of the temperatures tested.  Arf and Clathrin, meanwhile, were depleted in the 
late Golgi membranes compared to the whole cell extracts. Work done by other 
members of the lab have suggested that these membranes also lack detectable AP–1. 
 
The goal for these experiments was to observe whether late Golgi membranes would 
vesiculate or tubulate, in the presence of ATP, due to the flippase activity of Drs2p. The 
large variation in the membrane size would hinder analysis of this reaction. Furthermore, 
DRS2 and drs2-ts are very slow-growing strains and have other defects due to the loss of 
three of the four flippases in the essential gene family (Fig. 3-3A). To determine if the 
heterogeneity in membrane size was due to defects in the strains, I purified late Golgi 
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Figure 3-1.  Morphology and protein composition of TGN membranes purified from DRS2 
and drs2-ts. (A) Negative EM images of TGN membranes from DRS2 and drs2-ts, grown at 
27°C.  (B) Negative EM images of TGN membranes from DRS2 and drs2-ts, grown at 27°C 
then shifted to 37°C for 1 hour prior to harvesting. Scale bar: 100nm.  (C) Average diameter 
of the membranes imaged in (A) and (B). n > 200 membranes.  (D) Western blots for DRS2 
and drs2-ts TGN membranes (grown either at 27°C, or 27°C + 37°C for 1 hour) blotted for the 
presence of Drs2p, Arf1p, and clathrin heavy chain (CHC1). WCE: whole cell extract. GP: 
TGN membrane prep. 
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membranes from a wild-type strain (BY4742) and a kes1∆ strain. Kes1 is an oxysterol 
binding protein homolog in yeast and is a negative regulator of vesicle budding at the 
Golgi. The advantage of using a kes1∆ strain is that Drs2p-dependent phosphatidylserine 
flippase activity is hyperactive in kes1∆ TGN membranes (Muthusamy, Raychaudhuri, et 
al., 2009). 
 
When the late Golgi membranes from the WT and kes1∆ strains were imaged by negative 
stain EM, I observed more larger membranes (80-200nm) and considerably fewer small 
membranes (<50nm) in the preps (Fig. 3-2A).  Consequently, there was an increase in the 
average diameter of the membrane (around 150nm) (Fig. 3-2B).   The presence of more, 
larger membranes will make it easier to distinguish tubulation and vesiculation of the 
membranes in the future experiments.  Analysis of the membranes by Western blots 
showed that Drs2p, in the Golgi preps, was enriched compared to the whole cell extracts, 
while the (mostly) cytosolic proteins, Arf, Clathrin and Swa2p (or auxilin), were 
depleted in these samples (Fig. 3-2C). 
 
One interesting observation was that, on the Western blots, the Drs2p band migrated 
about 10kDa faster in the Golgi membrane preps than in the whole cell extract samples 
(Fig. 3-3B). Two possible reasons for this migration pattern are that: (a) Drs2p is getting 
cleaved during the membrane purification process, or (b) native Drs2p, at the late Golgi 
membrane, could be present in a cleaved form.  Although the following information was 
not known at the time these experiments were performed, as discussed in Chapter 2 of 
this thesis, cleaving the C-terminal tail of Drs2p, removes self-regulation and increases  
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Figure 3-2.  Morphology and protein composition of TGN membranes purified from wild-
type (WT) and kes1∆. (A) Negative EM images of TGN membranes from wild-type and kes1∆, 
grown at 27°C. Scale bar: 100nm.  (B) Average diameter of the membranes imaged in (A). n 
> 200 membranes.  (C) Western blots for wild-type and kes1∆ TGN membranes (grown at 
27°C) blotted for the presence of Drs2p, Arf1p, clathrin heavy chain (CHC1), and Swa2p 
(auxilin). For each sample, the well on the right represents half the amount of sample loaded 
in the left well. WCE: whole cell extract. GP: TGN membrane prep. 
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its activity (Zhou et al., 2013).  It is possible that Drs2p might be present in a more active 
form at the late Golgi; hence its presence, in purified late Golgi membranes, in the 
clipped form. Another possibility is that Drs2p is partially proteolyzed during the 
purification of the TGN membranes.  The initial sample (WCE) had very little, if any, of 
the faster-mobility form of Drs2p, which appeared after the purification of the TGN 
membranes.  Thus, proteolysis appears to occur during purification. In Fig. 3-3A, the 
relative growth rates of the strains used for these experiments is examined.  Serial 
dilutions were done of wild-type (WT), DRS2 (ZHY409), drs2-ts (ZHY410-3A), kes1∆, and 
drs2∆ (which was used as a control). DRS2 and drs2-ts are slow growing strains at all the 
temperatures tested, and drs2-ts is unable to grow at 37°C (which is non-permissive for 
the temperature sensitive strain, drs2-ts). DRS2 is also extremely slow-growing at 37°C. 
 
To test the influence that addition of ATP would have on the morphology of these Golgi 
membranes, each of the four strains were incubated with an ATP regeneration system at 
37°C. Samples were taken at 0 min and 15 min respectively and imaged by negative 
stain EM. The wild-type membranes, when imaged, exhibited both elongation and 
tubulation (Fig. 3-4A). When membranes were counted (n ~ 500), 8 times as many 
membranes exhibited tubulation, while 2 times as many membranes showed elongation, 
after 15min ATP incubation (compared with the 0min, +ATP control). In total, 
approximately 7% of WT membranes exhibited tubulation or elongation 15min after 
incubation with ATP, compared to 2.2% of the 0min (+ATP) control and 1.7% of the –
ATP (15 min) control (For table, see Fig. 3-4B).   
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Figure 3-3.  Growth rate of strains and cleavage of Drs2p in TGN preps. (A) Serial dilutions 
to determine the relative growth rate of the various strains used for TGN membrane preps 
at 27°C, 30°C, and 37°C. The plates were grown for 3 days.  (B) Western blot showing the 
difference in migration between Drs2p in whole cell extracts versus Golgi preps. WCE: 
whole cell extract. GP: TGN membrane prep. 
  
To examine whether ATP would have a similar effect on kes1∆ membranes or the 
quadruple mutant (DRS2 or drs2-ts; both grown at 27°C) membranes, the above 
experiment was repeated with samples of each of the respective membranes (Fig. 3-4 C-
E). When these membranes were imaged, tubulation or elongation of the membranes 
was not as easily detectable as with the WT membranes. However, another phenotype is 
evident between the +ATP, 15min sample and the –ATP, 15min control samples.  In 
kes1∆ and DRS2, the number of small membranes present in the +ATP sample (Fig. 3-4C 
and D, left panels) was significantly decreased compared to the control samples (Fig. 3-
4C and D, right panels). In the drs2-ts samples, however, the difference is not quite so 
stark. These membranes were grown at 27°C and should have active Drs2p. It would be 
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expected that when drs2-ts is incubated with ATP at 37°C, Drs2p should be inactivated 
and there should be no significant difference between +ATP (15min) and the control 
samples. When the experimental and control images are compared, this seems to be the 
case (Fig. 3-4E). However, ATP incubation is done at 37°C and it is possible that the 
short amount of time between ATP addition and the temperature of the sample reaching 
37°C might have caused a small amount of fusion of the membranes to occur. This is a 
possible explanation why there is a slight decrease in the number of small membranes in 
the +ATP drs2-ts samples compared to the control.  However, the change is not quite as 
drastic when it is compared to the +ATP samples of kes1∆ and DRS2.  
 
Another observation is that the number of large membranes in the population (in kes1∆ 
and DRS2, +ATP samples) increases after ATP incubation. From the images obtained, it 
appears that incubation of the membranes with ATP is causing membrane fusion. Re-
examining the WT membranes shows this to be true in that case as well – you can clearly 
see that there are more small membranes in the –ATP, 15min (Fig. 3-4A, lower panels) 
when compared to the +ATP sample. Thus, it seems that ATP incubation is causing 
membrane fusion and the elongation and/or tubulation that was being detected in the 
WT membranes may be the fusion of smaller membranes to form larger membranes.  
 
Another goal of this project was to define the influence that Drs2p activity had on 
clathrin-coated vesicle budding. Previous work from our lab has shown that AP-
1/Clathrin function is lost in drs2∆ cells, even though the coat is recruited to the TGN 
(Liu et al., 2008). One of the hypotheses presented in this chapter proposes that the  
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Figure 3-4.  Influence of ATP addition on late Golgi membranes. (A) Wild-type membranes 
were incubated in the presence or absence of an ATP regeneration system for 15min, at 37°C, 
and imaged by negative stain EM.  (B) Table showing the amount of elongation or 
tubulation observed in the wild-type samples at 0min and 15min, +/- ATP regeneration 
system.  (C) Negative EM of kes1∆ TGN membranes after incubation +/- ATP at 15min.  (D) 
Negative EM of DRS2 TGN membranes after incubation +/- ATP at 15min.  (E) Negative 
EM of drs2-ts TGN membranes after incubation +/- ATP at 15min. Membranes in (C) – (E) 
were harvested from strains grown at 27°C. Scale bar: 500nm. 
 
flippase activity of Drs2p generates membrane curvature and allows for the formation of 
clathrin-coated vesicles at the TGN (Liu et al., 2008). To this end, the goal was to 
establish a system where the Golgi membranes would provide Drs2p, while the cytosol 
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fraction would provide the factors (such as Arf, AP-1 and clathrin) needed for creating 
clathrin-coated vesicles. 
 
As observed in the Western blots, Golgi membrane preps lack many of the cytosolic 
proteins, such as AP-1 and clathrin, that are needed to make clathrin-coated vesicles (Fig. 
3-1D, Fig. 3-2C). Cytosol was purified from wild-type cells using a differential 
centrifugation approach (Vida, Graham, & Emr, 1990). Basically, cells were lysed and 
subjected to centrifugation at extremely high speeds to pellet most of the membranes 
and vesicles. The concentration of protein in the remaining supernatant, considered the 
cytosol, was determined by BCA Assay. When this cytosolic prep was imaged (Fig 3-5A, 
3mg/mL protein concentration), a lot of small structures, that resembled small 
“membranes” or “vesicles” similar to ones observed in late Golgi membrane preps, were 
observed. A Western blot of the cytosol preps showed that Drs2p was detectable in the 
prep (Fig. 3-5B); this suggested that vesicles were present in these preps, and these small 
vesicles did not pellet with the larger membranes during preparation of the cytosol. The 
presence of Drs2p in the cytosol proved problematic since I wanted the activity that was 
detected to come from, and be due to, the Drs2p present in the late Golgi membranes 
(especially when considering that the Drs2p present in drs2-ts was a mutant temperature 
sensitive form, and drs2-ts is an important strain in these experiments).  Furthermore, it 
is unclear how much AP-1 and clathrin is associated with these vesicles which would 
hinder the development of the in-vitro assay for the reconstitution of clathrin-coated 
vesicle budding. 
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Figure 3-5.  Purification and composition of cytosol. (A) Negative stain EM of cytosol 
purified from wild-type cells. 3mg/mL protein as determined by Bicinchoninic Acid (BCA) 
assay.  (B) Western blot showing the relative amounts of Drs2p, clathrin heavy chain 
(CHC1), Swa2p (auxilin), and Arf1p in the cytosol prep. The 100% sample contains 30µg of 
overall protein.  (C) Negative stain EM of cytosol after centrifugation at 300k x g for 1 hour. 
11mg/mL of protein as determined by BCA assay.  (D) Western blot showing the relative 
amounts of Drs2p, clathrin heavy chain (CHC1), Swa2p, and Arf1p in the cytosol prep 
imaged in (C). The 100% sample contains 55µg of overall protein.  (E) Western blot showing 
the relative amounts of GFP, Chc1p, Swa2p and Arf1p in the APL2-GFP cytosol prep, both 
before and after high speed centrifugation (left panel). Image of a tube showing the where 
the “Post-spin” and “Extra-supe” samples were derived. Scale bar: 100nm. 
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To remove the vesicles containing Drs2p, the cytosol was centrifuged at 300,000 x g for 1 
hour. The resulting sample was imaged at a concentration of 11mg/mL protein (Fig. 3-
5C), and there is a considerable decrease in the number of “vesicles” present in this 
supernatant sample. The Western blot (Fig. 3-5D), showed that Drs2p and clathrin heavy 
chain were undetectable in the 300,000 x g supernatant sample (Fig. 3-5D, Post), 
compared to the pre-spin sample (Fig. 3-5D, Pre). Meanwhile, Swa2 (auxilin) and Arf1, 
which are both cytosolic proteins, were present in similar amounts in both the pre-spin 
and 300,000 x g supernatant samples. 
 
It is possible that the vesicles containing Drs2p might near the bottom of the centrifuge 
tube rather than solely in the pellet.  The post-spin samples were being loaded onto the 
carbon grids (for negative EM) and into the gels (for Western blotting) had been taken 
from the top of the centrifuged sample. I was also attempting to make cytosol from 
APL2-GFP strain, and was facing the same issue, i.e. seeing Drs2p present in the prep. 
Both the post-spin sample (taken from the top of centrifuge tube), as well as an 
additional sample, called “extra-supe sample” (drawn from the bottom of the centrifuge 
tube above the pellet) were run on an SDS-PAGE gel and probed with antibodies for the 
presence of various proteins. When these samples were compared side-by-side, it is 
evident that the “extra-supe” sample is comparable to the pre-spin sample (Fig. 3-5E, left 
panel).  It appears that, during centrifugation, there is a gradient being formed in the 
tube (Fig. 3-5E, right panel), and that the heavier vesicles (which were expected to pellet) 
is actually settling into a layer at the bottom of the tube while the lighter, cytosolic 
proteins are remaining near the top. To confirm whether this is true of the cytosol 
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prepared from the wild-type strain, a Western blot was done with the “extra-supe” 
sample (bottom of the tube), and the same results were obtained (as was observed in Fig. 
3-5E) – the formation of the gradient in the centrifuge tube, and the presence of Drs2p in 
the “extra-supe” sample (data not shown; this data can be accessed from my electronic 
files: Data Images -> Western blots -> new western).  Since Drs2p, and by extension 
vesicles, are present in the cytosol preps, and centrifugation at higher speeds removed 
the clathrin in the sample, these cytosol preps were not useful for vesicle budding assays. 
 
Weaknesses and Future Directions 
 
Attempts to calculate tubulation or elongation in the kes1∆ and DRS2 strains were 
fruitless. It is possible that most of the membranes counted in the WT strain (Fig. 3-4A 
and B) were in the process of undergoing fusion when they were imaged which is why I 
was able to count membranes that were tubulating or elongating. Another disadvantage 
here is that it is not clear if the flipping activity of Drs2p is mediating this fusion. It is 
also likely that other proteins present on or in the Golgi membranes, or present in the 
samples is contributing to or causing this activity. Finally, it is unclear how many of the 
membranes contain or possess active Drs2p which is another limitation to these 
experiments. 
 
One way to address this problem is to use a tagged version of Drs2p to purify the Golgi 
membranes.  Drs2p membranes can be separated from membranes that do not contain 
Drs2p by the use of beads which could recognize a tagged version of Drs2p.  Another 
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possibility is to use immuno-gold techniques to determine which (and what percent of) 
membranes contain Drs2p. Negative EM staining of the cytosol (Fig. 3-5) shows that 
there is a lot of background in the cytosolic preparations which might affect my ability 
to identify changes due to Drs2p activity. One way to overcome this is to dilute the 
cytosol before addition and to supplement it with purified proteins that we know are 
essential for vesicle budding to occur. For instance, clathrin can be stripped off of 
vesicles or clathrin baskets and purified. Another option is to prepare the cytosol at a pH 
of 8.0 which would ensure that the clathrin in the prep is cytosolic and not associated 
with any membrane. 
 
The substantial number of small membranes within the DRS2 and drs2-ts preps could 
make the detection of changes, especially if the changes are slight, in membrane 
morphology difficult. The pellet that is obtained during the TGN membrane preps is 
relatively compact and difficult to resuspend. As a result, much force is used to 
resuspend the pellet. For instance, a combination of dounce homogenizing and high 
speed vortexing is used to loosen the pellet before it is added to the sucrose gradient for 
fractionation. Such forces might be fragmenting the Golgi, resulting in the large number 
of small membranes in the preps. 
 
A different approach, to resolve this issue, would be to pellet membranes onto a 
“sucrose cushion”, essentially two layers of sucrose at differing concentrations between 
which the membranes would settle during centrifugation. This would eliminate the need 
for large amounts of force to be used for membrane resuspension and might better 
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maintain the integrity of the late Golgi membranes.  The larger membranes can also be 
purified from the TGN membrane preps by size exclusion chromatography in a 
Sephacryl S–1000 column. One of the caveats of this process will be to determine 
whether Drs2p activity is maintained after this long process. 
 
Ultimately, the problem faced with the Golgi preps is their complexity. It is difficult to 
control the composition of the preps and any changes observed could be driven by the 
action of proteins or substrates that are not directly being assessed, but which are, 
nevertheless, present in these preps. The reconstituted system provides a purer, more 
direct approach to testing the same questions. 
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The Purification and Reconstitution of Drs2p 
 
Previous work done by Paramasivam Natarajan, in our lab, has demonstrated that 
Drs2p is necessary for flippase activity in late Golgi membranes (Natarajan et al., 2009; 
Natarajan et al., 2004). A senior graduate student, Xiaoming Zhou, has been successful at 
purifying and reconstituting Drs2p into proteoliposomes (Zhou & Graham, 2009). His 
work demonstrated that Drs2p is sufficient to catalyze flippase activity in vitro. However, 
the proteoliposomes used were too small (~40nm in diameter) to score morphological 
changes in liposome shape. The goal of this project was to recapitulate the experiments 
done by Xiaoming (i.e. the purification and reconstitution), and to move this work 
forward by developing assays to introduce Drs2p into giant unilamellar vesicles (GUVs) 
so that we can determine whether flippase activity, at the membrane, causes changes in 
membrane morphology. The importance of achieving this goal is that it then provides 
evidence for the importance of flippases at membranes and the role they play in vesicle-
mediated protein transport.  This section outlines experiments and assays that were 
designed and optimized for the purification and reconstitution of Drs2p.  
 
Results and Discussion 
 
It had been determined, from quantitative western blots, that there are about 300–500 
Drs2p molecules per TGN cisterna. To increase the yield of Drs2p obtained, Zhou 
constructed a yeast strain that has 10–20 fold overexpression of TAP–tagged Drs2p and 
HA–tagged Cdc50p (the Drs2p chaperone) using the strong glycerol–3–phosphate 
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dehydrogenase (GPD) promoter to drive their expression. The TAPN–tag for Drs2p was 
placed on both the N– and C–terminal ends. It was found that the N–terminally tagged 
TAPN–Drs2p, which was reconstituted into proteoliposomes, was active in vitro while 
Drs2p–TAPC is enzymatically dead (there was no flippase activity detected using this 
protein). Additionally, the purified TAPN–Drs2p was found to be sensitive to 
orthovanadate and has Mg+2–dependent ATPase activity (Zhou & Graham, 2009). Data 
suggests that phosphatidylserine (PS) is also the preferred substrate for Drs2p 
(Natarajan et al., 2004).  
 
To recapitulate the work done and published by Xiaoming, I first set about purifying 
and reconstituting Drs2p using protocols established in the lab. TAPN-Drs2p was 
purified by two-step purification methods using both its N-terminal Protein-A and 10x-
Histidine tags.  The protein yield using two-step purification method was low - about 
7ng/µL (Fig. 3-6A). Since more protein was needed for reconstitution into 
proteoliposomes, a single-step purification method was used utilizing the 10x-His tag on 
TAPN-Drs2p.  The concentration of Drs2p, in this case, was greatly improved – about 25 
ng/µL. However, there were a lot of other protein bands visible in the Coomassie (Fig. 
3-6B), suggesting that this sample is not as pure as the two-step purified material.  This 
protein sample is active and has a specific activity of about 0.3 µmol Pi/min/mg Drs2p 
(Fig. 3-6C) – similar values to those detected by Xiaoming Zhou (Zhou & Graham, 2009). 
 
This sample was then reconstituted, using adbsorbent Biobeads, in the presence of PC 
and 1mol% NBD-PS, and the seal of the resulting proteoliposomes was tested.  I found 
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that these proteoliposomes only had 3-5% resistance to quenching by dithionite (Fig. 3-
6D). This means that only 6-10% of the proteoliposomes in the population were 
completely sealed and were able to shield the NBD lipids in the inner membrane layer 
from quenching by dithionite (Fig. 3-6E). Liposomes that were reconstituted in the same 
manner, meanwhile, showed about 45% resistance to quenching by dithionite (Fig. 3-6D).   
 
These proteoliposomes were floated in a bipartite glycerol gradient to: (a) separate the 
proteoliposomes from unincorporated proteins and lipids, and (b) determine if these 
floated proteoliposomes, once separated away, would have a better seal.  When the five 
resulting fractions were run on an SDS-PAGE gel and coomassie stained, most of the 
protein is observed in fraction 3 (F3), and a little less in fraction 4 (F4), which is second 
from the top (Fig. 3-6F). The NBD-lipids are also primarily distributed between F3 and 
F4, when assessed by a fluorescence spectrometer trace (Fig. 3-6G).  The seals of these 
floated proteoliposomes don’t improve either.  Both fractions have only 3-5% resistance 
to ditihionite quenching (Fig. 3-6H).  Fractions F3 and F4 are slightly higher specific 
activities than the pure protein sample, around 0.35 – 0.4 µmol Pi/min/mg Drs2p (Fig. 
3-6I). 
 
At the time of these experiments, the issue of poorly sealed, or leaky, proteoliposomes 
was one that Xiaoming was facing as well.  Independently, he spent several months 
attempting to rectify this problem before his departure from Vanderbilt.  On my end, I 
made several changes to the reconstitution protocol to pinpoint the problem and 
identify potential solutions. Several options were considered to rectify this problem.  
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Figure 3-6.  Purification and Reconstitution of Drs2p using C12E9. (A) Two-step purification 
(coomassie stained gel) of Drs2p using ProteinA and 10x Histidine tags.  Drs2p was run on 
the gel in duplicate.  BSA standards (in ng) were run on the gel to enable quantitative 
calculations. (B) Coomassie stained gel of single-step purification of Drs2p using 10x 
Histidine tag. (C) Graph showing the specific activity of single-step purified Drs2p 
determined using ATPase assay.  (D) Fluorescence trace assaying the resistance to dithionite 
quench, of protein-free and proteo-liposomes.  Dithionite is added at 30sec, and 10% Triton 
X-100 is added at 150sec.  The trace is collected for 180sec. (E) Animation showing the 
difference in NBD-phospholipid quench in leaky versus properly sealed liposomes.  
Properly sealed liposomes will only have 50% resistance to quenching of the fluorescent 
probe as the other half of the NBD-lipids are protected by the sealed inner membrane of the 
proteoliposome. (F) Coomassie stained gel showing the distribution of Drs2p in floated 
fractions with the fractions from the bottom loaded on the left side of the gel and the 
fractions from the top of the tube loaded on the right side.  The well labeled “Prot” is an 
aliquot of the original sample, prior to flotation. (G) The distribution of NBD-lipids in the 
floated fractions (liposome vs. proteoliposome samples).  Where F1 is the fraction from the 
bottom of the tube and F5 is the fraction on the top. (H) Since F3 and F4 had the most NBD-
lipids, those proteoliposome fractions were assayed for resistance to quenching by dithionite. 
Dithionite is added at 30sec, and 10% Triton X-100 is added at 150sec.  The trace is collected 
for 180sec. (I) Graph showing the specific activities of the F3 and F4 proteoliposome samples 
(see (F-H)) determined using ATPase assay.   
 
 
First, it was possible that the proteoliposomes may need to be incubated for a longer 
period of time with the Biobeads. Normally, 100mg of methanol-activated Biobeads are 
added to a protein+lipid mixture and mixed by end-over-end rotation.  After 6 hours, 
200mg of activated Biobeads are added and the sample is mixed for another 12 hours.  
Thus, the sample is incubated with the Biobeads for a total of about 18 hours.   
 
Liposomes and proteoliposomes were formed using this established reconstitution 
protocol and they were tested for seal at 18h 45min post incubation with Biobeads (6h 
30min with 100mg, followed by 12h 15min with an additional 200mg).  The liposomes 
were 40% resistant to quenching by dithionite, while the proteoliposomes were only 4% 
resistant (Fig. 3-7A).  The samples were allowed to mix end-over-end for an additional 2 
hours and were then tested for seal.  At the 20h 45min time point, the liposomes 
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improved their seal to 43% while the proteoliposome seal was at approximately 5% (Fig. 
3-7B). At this point, 100mg of fresh Biobeads were added to the sample and it was 
allowed to mix for an additional 2 hours 15 min.  At the 23 hour time point, the seal was 
checked again.  This time the liposomes had an almost 50% resistance to dithionite 
quench while the proteoliposomes were still around 5% resistant (Fig. 3-7C).  The 
samples were floated to determine if the fractions would have an improved seal.  As 
determined by coomassie (to determine which fractions contained the most protein), and 
fluorescence traces (to determine which of the fractions contained the most fluorescent 
lipids), fractions F3 and F4 were chosen, in both the liposome and proteoliposome 
samples, and the seal was tested (data not shown).  In the liposome samples, F3 had 
about 42% resistance and F4 had 37% resistance to dithionite quenching (Fig. 3-7D).  
Both F3 and F4, of the proteoliposome sample had about 5% resistance to dithionite 
quenching (Fig. 3-7E).  In these experiments, both F3 and F4 proteoliposomes were 
active (Fig. 3-7F). 
 
Since preparation of protein takes a long time, and in order to optimize the 
reconstitution conditions, I switched to using liposomes.  At first, decreasing amounts of 
detergent were used during liposome formation (Fig. 3-7G). In the figure, 100% 
detergent is the amount of detergent normally used to reconstitute protein into 
liposomes.  The other values tested were 87%, 73% and 47% of detergent relative to the 
original amount. A decrease of 13% of detergent (87% sample), shows an increase in the 
liposome resistance to a value greater than 50% dithionite resistance. The problem with 
decreasing the amount of detergent is that a large number of multi-lamellar vesicles 
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form in these samples.  Future experiments, using proteoliposomes and a decreased 
amount of detergent, did not yield proteoliposomes that floated.  Rather, the lower 
levels of detergent kept most of the lipids in micellar form and the protein did not 
incorporate into liposomes (data not shown). 
 
One observation was that the previous batch of Biobeads were considerably drier than 
the batch that was in use.  As such, the new Biobeads were dessicated in a speed-vac for 
20min prior to methanol activation. The effect that normal Biobeads and the dessicated 
Biobeads had on liposome formation was compared.  Dessication of the Biobeads 
seemed to improve the seal of the liposomes by about 5% (Fig. 3-7H), so future 
reconstitutions (while using C12E9) were done with dessicated batches of Biobeads.   
 
Another thought was that other protein(s) that were co-purifying with the single-step 
purified Drs2p was affecting the ability of the proteoliposomes to seal.  To test this, 
Drs2p was purified away from smaller contaminating proteins using centrifugal filter 
systems with molecular weight cut-offs at 30 kDa. Unfortunately, I was not able to 
recover much of the Drs2p in the final eluate (data not shown).  This may be because the 
protein was getting trapped in the centrifugal column membrane. 
 
TAPN-Drs2p has two purification tags at its N-terminus – a Protein A module and a 10x 
Histidine module (Zhou & Graham, 2009; Zhou et al., 2013). Drs2p was purified, out of 
yeast, in two batches.  The first batch was purified using IgG beads against the ProteinA 
module, followed by elution of the protein by TEV cleavage. The second was purified 
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Figure 3-7.  Testing conditions to solve the leaky liposome problem. (A) Protein-free and 
proteo-liposome seal was assessed by fluorescence quenching assays after 18h 45min of 
incubation using BioBeads during the reconstitution protocol. (B) The samples from (A) 
were incubated for an additional 2h and seal was re-assessed at time 20h 45min. (C) Fresh 
Biobeads were added to the samples and allowed to incubate for over 2h.  At time 23h, seal 
was re-assessed.  (D) and (E) The samples were floated and F3 and F4 fractions (middle and 
second from top) were assessed for resistance to dithionite quench. Where (D) are liposome 
samples and (E) are the proteoliposome samples. (F) Specific activities of the F3 and F4 
samples assayed in (E). (G) Liposome samples were reconstituted using decreasing amounts 
of C12E9 and assayed for proper seal. Where 100% is the normal amount of detergent used 
during reconstitution, and 87%, 73% and 47% are corresponding decreases in the amount of 
detergent. (H) Biobeads were either dried in a Speedvac for 15min (Dessicated) or added 
directly from the jar (Normal) during reconstitution and the effect on liposome seal was 
assessed. 
 
 
using the Ni-NTA beads against the 10x Histidine module and elution by high 
concentration of imidazole. Each of these samples were reconstituted into PC + 1% 
NBD-PS liposomes and the resulting sample was tested for seal.  Side-by-side with the 
proteoliposome formation, I made liposomes using the same elution buffers that were 
used for the proteoliposome reconstitution. The reason for doing this, i.e. purifying 
using different tags, is that during the different single-step purifications (Protein A vs 
10x His), some of the contaminating proteins that co-purify with Drs2p are different 
between the preps. The hope was that one of these preps would lack the contaminants 
causing the leaky liposome problem and would allow the proteoliposomes to form 
proper seals during reconstitution. Furthermore, I increased the number of washes, 
during purification, to get rid of as many contaminating proteins as possible. During this 
experiment, the prep that I obtained for purification by 10x His was more pure than the 
one obtained for purification by the ProA module (Fig. 3-8E).   
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Meanwhile, the resistance of 10xHis-purified Drs2p proteoliposomes improved 
considerably.  They displayed 20% resistance to dithionite quenching which means that 
40% of the proteoliposomes formed had a good seal (Fig. 3-8A, B).  Comparatively, the 
ProA-purified Drs2p proteoliposomes were leakier.  They displayed about 10% 
resistance to dithionite (Fig. 3-8C, D).  All of the liposomes made were 50 – 60% 
resistance to dithionite quenching (Fig. 3-8A-D).  While I tested the seal of each set of 
proteoliposomes at two time points (18h and 21h), to determine if the additional 
incubation time improved the seal, there did not appear to be a significant difference 
between the samples at either time point (Fig. 3-8A vs B, Fig. 3-8C vs D). Furthermore, 
liposome traces show that differences in elution buffer does not appear to affect the seal. 
 
These proteoliposomes were then floated and the amount of protein in each fraction was 
determined by coomassie staining. In the 10x His purified Drs2p proteoliposomes, the 
protein is detected in the F4 and F5 fractions.  However, the bands are very faint.  There 
may be several reasons for this: (a) there may have been some protein degradation 
during the final incubation with Biobeads and preparation of fractions for flotation, (b) I 
started out with a slightly lower concentration of protein (5ng/µL concentration) than 
what I normally use (about 20ng/µL), and (c) the proteoliposomes has spread itself out 
over several fractions (Fig. 3-8F). Furthermore, the top two fractions (F4 and F5) which 
contains most of the proteoliposomes have 0.7 and 1.1ng/µL protein concentrations. 
This was disappointing because it was this sample that had the best seal. Additionally, I 
had pre-quenched the sample in the hopes of performing flippase assays with it. The 
fractions from the ProA-purified Drs2p proteoliposomes were also rather faint.  
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However, I did start out with more protein during reconstitution (10ng/µL 
concentration).  Fractions 3 and 4 for this sample had the most protein and had 
concentrations of 2 and 3.5ng/µL respectively (Fig. 3-8G).  
 
When the various fractions – F4 and F5 for 10x His sample, and F3 and F4 for ProA 
sample – were assayed for activity, it was obvious that the protein was not very active.  
When you look at  the average ATPase assay values (Fig. 3-8H) you can tell that there is 
very little difference between the sample versus the boil or vanadate control values.  The 
specific activities (Fig. 3-8I) of the samples do not accurately reflect the small variation 
because the differences in the amount of protein present in the fractions influence the 
specific activity.  Ultimately, I was not able to use these samples for flippase assays.  
Between the extremely low concentrations of protein present in the floated 
proteoliposomes and the low levels of specific activity, these samples were not useable 
for further experiments. 
 
To improve the purification and reconstitution protocols, I tried new protocols using 
different detergents.  The lab of Robert Molday (Coleman et al., 2009), had developed an 
assay for purification and reconstitution of ATP8A2 from bovine photoreceptor outer 
segments.  ATP8A2, along with ATP8A1, are two mammalian P4-ATPases that are the 
most closely related to Drs2p.  They, like Drs2p, use PS as a substrate. The protocol 
developed by the Molday group uses CHAPS and n-octyl-β-D-glucopyranoside as 
detergents and they purify the protein in the presence of lipids (Coleman et al., 2009). 
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Figure 3-8. Testing different protein purification conditions and its impact on 
proteoliposome seal. (A) and (B) Drs2p was single-step purified using 10x Histidine tag and 
eluted by imidazole.  (C) and (D) Drs2p was single-step purified using Protein A tag and 
eluted by cleavage using TEV protease.  (A) and (C) Protein-free and proteo-liposome seal 
after 18h incubation with Biobeads during reconstitution. (B) and (D) Liposomes from (A) 
and (C) after 4 additional hours of incubation with Biobeads. (E) Coomassie stained gel 
showing the single-step purified Drs2p from 10x His samples (left well) and ProA samples 
(right well). (F) and (G) Gels looking at the distribution of protein from floated fractions of 
10x His proteoliposomes (F) and ProA proteoliposomes (G). (H) nmol of Pi released by the 
fractions when assayed for ATPase activity.  Each of the samples also has a Boil and 
vanadate (“Van”) sample associated with it.  These samples were run in duplicate. (I) The 
specific activities of the 10x His and ProA fractions, F3 and F4.  The “-B” samples are sample 
minus its respective boiled control sample and “-V” samples are sample minus its respective 
vanadate control sample. These values were calculated from raw values presented in (H). 
 
 
Dialysis cassettes are used, instead of Biobeads, to remove the detergent. I developed a 
protocol to mirror the changes of the Molday protocol and to adapt it to Drs2p (see 
Protein Purifications and Reconstitutions Protocols section). The purified protein was 
run on an SDS-PAGE gel and coomassie stained to determine yield. The protein was 
eluted from the column three times.  In the first two eluates, there is a double band 
running at about 150kDa (Fig. 3-9A). The concentration of eluates are 37 and 21 ng/µL 
respectively. The third eluate (19 ng/µL) only possesses the faster migrating of the two 
bands. The protein from the first elution was reconstituted into PC + 1% NBD-PS 
liposomes and an aliquot was run in the fourth lane. There is only one band present for 
Drs2p (the faster migrating band) which suggests that the upper band might have 
degraded to form the lower band.  The proteoliposomes have a protein concentration of 
19 ng/µL (Fig. 3-9A). 
 
The proteoliposome sample was assayed for ATPase activity and was so active that it 
had to be diluted 20x so that the activity would fall within the measurable range of the 
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assay. The protein was assayed, for activity both in the presence and absence of 
detergent to determine whether the presence of the membrane influenced the activity of 
the protein. In the presence of detergent, the protein had a specific activity of 3.5 µmol 
Pi/min/mg Drs2p, while in the absence of detergent the specific activity was higher, 
about 5.2 µmol Pi/min/mg Drs2p (Fig. 3-9B). This suggests that the presence of the 
membrane stabilizes the protein and enhances its function. The reconstituted protein 
was checked for seal and it was almost 25% resistant to dithionite quenching (Fig. 3-9C).  
This was promising. 
 
The proteoliposome sample was floated and the amount of proteins in the fractions were 
assessed by running them on, and coomassie staining, an SDS-PAGE gel (Fig. 3-9D). 
Most of the protein remained in the bottom fractions with a very small percentage 
floating to F4, which is one of the two fractions which had most NBD-lipids (the other 
being F5). Calculations show that only 1 Drs2p molecule is present in every 400 
liposomes. Xiaoming was able to incorporate 1 Drs2p molecule in every 2-3 liposomes 
using his protocol. These data suggest that the reconstitution protocol was unsuccessful.  
 
Fractions F3 and F4 were assayed for ATPase activity and it was found that they had 
very high specific activities – F3 was 60 µmol Pi/min/mg Drs2p, and F4 was 115 µmol 
Pi/min/mg Drs2p. Both these values are significantly higher (150 – 300 fold higher) than 
specific activities that were previously published.  The actual specific activity of F3 and 
F4 might be slightly different since the calculation of the amount of Drs2p in those  
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Figure 3-9.  Purification of Drs2p using CHAPS and n-octyl-β-D-glucopyranoside. (A) 
Coomassie stained gel showing single-step purified Drs2p.  P1 – P3 are three different 
elutions from the same column.  PL is the proteoliposome sample after reconstitution. (B) 
The specific activity of proteoliposomes reconstituted using single-step purified Drs2p both 
in the presence (left bar) and absence (right bar, “no detergent”) of detergent during the 
ATPase assay. (C) Fluorescence trace of the proteoliposome sample showing approximately 
25% resistance to quenching by dithionite. Dithionite was added at 30sec and 10% Trition X-
100 was added at 150sec. The trace was run for 180sec. (D) Distribution of Drs2p in fractions 
after flotation. Where F1 is the fraction at the bottom of the centrifuge tube and F5 is the 
fraction at the top. (E) Specific activity of F3 and F4 fractions as detected on the gel in (D). 
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samples is an estimate extrapolated from the equation for the BSA standards (from gel 
image, Fig. 3-9D). F3 was estimated to have 0.7 ng/µL and F4 was estimated to have 0.18 
ng/µL of Drs2p.  Even if these values are slightly off, it doesn’t take away from the fact 
that these preps are extremely active, especially when compared to our former 
purification and reconstitution methods. 
 
Since the reconstitution did not work with n-octyl-β-D-glucopyranoside, I substituted 
C12E9 into the purification and reconstitution protocols.  It seemed that purifying the 
protein in the presence of lipids as well as the other minor modifications that were made 
to the protocol might enhance the yield and overall activity of the protein. To that end, 
Drs2p was purified using this protocol, reconstituted by dialysis, and the protein yield 
was assessed by Coomassie staining. A lot of background bands were observed on the 
gel, and the yield of protein was very low compared to the other proteins in the solution 
(Fig. 3-10A). When this sample was reconstituted (using C12E9 and dialysis), there was 
absolutely no resistance to dithionite quenching (Fig. 3-10B). I observed that the sample 
seemed to have detergent in it even after the dialysis step (sample was a bit sudsy).   
 
After a literature and web search, it became clear that n-octyl-β-D-glucopyranoside has a 
critical micelle concentration (CMC) of 23-25mM (0.67-0.73% w/v), while C12E9 has a 
critical micelle concentration of 0.05mM (0.003% w/v). Since n-octyl-β-D-
glucopyranoside has such a high CMC, it can be removed from a solution by dialysis or 
gel filtration.  C12E9, on the other hand, has a very low CMC, which inhibits removal by 
these methods. This is why C12E9 was not removed by dialysis, and why, as a result, the 
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proteoliposomes did not seal (i.e. the presence of the detergent).  C12E9 removal from a 
solution, by dialysis cassettes, can be achieved with extremely long incubation times 
(several days up to a week or so), but for my purposes, this would mean degradation of 
the protein. 
 
The protocols modified from the Molday lab were revised again. The purification 
protocol was kept intact, including the detergents used, and the reconstitution protocol 
was modified.  Instead of removing the detergent using dialysis, the final eluate was 
split into two. One aliquot was reconstituted using dialysis and the other aliquot was 
reconstituted using Biobeads.  It seemed likely that the reason dialysis had not worked 
initially was because, when the reconstituted sample (with octylglucoside) is being 
dialyzed, the detergent may be being removed too quickly from the sample.  This is 
probably leading to the formation of liposomes rather than proteoliposomes.  It is also 
possible that such liposome formation is happening at a faster rate than the proteins are 
capable of incorporating into the membrane bilayer.  I hoped that using Biobeads might 
slow down the rate of detergent removal.  The dialyzed samples were to act as a control. 
 
The purified protein was run on a gel and coomassie stained to determine yield.  The 
first elution of protein had a concentration of 18 ng/µL (Fig. 3-10C). After the protein 
and lipids were mixed, an aliquot was taken which was also run on the gel (see lane 
“PL”, Fig. 3-10C). After reconstitution, either by Biobeads or by dialysis, the resulting 
proteoliposomes were run on the same gel as the above samples. The proteoliposome 
samples from the Biobeads (see lane “Bb”, Fig. 3-10C), had a very faint band for Drs2p.  
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In fact, it looked like most of the protein was stuck in the well of the gel. Compare that 
with the proteoliposome samples from the dialysis cassette (see lane “Di”, Fig. 3-10C), 
where there is a distinct band for Drs2p (at about 150kDa) and there is no protein 
detectable in the well.  It appears that, for some reason, incubating protein (that has been 
reconstituted with n-octyl-β-D-glucopyranoside in the presence of Biobeads) is causing 
protein aggregation. 
 
A trace to determine the seal of the proteoliposome samples shows that in both 
reconstitution samples, there is 25% resistance to quenching by dithionite (Fig. 3-10E).  
When these samples are floated, meanwhile, very little, if any, of the protein is found in 
the top fractions (Fig. 3-10D).  Most of the protein is found in the lower fractions and 
separated from most of the NBD-lipids.  In this case too, the protein in the Biobeads 
sample is found in the wells of F1 and F2 (Fig. 3-10D).  A trace for the fluorescence of the 
fractions also shows that most of the lipids float to the top (data not shown), indicating 
that liposomes formed, but the protein is not incorporating into them. 
 
The activity of these proteoliposome samples were tested. From the average ATPase 
activity, measured in nmol Pi released, the dialyzed samples have higher activities than 
the Biobeads samples (Fig. 3-10F). However, depending on how you calculate the 
specific activity – whether you use the value for the amount of Drs2p from the band on 
the gel only (Fig. 3-10G), or you include the protein in both the band and the well (Fig. 3-
10H) – you get two different values. When I calculated the specific activity using the  
 97 
 
 
 
 
 
 
 
Figure 3-10.  Substitution of C12E9 instead of CHAPS and octylglucoside. (A) Single-step 
purified TAP-Drs2p purified using C12E9 as substituted into the protocol instead of CHAPS 
and octylglucoside.  (B) The proteoliposome samples had absolutely no resistance to 
quenching by dithionite.  The black and red lines represent two different lipid compositions 
used during reconstitution. (C) Drs2p was re-purified using the C12E9 substitution protocol 
(P1 – P4 are different eluates off the same column) and mixed with lipids for reconstitution 
(“PL” sample).  This sample was split into two and reconstituted using either Biobeads (Bb) 
or Dialysis (Di). (D) The resulting proteoliposomes were floated and the fractions run on an 
SDS-PAGE gel. Where F1 is the bottom fraction and F5 is the top. (E) Seal of 
proteoliposomes reconstituted using either Biobeads or Dialysis. (F) nmol of Pi released for 
Biobeads and Dialysis proteoliposomes.  The specific activity of these samples was 
calculated using either the band detectable for Drs2p only (G) or the amount of protein in 
both the band and stuck in the well (H).  
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amount of protein found at the 150kDa band and the well (which I believe is a more 
accurate representation of the amount of Drs2p present in the tube), the graph shows 
that the dialyzed sample is more active than the sample incubated with Biobeads (Fig. 3-
10H).  Thus, it seems that n-octyl-β-D-glucopyranoside and dialysis is the best method to 
give me the most active protein; however, it has still not solved the leaky liposome 
problem.  
 
Please note that, for the ATPase assays, the samples were diluted 25-fold in order to 
have the activity fall within the measurable range of the assay. 
 
Looking through general protein purification papers from other labs, and a seminar talk 
at Vanderbilt by Tina Iverson (Dept. of Pharmacology, Dept. of Biochemistry) about 
different purification methods, led me to look closely at other detergents that are 
commonly used for protein purification.  C12E8 is a popular choice and closer inspection 
of C12E8 shows that, structurally, it is similar to C12E9 (Fig. 3-11A).  Additionally, both 
detergents have similar CMC’s – 0.05mM (0.003%) for C12E9 and 0.09mM (0.0048%) for 
C12E8. The slightly higher CMC for C12E8 makes it likely to allow more lipids to remain 
free in the solution allowing for better incorporation of the protein into liposomes 
during reconstitution.  Furthermore, this detergent would fit in very well with the 
existing protocols in the lab. 
 
Both TAPN-Drs2p (using the 10x His tag) and Drs2p-TAPC (using the calmodulin 
binding peptide (CBP) tag) were single-step purified using C12E8.  Minor modifications 
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were made to the C12E9 purification protocol to adapt it for use with C12E8, as well as 
to incorporate those techniques that would improve aspects of the purification and 
reconstitution (see Purification protocols section). When the gel was run for these two 
samples, TAPN-Drs2p ran as a slightly faster migrating band compared to Drs2p-TAPC 
(Fig. 3-11B). From other on-going work in the lab (see Chapter 2 of this thesis), I learned 
that this was likely due to clipping of the protein during purification. Furthermore, 
purification using C12E8 yielded larger concentrations of protein. TAPN-Drs2p, in the 
figure, has a concentration of 40 ng/µL and Drs2p-TAPC has a concentration of 65 
ng/µL (Fig. 3-11B) – much higher that what was previously purified. TAPN-Drs2p was 
also active, with a specific activity of 0.23 µmol Pi/min/mg Drs2p, while Drs2p-TAPC 
had very little activity (Fig. 3-11E).  This result agreed with previously published data. 
 
When the two sets of protein were reconstituted into proteoliposomes (PC + 1% NBD-
PS), they were both about 15% resistant to quenching by dithionite (Fig. 3-11D).  Further 
work improved this seal to be between 20-25% resistance (data not shown). Figure 3-11C 
shows a coomassie image of the proteoliposome samples. These proteoliposomes were 
also very active. TAPN-Drs2p had a specific activity of 0.85 µmol Pi/min/mg Drs2p 
while Drs2p-TAPC continued to have negligible activity (Fig. 3-11F).  This improvement 
in the activity could be due to the presence of a membrane that is stabilizing the protein. 
Best of all, a portion of the proteoliposomes floated (Fig. 3-11G).   
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Concluding Remarks 
 
It was the development of the protocols utilizing C12E8 that allowed me to perform the 
experiments that led to the publication of the work regarding auto-inhibition of Drs2p 
by its C-terminal tail (See Chapter 2 in this thesis).  Furthermore, it enabled me to use the 
reconstituted samples for flippase assays (also found in Chapter 2 in this thesis) (Zhou, 
et al., 2013). 
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Figure 3-11.  Purification of Drs2p using C12E8. (A) The chemical structure and critical 
micelle concentrations of C12E9 and C12E8. (B) Coomassie stained gel of single-step 
purification of TAP-Drs2p and Drs2-TAP. (C) Proteoliposome samples (DOPC + 1% NBD-
PS) of TAP-Drs2p (lane A) or Drs2p-TAP (lane B). (D) Resistance to dithionite quenching of 
the samples shown in (C), where the black line is TAP-Drs2p and the red line is Drs2p-TAP. 
(E) Specific activity of the protein samples from gel in (B), and (F) specific activity graph of 
proteoliposomes of gel in (C).  (G) Flotation of fractions of TAP-Drs2p.  Where P is a sample 
of the protein, and F1-F5 are fractions (bottom -> top). 
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Electroformation of Giant Unilamellar Vesicles (GUVs) 
 
The process of vesicle budding, within a cell, is tightly regulated and occurs at a very 
rapid pace (Kinuta et al., 2002).  Cargo proteins are selected and recruited to sites of 
vesicle formation, membranes deform and this deformation is captured by proteins, 
which shape the budding membrane into transport vesicles (Graham & Kozlov, 2010; 
Kirchhausen, 2000b). It is important in the trafficking field to determine the major 
players in this reaction and the role that they play.  It is especially important to note 
which proteins are responsible for creating this membrane curvature – the point at 
which a vesicle can begin to take shape. Much work has been done purifying cytosolic 
proteins (such as Arf) and adding them to artificial membranes to show that they are 
able to cause membrane deformation (Beck et al., 2011; Matsuoka et al., 1998; Spang, 
Matsuoka, Hamamoto, Schekman, & Orci, 1998; Takei et al., 1998).  However, this 
deformation seems to be a product of protein crowding (Stachowiak et al., 2012).  The 
question then is – what protein(s) are able to create membrane curvature within the 
tightly regulated and spatially controlled environment of the cell? Our lab has 
hypothesized that Drs2p is a major player in this process.   
 
Proteoliposomes containing purified Drs2p are excellent for in vitro experiments testing 
ATPase and flippase activities of the protein.  However, these structures are very small, 
about 40nm in diameter, and much smaller than most transport vesicles (which are 50-
100nm in diameter) (Kirchhausen, 2000b; Zhou & Graham, 2009). One way to address 
the role of Drs2p on membrane morphology is to incorporate Drs2p proteoliposomes 
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into giant unilamellar vesicles (GUVs).  GUVs are 5-100µm in diameter, so they are 
easily imaged by optical microscopy and experiments can be done in real time.   
 
There are several techniques for GUV formation.  Uncontrolled swelling involves drying 
lipids onto a film and then rehydrating them to form GUVs (Criado & Keller, 1987; 
Manley & Gordon, 2008). Another technique is called electroformation and is the major 
technique that will be addressed in this section. In electroswelling, lipids are dried down 
onto a conductive slide and then rehydrated in the presence of an A/C electric field 
(Farge & Devaux, 1992; Girard et al., 2004; Mathivet, Cribier, & Devaux, 1996; 
Papadopulos et al., 2007).  The advantage of the latter technique is that the GUVs are 
unilamellar and homogeneous in size.   
 
In this chapter, I introduce work that was developed to electroform lipids into GUVs 
and to grow Drs2p proteoliposomes into GUVs. Different electroformation techniques 
are also discussed, and technical aspects (questions, trouble-shooting, etc.) that were 
faced during the course of the experiments. 
 
As this project was initiated, the goal was to provide a direct test of the role that Drs2p 
flippase activity plays in membrane deformation and budding. 
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Results and Discussion 
 
Xiaoming Zhou developed protocols for electroformation of giant unilamellar vesicles 
(GUVs) both in the absence and presence of Drs2p. He was able to successfully form 
protein-free GUVs (as published in his thesis).  Using these same protocols as a starting 
point, Charles Day and I began work to grow Drs2p proteoliposomes into GUVs.  I 
provided Charlie with Drs2p proteoliposomes and, using a combination of GUV 
protocols #1 and #2 (see “Protocols” section above), he electroformed them into GUVs at 
both room temperature and 4°C.  The changes made included spreading, and drying, a 
film of lipids (DOPC and Rho-PE) onto the ITO slides. After this, the proteoliposome 
sample was spread on top and gently dehydrated the solution. Then, the sample was 
electroformed in the presence of the appropriate buffers. 
 
The GUV sample was analyzed by running it, as well as a sample of the proteoliposome, 
on SDS-PAGE gels and staining with coomassie as well as immunoblotting. The GUV 
sample, since it was diluted during formation by the electroformation buffer, was 
loaded in at 5-fold the amount of the proteoliposome sample. In both the 
proteoliposome and GUV lanes (in the coomassie and Western blot), bands are visible 
for Drs2p (Fig. 3-12A and B). In Fig. 3-12C, we see that the GUV sample also had 
measurable specific activity (when compared to the DOPC+1% NBD-PS+ 5% PI4P 
proteoliposome sample). The seal of the GUV sample was tested by the dithionite 
quenching assay and it was found that there was almost 50% resistance to quenching by 
dithionite (Fig. 3-12D). These data indicate that the process of electroformation did not 
adversely affect the structure and activity of Drs2p. The question then becomes – is 
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Drs2p present in the GUV structures?  And can we detect changes in membrane 
morphology? 
 
Charlie worked on optimizing our electroformation and imaging conditions.  He 
determined that working with 1V and 10Hz was ideal for producing the best quality 
GUV structures (Table 3-1).  As shown in Fig. 3-12E, when a GUV is 20µm or larger (as 
in the lower panel), it makes the imaging easier – the larger size allows for better 
detection of these structures and these larger GUVs tend to move less making the 
images clearer.  When the proteo-GUV structures were imaged, we found that the Rho-
PE (Fig. 3-12F, left panel) – present in the lipid film – co-localized with the NBD-PS (Fig. 
3-12F, center and right panels) – present in the proteoliposome samples. This co-
localization (Fig. 3-12F, right panel), suggests that the proteoliposomes are merging with 
the lipid film to create these GUVs.   
 
However, it was still unclear whether Drs2p was present in these structures.  This 
method of GUV formation gives a very heterogeneous population of membranes (Fig. 3-
12G).  There is a mix of large and very small vesicles, as well as many membrane tubules.  
Only a few GUVs are formed that are suitable for imaging and reproducibility of the 
data is difficult since there’s a great variation between the different GUV preparations.  
Also, addition of ATP to the few GUVs that could be imaged did not yield any positive 
results (data not shown).  While this suggests that the GUVs with NBD-PS may not 
contain Drs2p, it doesn’t exclude that possibility.  There are a few explanations that 
could fit.  It is likely that the NBD-PS, which has an NBD moiety on a C6 chain, is 
dissociating from the proteoliposomes during electroformation and, thus, the GUVs we  
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Figure 3-12.  Basic electroformation techniques and assays for activity. Coomassie stained 
gel (A) and Western blot (B) of Drs2p proteoliposomes and electroformed GUV sample. 
Five-fold amount of the GUV sample was loaded compared to the proteoliposome sample. 
(C) Specific activity of proteoliposomes versus GUVs.  The GUV sample had 5-fold greater 
amount of sample added than the proteoliposome sample. (D) Checking the seal of the GUV 
samples using fluorescence traces. The red versus black lines indicate different lipid 
compositions for the GUVs. (E) Larger GUVs are easier to image.  Scale bars: 5µm (left) and 
20µm (right). (F) Rho-PE from the lipid film and NBD-PL from the proteoliposomes are both 
found in the GUVs. Scale bar: 10µm. (G) Other structures visible after electroformation. 
Scale bar: 10µm. 
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observe in the green channel results from the transfer of NBD-PS from the 
proteoliposomes to the GUVs, rather than a merging of the entire membrane.  Another 
possibility is that since we have such a small number of GUVs to image, there are no 
active Drs2p molecules present in those structures.  Ultimately, we need to improve the 
yield of GUVs and the ability to detect Drs2p in proteo-GUVs.  
 
 
 
Charlie visited the lab of Sarah Veatch at the University of Michigan and learned their 
technique for forming GUVs.  Sarah is well known for her work with artificial 
membranes and Charlie was able to pick up several technical tips and tricks to enable us 
to form better GUVs.  The protocol, provided by the Veatch lab, has been copied into the 
“Protocols” section of this Appendix chapter.  The main changes include the techniques 
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used to spread the lipids on the ITO slides and the voltage and frequency at which the 
structures are electroformed.  Using this technique, Charlie was able to form protein-free 
GUVs using DOPC+ DilC12 (Fig. 3-13A) as well as DOPC and Rhodamine-PE (Fig. 3-
13B).  These GUVs were large compared to the size of the GUVs that we previously 
made, and were on the order of 20 – 150 µm in diameter.  When the same protocol was 
used to make proteoliposomes (including spreading the proteoliposomes on top of the 
dried lipid film), we found the proteo-GUVs that were forming were similar to the ones 
previously formed.  The proteo-GUVs were small, with the largest ones having sizes of 
about 10µm (Fig. 3-13C and D).  Furthermore, both Rho-PE (red, present in the lipid 
film), as well as NBD-lipids (green, present in the proteoliposome samples) were 
detected in the proteo-GUVs. Again, this suggests that the proteoliposomes and the lipid 
film are swelling into the GUV structures and it is possible that Drs2p can be found in 
them. However, experiments where ATP was added to these structures were fruitless, 
since the membranes exhibited no changes to membrane morphology (data not shown).  
So, the same questions remain as did with the previous protocol and preps – is Drs2p 
present in these proteo-GUVs? Are the NBD-lipids that we are observing from the 
merging of proteoliposomes into these structures or are they from micelles present in the 
samples? 
 
I had the opportunity to visit Denmark and learn GUV electroformation techniques from 
them.  The lab of Thomas Günther-Pomorski (at LIFE) was working a project where they 
were trying to reconstitute purified proton pump, from A. thaliana, into proteoliposomes 
and then incorporate this protein into GUVs. The goals of my visit included learning 
techniques from them (especially a different technique for electroformation), as well as  
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Figure 3-13.  Electroformation of GUVs learned from the lab of Sarah Veatch. (A) GUVs 
formed in the lab of Sarah Veatch using DOPC + DilC12. (B) GUVs electroformed at 
Vanderbilt using the same techniques used in (A). Lipids are DOPC + Rho-PE.  Scale bar for 
(A), (B): 20µm. (C) and (D) Electroformation of proteo-GUVs. Rho-PE from lipid film and 
NBD-PS form proteoliposomes.  Merged images are shown. Scale bar for (C), (D): 10µm. 
 
setting up a collaboration to combine our efforts and data into a larger paper.  Prior to 
my visit, I purified large amounts of Drs2p and shipped it to their lab. These stocks of 
Drs2p had been assayed for yield (and concentration) and ATPase activity. I’ve included 
their reconstitution, ATPase assays, and GUV formation protocols in the Appendix 
chapter of this thesis.   
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The Drs2p was reconstituted and re-assayed for ATPase activity in Copenhagen.  The 
Drs2p proteoliposomes had ATPase specific activity and Drs2p was detectable by 
coomassie staining. These proteoliposomes were electroformed into GUVs by spotting 
the samples onto ITO slides, partially dehydrating the samples, and electroforming for 
over 6 hours in the presence of a sucrose solution. All of the imaging in Copenhagen was 
done with a DIC microscope.   
 
In Fig. 3-14, frames from movies for 2 of the GUVs, which tubulated after the addition of 
ATP, are presented (Fig. 3-14A and B).  The GUVs shown are composed of DOPC and 
20% DOPS. There are distinct tubes growing out of the larger GUV structure.  Upon 
viewing the movie (which can be found with my electronic data), you can see these 
tubes begin to form within moments of ATP addition.  As the tubes elongate, the main 
body of the GUV (which begins as a semi flaccid structure), becomes taut due to the 
increased loss of phospholipids from the inner leaflet.  Within 30-40 seconds, the 
reaction is complete - the GUV tightens as the tubes grow and eventually bursts, 
probably because it can no longer sustain the pressure associated with the redistribution 
of the lipids and the need to maintain membrane bilayer coupling.  
 
Drs2p was reconstituted into several lipid compositions (see below), which were then 
tested for changes in GUV membrane morphology.  In all, of about 50 experiments done, 
only 3 of the experiments yielded GUVs where we were able to see such directed growth 
of the membrane tubules.  One issue that was constantly faced was difficulty in finding 
GUVs to image, especially considering that we were using DIC imaging.  In Fig. 3-14, 
you can see how difficult it is to distinguish GUVs from the background of the slide.  
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Furthermore, these GUVs are constantly flowing so finding a GUV and capturing it is 
quite difficult. Lisa Theorin, our Danish collaborator, helped with the imaging.  When 
ATP was added to the sample, it exacerbated GUV movement.  In addition to flowing, 
the GUVs often tended to float.  This was an additional layer of difficulty because the 
GUV would move out of the field of focus.  As a result, I was constantly trying to re-
focus to find it.  This was often unsuccessful. Moreover, because the GUVs were 
bursting within seconds, there was only one shot at collecting data on each slide. 
 
Figure 3-14.  Assaying GUVs for changes in membrane morphology after ATP addition. (A) 
and (B) Upon addition of ATP at time = 0sec, the GUVs immediately began tubulating and 
producing thin and long projections from different parts of the GUV.  As these tubes grow, 
the main body of the GUV became more rigid. When the GUV was no longer able to 
withstand the pressure resulting from the growth of these tubes, it finally burst.  The light 
blue arrows point to the tubes that are forming. The entire reaction lasts about 40 seconds.  
Imaging was done using microscopes with DIC capabilities. For these experiments, Drs2p 
was reconstituted into proteoliposomes consisting of DOPC and 20% DOPS.  
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Lipid conditions tested for GUV electroformation: 
 DOPC  
DOPC + 20% DOPS 
DOPC + 20% DOPS + 1% PI4P 
DOPC + 0.1% Rhod-PE 
DOPC + 20% DOPS + 0.1% Rhod-PE 
DOPC + 10% DOPS 
DOPC + 10% DOPS + 1% PI4P 
 * These samples were assayed with and without ATP, and with ATPγS 
 
In the US, I worked to recapitulate the experiments done in Denmark.  I brought back 
ITO slides and silicon spacers from their lab.  The reason being that they did not have 
catalog information or technical specifications for any of these items.  As a result, neither 
they, nor I, were able to order more quantities of these items. The electroformation 
generator that was being used, was also quite different from the one at LIFE. So, I wasn’t 
able to recapitulate the settings on the machine.  I tried to find (and purchase) a 
generator that was similar but was unable to do so.  Again, they were unable to provide 
any purchase information for their equipment.  I tried to make the GUVs with as close 
settings as possible on our machine, but I wasn’t able to obtain any GUVs.  When I tried 
to adapt the Veatch protocols (since we had previous success using their settings on our 
generator), it scorched the ITO slides from Denmark.  This tells me that their ITO slides 
have a different (probably lower) level of conductivity than the ones we’re using.  
Unfortunately, there is no way to know what those levels are. 
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Moreover, since I wasn’t able to find a lab or inverted microscope that had DIC settings, 
I resolved to use fluorescence instead.  This was also helpful because it meant that I 
would be able to find the GUVs much more easily in the field of view, even if there was 
a low yield of GUV structures in my sample.  
 
Since it was difficult to recapitulate the Danish group’s protocol, I used techniques from 
both the Danish group and the Veatch lab (as well as trial-and-error) to develop a 
protocol that gave me consistent preps of GUVs.  These GUVs were large and could be 
easily found using a fluorescent microscope (Fig. 3-15A and B).  Furthermore, a lipid 
film was no longer deposited onto the ITO slides, so all the lipids in the GUVs came 
from proteoliposomes. Most of the proteoliposomes had 1% NBD-lipids or 0.1% Rho-PE 
which made GUV detection by fluorescence microscopy easier.  This protocol is the last 
protocol provided in the “GUV Protocols” section in the Appendix chapter.  
 
When imaging these GUVs, some of the same issues arose that were faced with the 
GUVs in Denmark. These GUVs tended to flow within the plane of imaging and 
sometimes floated to the surface of the sample (out of the field of view). This was a 
problem especially during ATP addition.  Furthermore, small changes in the osmolarity 
of the solution caused big changes in the GUV structure (Fig. 3-15C).  They tended to 
become flaccid and often elongated into tubular structures or had large tubules extend 
from their main body.  Occasionally, they re-formed into circular GUVs.  Some GUVs, 
meanwhile, were extremely taut and burst when ATP was added to the solution. It was 
also essential to image these GUVs quickly because evaporation on the slides caused 
rapid changes in osmolarity and, as a consequence, in the flaccidity or tautness of the   
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Figure 3-15.  New electroformation techniques using fluorescence analogs. GUVs were 
electroformed using DOPC + Rho-PE (trace) + Drs2p (A), or DOPC + NBD-PC (1%) + Drs2p 
(B) to test a new electroformation technique using a fusion of the Veatch and Danish 
protocols.  Scale bar: 50µm. (C) Large bulbs and tubes extend out of the GUVs due to 
uncontrollable shifts in the osmolarity of the solution. (D) GUVs trapped in a microfluidic 
chamber (see light blue arrows).  Images obtained using DIC.  
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GUV membrane. Thus, imaging these samples, especially during ATP addition, was 
difficult. 
 
I was able to detect tubulation similar to those observed in Denmark in these samples.  
The proteo-GUVs used to form the same types of tubes observed previously and then 
burst, when the pressure of tubule formation was too great for the GUV structure.  None 
of these tubulation events were captured by video because the GUVs used to float away 
faster than I could turn on the camera while tracking their movements. 
 
Several different techniques were attempted in order to improve imaging GUVs both 
before, during, and after ATP addition.  First, the GUVs were sunk to separate the larger 
GUVs from smaller GUVs.  Since GUVs are electroformed in the presence of sucrose and 
imaged in the presence of the same concentration of glucose, the GUVs tended to sink.  
This is because sucrose is denser than glucose even though they were present in the 
imaging sample in equimolar concentrations. To sink GUVs, you must gently pipet the 
GUVs (after electroformation) into a glucose solution of equimolar concentration to the 
sucrose concentration used during electroformation.  Allow the GUVs to settle for 
several minutes and then remove small aliquots from the bottom of the tube. When this 
process is done using protein-free GUVs, one tends to get a large GUVs concentrating at 
the bottom of the tube (also see Fig. 3-13A and B for an example). However, when this 
process was done using proteo-GUVs, the large GUVs in the population were not 
separable from smaller membrane structures – in fact, no GUVs could be isolated.  
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An alternate approach was, during ATP addition, to decrease the disturbance to the 
solution on the slide by adding in the ATP using a syringe or gel-loading tip.  The idea 
was that adding ATP, in this manner, would be much gentler than pipetting a drop onto 
the surface of the solution.  While this did decrease the movement a little, it was not 
enough to help with the imaging issues. I worked with Yuantai Wu (lab of Chris 
Janetopoulous) to add ATP using a micro-injector.  This device is commonly used in the 
Janetopoulous lab to gently add reagents at a specific location on the slide for 
chemotaxis experiments.  The micro-injector is hooked up to a microscope which enables 
imaging during addition of the desired reagents. This technique, again, did not work.  
There were several reasons for this – (a) we could not control or determine the amount 
of ATP that was being released by the micro-injector, (b) while the Janetopoulous lab 
uses cells (which adhere to the surface of the glass slide and moves less than GUVs), the 
GUVs are free floating and addition of ATP caused them to float out of the field of view, 
and (c) many of the GUVs burst during addition of ATP and/or had large tubules form 
due to sudden changes in the osmolarity of the solution (as described previously).  The 
videos showing this phenomenon can be found with GUV imaging data in my data 
folders. 
 
I worked with Neil Dani (Kendal Broadie lab) and Greg Pask (Larry Zweibel lab) to try 
to hold GUVs in place during ATP addition using a suction pipet and applying a gentle 
vacuum. We attempted the application of this vacuum both by manual and 
computerized methods. No matter how low the vacuum pressure applied, the GUVs, 
because they did not have a cytoskeleton or other mechanism that gave them structure, 
were getting sucked into the micro-pipet tip. In collaboration with the lab of John 
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Wickswo, I worked with Tommy Byrd and Kailey MacNamara to trap the GUVs in 
microfluidic devices.  The goal was to flow the GUVs into these structures and then flow 
ATP into the system.  When ATP makes contact with the GUVs, we can observe 
tubulation through a microscope and camera system that is hooked up to these devices.  
While GUVs were easily trapped in the microfluidic devices (Fig. 3-15D), and ATP was 
flowed in, we were not able to observe tubulation because the objectives on their 
microscope were not powerful enough to detect the small changes in the GUVs. Also, 
the objectives in their microscope could not be changed because of the way the system 
was set up. Most of the imaging was done in DIC.  We tried to move into fluorescence 
microscopy but because the objectives did not provide sufficient magnification, nothing 
could be detected.  Thus, there are several issues that remain with imaging the GUVs 
and getting good quality videos for publication.  On a basic level, the tubulation of the 
GUVs (during ATP addition) could be observed and captured, but the question still 
remains – where is Drs2p during this event? On the tube? On the GUV? At the 
intersection between the two?  
 
To better answer this question, a protein labeling kit for Alexa 488 (which dyes proteins 
for fluorescence in the green channel) was used to label purified Drs2p. After trying 
several methods, the following method worked best for labeling Drs2p.  After 
incubation of Drs2p with the dye, the protein-dye mixture was applied to a Ni column 
and the excess dye was allowed to flow through.  The column (with labeled Drs2p) was 
washed to remove traces of the dye and the labeled protein was eluted using imidazole. 
A separate sample of Drs2p was treated as a mock labeled control – it was not labeled 
(but was incubated with the same buffers) and was passed through the Ni column just  
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Figure 3-16.  Chemical labeling of Drs2p. (A) Single-step purified Drsp2 was labeled using 
an Alexa-488 chemical dye. Coomassie showing pure protein (TAP-Drs2), protein post-
labeling (Post-label, where “*” is labeled protein and “m” is mock control), and labeled 
protein after application to a Ni+2 column (where “*” is labeled protein and “m” is mock 
control). (B) The gel in (A) was analyzed using a Typhoon scanner to determine if Drs2p 
fluorescence could be detected on the gel. Where “Ni elu**” is labeled protein, and a few of 
the flow-through and wash samples are also run on the gel. (C) GUVs were electroformed 
using the labeled Drs2p and imaged.  Rho-PE was present in the lipid mixture added during 
reconstitution. (D) GUVs (with Rho-PE in red) electroformed and imaged using either 
labeled Drs2p (top panels) or unlabeled Drs2p (bottom panels). Scale bar: 10µm. (E) Proteo-
GUVs with labeled Drs2p (same samples as used in (D)) both before and 5 min after 
addition of ATP.  
 
like the labeled sample.  Aliquots of these samples were run on an SDS-PAGE gel.  The 
gel was imaged using a Typhoon system to try and pick up the fluorescence of the 
labeled sample (Fig. 3-16A), and the gel was then stained with Coomassie to determine 
amount of protein (Fig. 3-16B). From these images, you can see that after elution of the 
protein from the Ni column, it was difficult to detect any protein on the Coomassie (for 
the labeled and mock samples). Also, I hoped to detect a clear fluorescent band on the 
Typhoon exposed gel image, but was unable to do so. This suggests that the protein is 
not getting labeled. Furthermore, the Drs2p is unable to interact with the Ni beads (since 
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it’s flowing through and there’s no band detectable for Drs2p on the Coomassie). 
Another attempt at labeling showed that most of the Drs2p is not present in the flow-
through (data not shown). ATPase assays on the remaining protein shows that there’s 
barely any ATPase activity (data not shown).  This could be either because there’s so 
little protein present or because the label is interfering with the protein activity. 
 
Since there were a few (faint) bands detectable for labeled Drs2p in the Typhoon images, 
I reconstituted the labeled Drs2p (into PC + 0.1% Rho-PE) and electroformed the 
proteoliposomes into GUVs.   When imaged, several GUV structures that fluoresced 
green were detected (Fig. 3-16C).  These labeled structures, though, looked like they 
were filled with dye instead of having a circular fluorescence (suggesting labeling of the 
membrane) like the Rho-PE. Although several attempts were made, none of these 
structures tubulated during ATP addition.  
 
Lisa Theorin (from Denmark) visited our lab to learn these techniques, and during her 
time here, worked on labeling Drs2p and imaging proteo-GUVs. She successfully 
purified, labeled and reconstituted Drs2p into PC + 0.1% Rho-PE proteoliposomes, and 
electroformed them into GUVs.  When these samples were imaged, Alexa dye was 
detected in the membrane of the GUV (Fig. 3-16D, top panels).  Such fluorescence was 
not detected in the mock-labeled samples (Fig. 3-16D, bottom panels).   
 
Lisa’s samples were used to test for tubulation of the GUVs during ATP addition.  If 
Drs2p had indeed been labeled, most of the GUVs that fluoresce in the green channel 
should tubulate during ATP addition.  However, when ATP was added, no changes in 
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GUV morphology were detected.  Moreover, at least 50 GUVs that fluoresced in the 
green channel were tested and none of them had any tubulation or elongation 
phenotypes.  In Fig. 3-16F, an experiment is shown where a labeled proteo-GUV is 
imaged, both before, and 5 minutes after, ATP addition. There are no changes to the 
GUV membranes in any of the frames. So, either the Alexa-488 labeled Drs2p is inactive, 
or it is possible that the flippase activity of Drs2p is not capable of deforming 
membranes as we hypothesized. 
 
 
Weaknesses and Future Directions 
 
Ultimately, Drs2p was electroformed into proteo-GUVs that could be imaged with 
fluorescence microscopy. Tubulation of these membranes was also observed and, at a 
preliminary level, captured by video.  The dependence on ATP addition, of this 
particular type of membrane tubulation, suggests that this reaction is Drs2p-dependent. 
Unfortunately, there are several technical issues that plague this project – GUVs that 
flow and float, proper labeling of Drs2p, and appropriate imaging techniques.  
 
Improving imaging techniques will enable the rapid collection of better quality images 
and videos.  In addition to the approaches attempted (as described in this section), I 
tried to gently tether the GUVs to the surface of a steptavidin coated slide, by 
incorporating small amounts of biotinylated phospholipids in the GUVs, but not much 
work was done with this protocol. Optimizing conditions for gently tethering GUVs 
might enable the reduction of GUV flow and flotation during data collection. Gerdi 
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Kemmer (from the Pomorski lab), provided a basic protocol which she developed and 
this is included in the “Electroformation Protocols” section of the Appendix chapter.  
 
Answering the question of where Drs2p is, relative to the tubulation event, will be a 
major step towards completing this project. At the 2012 ASCB conference, I had the 
opportunity to speak to several scientists who were experts or were actively working in 
the area of GUV formation.  While most of them work primarily with cytosolic proteins, 
they were kind enough to give me some feedback about this project. One of their 
suggestions was to avoid using fluorescence labeling kits to label Drs2p. In their 
experience, they observed much secondary labeling of the membrane by these dyes 
(which may explain the results that were observed).  Their advice was to clone GFP onto 
Drs2p or clone in SNAP tags into the protein, so that these tags could be chemically 
labeled.  It is unclear what effect, if any, these cloning steps might have on the 
purification, yield, and activity of Drs2p.   
 
Based on these suggestions, the best way to proceed to complete this project is to clone 
GFP onto the N-terminus of Drs2p, between the TAP tag and the protein. This protein 
will, most likely, be active because GFP-Drs2p is a construct that is commonly used in 
the lab for in vivo experiments. However, the stability of the protein structure and 
activity of Drs2p, after protein purification, will have to be determined experimentally. 
 
 
 
 
 123 
Other questions that need to be addressed include the following: 
– Was the tubulation observed in Denmark (and in the recapitulated experiments) 
due to the flippase activity of Drs2p?  (labeling the protein will help answer this). 
The protein used for these experiments was single-step purified and there are 
many proteins that co-purify with Drs2p.  Are any of these proteins causing or 
contributing to the tubulation that was observed? 
– Can active preps of GFP-Drs2p be obtained? 
– Is Drs2p truly incorporated into the proteo-GUVs we’re imaging? 
– If Drs2p is chemically labeled, is it still active? 
An email from Lisa indicated that when they chemically labeled their purified 
proton pump, it was no longer active. This could be why addition of ATP to 
our labeled Drs2p-GUVs failed. 
 
Other aspects to look into include different methods for making GUVs, such as using 
fusion of proteoliposomes to create GUVs by using fusogenic peptides, lipids, or 
proteins (such as SNAREs). Although this makes the system more complex, it might 
resolve many of the issues that are present in the current system and results in the 
formation of larger sized proteo-GUVs with several molecules of protein present. 
 
 
 
 
  
 124 
 
CHAPTER IV 
 
SUMMARY AND FUTURE DIRECTIONS 
 
The movement of proteins from the Golgi complex to various parts of the cell is 
mediated by small transport vesicles. These vesicles bud off from the Golgi and carry 
with them macromolecules and proteins that are targeted to the various organelles or 
regions of the cell (Bonifacino & Glick, 2004).  This trafficking is essential for the normal 
function and growth of a cell.  In Saccharomyces cerevisiae, Drs2p, the founding member 
of the type IV P–type ATPase (P4–ATPase) family, is known to be responsible for aiding 
in the formation of these transport vesicles from the trans–Golgi network (TGN) and 
early endosomes (C. Y. Chen et al., 1999; Graham, 2004; Hua et al., 2002).  This is 
achieved by the flipping of specific phospholipids from the exoplasmic to the 
cytoplasmic leaflet of the membrane.  Such translocation results in membrane 
asymmetry, and also allows for the formation of transport vesicles in association with 
specific adaptors, coat proteins (such as clathrin), and cargo. 
 
The plasma membrane of most eukaryotes is asymmetric in both protein and lipid 
composition.  The lipids that are typically found in the extracellular leaflet of the 
membrane bilayer are phosphatidylcholine (PC) and sphingomyelin, while 
phosphatidylserine (PS), phosphatidylethanolamine (PE) and phosphatidylinositol (PI) 
are found in the cytosolic leaflet (Devaux, 1992; Zachowski, 1993).  This difference in 
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membrane lipid composition is critical to the normal functioning of the cell.  For instance, 
loss of membrane asymmetry that leads to the exposure of PS on the extracellular face of 
the cell can trigger various signals including platelet activation, clearance of senescent 
red blood cells and phagocytosis of apoptotic cells (Williamson & Schlegel, 2002; Zwaal, 
Comfurius, & van Deenen, 1977; Zwaal & Schroit, 1997).  
 
Phospholipids are amphiphilic molecules that consist of hydrophilic heads and 
hydrophobic tails.  Several phospholipids can come together to form energetically 
favorable structures, such as micelles and bilayers, which allow them to expose their 
hydrophilic head groups to the aqueous exterior and bury their hydrophobic tails 
(Alberts, Johnson, et al, 2008).  Phospholipids are able to diffuse very rapidly through 
the plane of the leaflet.  However, they are unable to translocate from one leaflet of the 
membrane bilayer to the other without overcoming a substantial energy barrier (Daleke, 
2003; Dolis, Moreau, Zachowski, & Devaux, 1997; Pomorski, Holthuis, Herrmann, & van 
Meer, 2004).  The half–time for spontaneous phospholipid flip–flop in liposomes is on 
the order of several hours to days depending on the lipid and the membrane.  
 
Several types of protein transporters exist which are able to cause rapid phospholipid 
flip–flop across the membrane. These transporters are classified according to substrate 
specificity, requirement for energy and direction of transport. The major focus of our lab 
is on phospholipid translocases, or ATP–dependent flippases.  Flippases use energy 
from ATP hydrolysis to translocate specific phospholipids such as PS and PE from the 
lumenal leaflet to the cytosolic leaflet of a membrane. This activity is uni–directional and 
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ATP–dependent (Daleke, 2003; Dolis et al., 1997; Graham, 2004; Menon, 1995; Pomorski 
et al., 2004). P4-ATPases are believed to be the proteins responsible for generating such 
phospholipid asymmetry in biological membranes.  The Drs2p/ATPase II subfamilies of 
P-type ATPases have been implicated as the enzymes that catalyze this activity. 
 
The yeast P4–ATPase, Drs2p, is an integral membrane protein possessing 10 
transmembrane segments (C. Y. Chen et al., 1999; Hua et al., 2002).  There are four 
additional members of the P4–ATPase family in S. cerevisiae, namely Dnf1p, Dnf2p, 
Dnf3p and Neo1p (Catty, de Kerchove d'Exaerde, & Goffeau, 1997; Graham, 2004; Hua 
et al., 2002).  Drs2p, along with Dnf1p, Dnf2p and Dnf3p, forms a group of essential 
genes.  This means that presence of any one of these genes will allow for cell viability 
but deletion of all four of these genes will be fatal to the cell (Hua & Graham, 2003).  
Such a relationship suggests a certain degree of functional redundancy between these 
P4–ATPases. These proteins are typically associated with a β subunit (Cdc50p for Drs2p, 
Lem3p for both Dnf1p and Dnf2p) and form a heterodimeric complex. The association of 
the β subunit to the P4–ATPase (α subunit) is required for the ER export of this α–β 
subcomplex and proper localization. While Drs2p is normally localized to the TGN of a 
cell, it is thought to cycle between the TGN and the early endosomes, as well as to the 
plasma membrane, early endosomes and back to the TGN.  Drs2p facilitates the 
formation of clathrin–coated vesicles from the TGN and early endosomes (Liu et al., 
2008).   
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Clathrin–coated vesicles are found in all nucleated cells, from yeast to humans.  These 
vesicles enable the trafficking of various proteins and lipids between organelles, 
especially between the plasma membrane and the endosomes, and between the TGN 
and the early endosome (Liu et al., 2008).  For clathrin–coated vesicles (CCVs) to form, a 
variety of adaptor proteins and associated proteins are essential. The heterotetrameric 
adaptor protein, AP-1, is involved in CCV formation at the TGN while AP-2 functions in 
endocytosis at the plasma membrane.  Initiation of vesicle formation, at the TGN, occurs 
when Arf1–GTP (ARF1, ADP–ribosylation factor 1) is recruited to the membrane. Arf1-
GTP then proceeds to recruit AP-1 which recognizes and binds a variety of cargo 
proteins (Kirchhausen & Harrison, 1981; Ungewickell & Branton, 1981). Cytosolic 
clathrin is then recruited to the bound adaptor proteins.  Clathrin organizes itself into 
hexagons and pentagons which enable it to enlarge the budding vesicle (Kirchhausen & 
Harrison, 1981).  Membrane deformation increases as more coat proteins are assembled 
onto the vesicle.  The protein amphiphysin then binds clathrin and acts as a receptor for 
dynamin which works to pinch off the fully formed vesicle at the bud neck.  Hsc70–ATP 
and auxilin are responsible for driving the disassembly of the clathrin coat, once the 
vesicle has been formed (Ahle & Ungewickell, 1989). 
 
As described in the Introduction (see section on “Membrane Asymmetry and Membrane 
Curvature”), there are several hypotheses about how membrane curvature is captured 
and the proteins responsible for creating this curvature.  In the Graham lab, we favor the 
model that Drs2p, by its unidirectional flippase activity, is responsible for creating 
positive membrane curvature at sites of vesicle budding.  Our lab has been able to show 
 128 
that in the absence of Drs2p, there is no AP-1/CCV function even though the coat is 
recruited to the TGN (Liu et al., 2008).  By electron microscopy, these Golgi membranes 
in drs2∆ cells are enlarged, cup-shaped structures with much less curvature than the 
tubular-vesicular structure of Golgi cisternae in wild-type cells.  We hypothesize that 
Drs2p contributes to membrane curvature based on the appearance of Golgi cisternae in 
drs2∆ cells and predications based on the bilayer-couple hypothesis.  Drs2p, we 
hypothesize, flips phospholipids from one leaflet to the other, expands the outer leaflet 
causing the creation membrane curvature which is captured by curvature-sensing 
proteins that are able to recruit AP-1 and clathrin onto the membrane (Graham & Kozlov, 
2010). However we have no direct evidence that Drs2p activity causes membrane 
bending. 
 
While phospholipid translocase activity had previously been observed in erythrocyte 
membranes, there had been no work correlating this activity to a particular class of 
proteins.  The first indication that phospholipid translocase activity was due to the 
action of P4-ATPases, came when Paramasivam Natarajan (of the Graham lab) 
published his work looking at flippase activities in purified trans-Golgi membranes from 
the yeast, S. cerevisiae.  Natarajan was able to show that activating these TGN 
membranes resulted in the translocation of spin-labeled analogs of phosphatidylserine 
(PS). Furthermore, he was able to demonstrate a Drs2p substrate specificity for PS over 
PC (phosphatidylcholine) (Natarajan et al., 2004).  
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Finally, it was in 2009, when independent publications from the Graham and Molday 
groups, showing the purification, reconstitution and in vitro flippase activities of P4-
ATPases, that this work was directly tested (Coleman et al., 2009; Zhou & Graham, 2009).  
This was some of the first work demonstrating, in a reconstituted system, that flippases 
were able to flip a phospholipid across a membrane bilayer. Prior to this, several groups 
had been successful in purifying ATPase II/Atp8a1, but not in reconstituting it or 
demonstrating flippase activity (Ding et al., 2000; Moriyama & Nelson, 1988; Paterson et 
al., 2006; Xie, Stone, & Racker, 1989).  The Graham lab was able to show flippase activity 
for Drs2p, while the Molday lab demonstrated this in ATP8A2.  Initially there was much 
genetic evidence to suggest that these P4-ATPases were flippases but these observations 
could just as easily have been attributed to secondary transport mechanisms.  It was the 
detection of flippase activity at the TGN (Natarajan et al., 2004), as well as the plasma 
membrane and secretory vesicles (Alder-Baerens et al., 2006; Pomorski et al., 2003; 
Riekhof & Voelker, 2006; Stevens, Malone, & Nichols, 2008) that gave convincing 
evidence that these proteins were indeed flippases.  The work by these groups, coupled 
with the biochemical evidence presented by the Graham and Molday labs have further 
cemented the notion that P4-ATPases are phospholipid flippases. 
 
While this work brought considerable progress to the field, the question remained – 
what influence, if any, does the flippase activity of P4-ATPases have on membrane 
morphology?  To  answer this question, I used a combination of purified Golgi 
membranes and negative stain EM to observe changes in membrane morphology.  Golgi 
membrane purification was a technique developed by Paramasivam Natarajan 
 130 
(Natarajan & Graham, 2006). TGN membranes were purified from strains which lacked 
four of the five yeast P4-ATPases (Drs2p, Dnf1p, Dnf2p, and Dnf3p), which are the four 
flippases that form an essential gene family.  These strains were kept alive with either a 
wild-type or temperature-sensitive form of Drs2p (DRS2 or drs2-ts).  The advantage of 
using these strains was that changes in membrane morphology, due to the flippase 
activity of the protein, could be primarily attributed to the function of Drs2p.  I found 
that late Golgi membranes, purified from these strains (which are extremely slow-
growing), were very heterogeneous in size (Fig. 3-1A and B).  It suggested that the Golgi 
membrane was fragmenting during purification.  However, Drs2p was considerably 
enriched in the Golgi membranes when compared to whole-cell extracts (Fig 3-1D). 
 
Since these samples (due to the heterogeneity in size of the membranes) were not ideal 
for further assays, I purified membranes from wild-type and kes1∆ cells.  The hope was 
that, by using kes1∆ membranes, there would be greater amounts of flippase activity 
detectable since Drs2p-dependent PS flippase activity is hyperactive in these strains 
(Muthusamy, Raychaudhuri, et al., 2009).  Late Golgi membranes from these strains 
yielded membranes which were larger, and easier to visualize using EM (Fig. 3-2A), 
with average membrane diameters around 150nm (compared to ~70nm for the 
quadruple mutant strains) (Fig. 3-2B).  After addition of ATP, via an ATP regeneration 
system, and incubation for 15min at 37°C, wild-type membranes showed some 
tubulation and elongation (Fig. 3-4A).  When these experiments were repeated with the 
three other strains (kes1∆, DRS2, and drs2-ts), obvious tubulation and elongation were 
not apparent.  What was apparent, was that it looked like there was fusion of smaller 
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membranes to form larger membranes (Fig. 3-4 C-E). Looking over the wild-type 
membrane data seems to suggest the same phenomenon.   
 
Ultimately, while tubulation and elongation of the membrane (i.e. the creation of 
membrane curvature), cannot be ruled out since it was present in such a small 
percentage of the membranes, it is just as likely that activation of the membranes by ATP 
is causing vesicular fusion.  This fusion, as it occurs, gives the appearance of tubulation 
and elongation.  Finally, these experiments were designed to determine the influence of 
flippase activity on membrane morphology.  Since these are native Golgi membranes 
which have many integral proteins present in the membrane, and cytosolic proteins that 
may be associated with the membrane, we cannot rule out the possibility that the 
changes in membrane morphology are due, either directly or indirectly, to the function 
of any number of these proteins.  If it is possible to detect Drs2p on these membranes, by 
either immunogold labeling or affinity purifying these membranes against Drs2p 
antibodies so that all the membranes assayed possess at least one molecule of Drs2p, we 
will be much closer to determining whether the tubulation/elongation morphology or 
the membrane fusion, is in fact due to the activity of Drs2p phospholipid translocation.  
 
To tie the influence of flippase activity to the generation of membrane curvature, as well 
as a potential role in the formation of transport vesicles, I attempted to recapitulate 
clathrin-coated vesicle budding using purified cytosol preps and Golgi membranes from 
my various strains. The cytosol preps were chock full of small vesicles that contained 
Drs2p (Fig. 3-5B). Attempts at purifying away these vesicles and obtaining a sample 
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containing only cytosolic proteins were unsuccessful (Fig. 3-5E).  Initial experiments 
where late Golgi membranes were incubated with ATP and cytosol were also not 
conclusive.  Improving cytosol purification conditions or purifying cytosolic proteins 
(involved in formation of transport vesicles) and adding them back into the reaction 
may alleviate this problem.   
 
Furthermore, at the time of these experiments, the role of the C-terminal tail of Drs2p 
was not very clear.  Perhaps using Drs2p strains lacking the C-tail or enzymatically 
removing the C-tail will ensure that most of the Golgi membranes will possess active 
Drs2p (Zhou et al., 2013).  This change will, hopefully, increase the amount of flippase 
activity at the membrane and make changes in membrane morphology more apparent. 
 
Since a major flaw with the Golgi membrane experiments was their complexity and our 
inability to control membrane composition, I transitioned to working with the 
reconstituted system in the hopes of gaining clearer results.  Although learning the 
purification and reconstitution techniques was expected to be fairly straightforward – 
these protocols had been previously published from our lab – it was anything but.  I was 
able to purify the protein and, in my hands, Drs2p had ATPase activity values similar to 
our previously published results.  The major issue faced with these techniques was that 
reconstitution of Drs2p into properly sealed proteoliposomes was unsuccessful. This 
was a major setback and was one that was faced by Xiaoming Zhou as well (he 
developed these techniques).  As a result, considerable amounts of time were spent 
trying to fix the “leaky liposome” problem.  This included experiments tweaking every 
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aspect of the purification and reconstitution protocols (this work is detailed in the 
beginning of the Chapter 3, Section 2).  Finally, it was switching detergents, from C12E9 
to C12E8 (Fig. 3-6 versus Fig. 3-11), that enabled the formation of properly sealed 
proteoliposomes.  
 
This single change improved the purification and reconstitution protocols considerably.  
In single-step purified Drs2p samples, the concentration of protein jumped from 
25ng/µL to almost 55ng/µL (Fig. 3-11B).  Furthermore, the ATPase activity of the 
samples increased 10-fold (Fig. 3-11E and F). Finally, while Drs2p reconstituted in the 
presence of C12E9 had 3-5% resistance to quenching by dithionite, Drs2p reconstituted 
in the presence of C12E8 was 25 – 30% resistant to dithionite quenching (Fig. 3-11D).  
This means that 50 – 60% of the proteoliposomes were sealed.  This improvement in seal 
now allowed me to move forward with performing flippase assays and preparing 
proteoliposomes for electroformation into giant unilamellar vesicles.  Best of all, these 
results were consistently reproducible and other graduate students in the lab were able 
to successfully reproduce these results. 
 
During the attempts at improving proteoliposome seal, I attempted to purify and 
reconstitute Drs2p using a protocol developed by the lab of Robert Molday (Coleman et 
al., 2009).  In their protocol, the detergents that were used included CHAPS and n-octyl-
β-D-glucopyranoside.  Furthermore, the protein was purified in the presence of lipids.  
Purifying Drs2p in this manner produced high yields of Drs2p that had significantly 
higher specific activities than samples produced either prior to or since. In fact, the 
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activity was almost 100-fold higher than what was published by Xiaoming (Fig. 3-9E). 
Although these Drs2p samples did not reconstitute into proteoliposomes, the 
foundations exist for creating protocols to purify and reconstitute very active protein.  
Furthermore, if future experiments require active, non-reconstituted protein, this would 
be an ideal technique to purify highly active Drs2p. 
 
Since formation of properly sealed proteoliposomes containing active Drs2p was 
successful, I worked to visualize changes in membrane morphology due to Drs2p 
flippase activity.  A growing field exists for the study of artificial membranes and 
protein association to these membranes.   Some of these membranes, called giant 
unilamellar vesicles (GUV’s) are particularly useful for these types of experiments since 
they are large (10-200µm), and can easily be visualized using fluorescence microscopy.  
Furthermore, these structures can be observed and imaged in real-time, which is a 
distinct advantage over EM experiments.   
 
The trouble faced was that Drs2p is a 10-pass transmembrane protein and not much 
literature exists on the reconstitution of such large proteins into giant unilamellar 
vesicles. Purified Drs2p degrades rapidly so it was essential that Drs2p be able to 
maintain its structure and activity during the electroformation process.  Through much 
trial-and-error, as well as successful collaborations with various labs (including Charles 
Day (Kenworthy lab), Sarah Veatch lab, and Thomas Günther-Pomorski lab), protocols 
were developed for electroforming Drs2p into GUVs.  Initial attempts at making proteo-
GUVs yielded preps with detectable levels of Drs2p (as assayed by Coomassie staining 
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of SDS-PAGE gels and Western blots, Fig. 3-12A and B). Furthermore, these  preps had 
detectable levels of ATPase activity, although the sample needed to be added to the 
assay in 5-fold excess (Fig. 3-12C). Finally, when these proteoliposomes containing 
Drs2p and NBD-phospholipids were electroformed in the presence of a lipid film 
containing Rhodamine-PE, we could detect incorporation of both the NBD-PS and the 
Rho-PE into the GUV structures.  This suggests that the proteoliposomes and the lipid 
film is fusing to form the GUVs (Fig. 3-12F).  However, it can be argued that the NBD-
lipids are dissociating from the proteoliposomes, or free NBD-lipids from the mixture, 
are incorporating into the GUVs and this is the fluorescence is being detected.  
Ultimately, using these techniques, we have no way of knowing whether, and how 
much, Drs2p is incorporating into the GUVs. 
 
In collaboration with Lisa Theorin in the Pomorski lab, I generated preliminary videos 
showing tubes forming from proteo-GUVs, upon ATP addition (Fig. 3-14). This suggests 
that Drs2p proteoliposomes are in fact incorporating into the GUVs.  Additionally, this 
is the first time we are able to show the effect of Drs2p on membrane morphology.  
Furthermore, this tubulation is surprisingly different from anything we had expected to 
see.  Our initial hypothesis, based upon observations by the groups of Thomas Günther-
Pomorski and Andreas Herrmann showed that, when phospholipids are added 
exogenously to a GUV, the entire body of GUV undergoes a shape change as large 
tubules form and extend outward (Papadopulos et al., 2007).  The addition of the 
phospholipids to the outer leaflet would cause an expansion in the outer leaflet when 
compared to the inner leaflet.  This is the reason for the formation of such tubules.  This 
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manner of tubulation (similar to the images shown in Fig. 3-15C) was what I expected to 
see during ATP addition. The difference in the type of tubulation observed indicates that, 
in addition to flipping phospholipids, Drs2p is also working to stabilize the membrane 
at the site of increasing curvature.  The conviction that this tubulation is due to the 
flippase activity of Drs2p is further cemented by the observation that these changes to 
GUVs are observed only upon addition of ATP.  
 
However, many questions (as detailed in the Future Directions section of the Chapter 3, 
Section “Electroformation of Giant Unilamellar Vesicles”) remain concerning the 
localization of Drs2p along the growing tubes and the presence of Drs2p in the GUV 
structures.  Since labeling of the Drs2p yielded protein which, in spite of ATP addition 
and analysis of over 50 membranes possessing Alexa-488 labeled-Drs2p, was inactive 
(Fig. 3-16E), the only option was to find alternative methods to labeling Drs2p.  
 
Experimentally addressing these questions will enable us to have clearer understanding 
about the role that Drs2p plays on membrane morphology (especially in the proteo-
GUVs).  Some ways to achieve this is by cloning GFP onto Drs2p which will enable 
detection of Drs2p in the GUVs and allow the experimenter to target GUVs that contain 
Drs2p. Other suggestions by leading scientists in the field include using SNAP tag 
systems to achieve labeled, active protein. This assay, once set up and optimized, will be 
very useful in addressing questions that go beyond the role of Drs2p in membrane 
curvature.  For instance, it will now be possible to test the influence of specific proteins 
(especially regulators of flippases) on Drs2p flippase activity since we can purify and 
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add these proteins into the proteo-GUV system.  Furthermore, GUVs of different 
phospholipid compositions can be created and the influence and effect of these 
molecules can be tested, both in regards to Drs2p and to the membrane as a whole.  For 
instance, such systems will be significant in the field of microdomain and lipid raft 
formation. We can also ask questions that will help identify the major players and the 
sequence of steps involved in the budding of mature transport vesicles from a 
membrane. 
 
I was able to use my optimized purification and reconstitution techniques to complete 
experiments looking at the influence of the C-terminal tail of Drs2p on regulating Drs2p 
activity (Zhou et al., 2013).  The observation, initially made by Xiaoming, that C-
terminally TAP-tagged Drs2p was enzymatically dead when compared to N-terminally 
tagged Drs2p (Fig. 2-1) spurred the exploration of whether the C-tail of Drs2p functions 
as an R domain to regulate Drs2p activity.  Several P-type ATPases have regulatory 
domains in either their N-terminus or C-terminus.  These domains serve to auto-regulate 
the activity of the ATPase and can also serve as sites of interaction with other proteins.  
Several examples of these are given in the Introduction to Chapter 2 (Au, 1987; P. James 
et al., 1988; Palmgren et al., 1990; Portillo et al., 1989; Rasi-Caldogno et al., 1992, 1993, 
1995). Previous work from the Graham lab had shown that the Drs2p C-tail has motifs 
that can bind phosphatidylinositol 4-phosphate (PI(4)P) and Gea2p (a yeast Arf-GEF).  
The presence of PI(4)P or the addition of Gea2p to purified Golgi membranes also 
activated Drs2p flippase activity (Natarajan et al., 2009).  Coupled with Xiaoming’s 
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observations, we hypothesized that the C-terminal tail of Drs2p plays a major role in the 
self-regulating flippase activity. 
 
In our experiments, enzymatically removing the C-terminal tail of Drs2p conferred 
higher levels of ATPase activity to the protein (Fig. 2-4).  Drs2p activity, which is 
stimulated by the presence of PI(4)P was considerably increased in samples that 
possessed the full-length C-tail (Fig. 2-7D and E).  When the C-tail was removed, PI(4)P 
had no influence on Drs2p activity (Fig. 2-7F).  Moreover, the flippase activity of tail-less 
Drs2p had similar values to full-length Drs2p activated by the presence of PI(4)P.   
 
Thus, we surmise that, within cells, the C-tail of Drs2p is responsible for auto-inhibition, 
and this inhibition is removed when the tail comes in contact with PI(4)P. This is the first 
evidence that PI(4)P directly interacts with Drs2p to regulate its activity.  It is still 
unclear whether clipped Drs2p is found in vivo, although Western blots show no sign of 
such a moiety (Fig. 2-5).  The Sec7 domain of Gea2p, which was shown to be a regulator 
of Drs2p in TGN membranes, was shown to have very little effect on Drs2p activity in 
the reconstituted system (Fig. 2-6).  It is likely that this is due to the absence of Arl1-GTP, 
as proposed by the work of Fang-Jen Lee’s lab (Tsai et al.). The Lee group was able to 
show that three proteins – Drs2p, Arl1p and Gea2p – form a stable ternary complex at 
the TGN.  Additionally, these proteins directly interact with each other.  It is possible 
that Arl1p is associated and co-purifies with Golgi membranes.  This may serve to 
explain why, in purified late Golgi membranes, addition of exogenous Gea2p stimulates 
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Drs2p activity while it doesn’t in the reconstituted system (Natarajan et al., 2009; Zhou et 
al., 2013).   
 
In conclusion, the work presented in this thesis provides support for the model of how 
Drs2p creates membrane curvature and works to create transport vesicles. A new role 
for the C-terminal tail, in regulating Drs2p activity at the membrane, has been identified.  
Strong preliminary data showing the creation of membrane curvature and tubulation, 
upon ATP addition to Drs2p proteo-GUVs, has been detailed. I have also improved and 
re-established the purification and reconstitution methods for Drs2p.  Furthermore, new 
insight has been gained on how to improve these purification conditions.  A novel 
technique for electroformation of large integral membrane proteins has been developed 
and the foundations for answering an important question in the protein trafficking field 
– i.e. what role do flippases play in the creation of membrane curvature and how do 
they affect the formation of transport vesicles – has been presented.  These tools will 
provide the foundation for further exploration of many important questions in the 
trafficking field. Finally, new roles for Drs2p regulators have been defined, which will 
aid in future experiments by allowing researchers to improve the conditions for testing 
flippase activities.   
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APPENDIX 
 
PROTOCOLS FOR PURIFICATION AND IMAGING OF LATE GOLGI MEMBRANES 
 
 
Yeast Strains used 
Information about strain backgrounds can be found in the following papers: 
 Quadruple mutants: (Natarajan et al., 2004) 
 kes1∆:  (Muthusamy, Raychaudhuri, et al., 2009) 
 
 
 
Negative Staining and Electron microscopy 
Protocols for Preparation of Carbon grids and Negative staining can be found in my lab 
notebook.  Melanie Ohi graciously provided these protocols as well as access to an 
electron microscope.  More details about these protocols can be found in her paper (Ohi, 
Li, Cheng, & Walz, 2004).  
 
 
Differential Centrifugation Assays: 
**  Protocols for Kex2 and GDPase assays can be found in the original paper (Natarajan 
& Graham, 2006). 
  **  Bicinchoninic Acid (BCA) Assay protocol is provided with the BCA kit (Sigma). 
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Cell Fractionation (late-Golgi membrane prep)  
* This protocol is modified from Natarajan, et al. (2006) 	  
1.   Inoculate the appropriate amount of cells into 1000mL or 2000mL of YPD and allow 
it to grow, overnight at 30°C (or 27°C for ts-strains), to an OD600 of 0.4 – 0.45 
OD/mL.  RECORD the OD600 of the culture in the morning. 
 
2.   Temperature shift all or part of the culture if needed for the experiment.  If a 
temperature shift is not needed, allow the culture to grow to an approximate OD600 
of 0.5 – 0.65 OD/mL.  RECORD the OD600 of the culture. 
 
3.   Harvest the cells by centrifugation at 6000rpm for 10 minutes (Sorvall GS-3 rotor).  
 
4.   Wash the pellet with 10mM Na Azide.  Spin at 6000rpm for 5 minutes (Sorvall SS-34 
rotor).  Pour off supernatant. 
    
   500µL  1M Na Azide (NaN3)    Total volume: 50mL 
   45mL  ddH2O 
  
 * For 1 Liter of cells use 100mL.   
 
5.   Resuspend the cells in softening buffer at 10 OD/mL.  Incubate the cells, on ice, for 
10 minutes.  Spin at 6000rpm for 5 minutes.  Pour off supernatant. 
    
  Softening Buffer = 0.1M Tris-Cl, pH 9.4 + 40mM 2- (or β-) mercaptoethanol + 
10mM Na Azide  
    
   5mL  1M Tris-Cl, pH 9.4    Total volume: 50mL 
   500µL  1M Na Azide 
   44.36mL  ddH2O 
   140µL  100% β-mercaptoethanol  
 
6.   Resuspend the cells in spheroplasting buffer at 50 OD/mL. 
    
  Spheroplasting Buffer = 1M Sorbitol + 20mM Tris-Cl, pH 7.5 + 10mM Na Azide   
    
   3.75mL  4M Sorbitol     Total volume: 15mL 
   300µL  1M Tris-Cl, pH 7.5 
   150µL  1M Na Azide 
   10.8mL  ddH2O 
    
 * Combine the cells from all of the 50mL spun tubes into one spin tube (per strain) with buffer. 
 
7.  Take 10µL of sample and dilute it to 1mL with water.  Mix well and measure the 
OD600. RECORD the value obtained. 
 
8.   Add to the cells, 1µL per 5 OD’s of cells, a 10mg/mL solution of Zymolyase. 
    
 * This amount can be between 100 – 250µL of 10mg/mL Zymolyase per strain. 
 
9.   Incubate the tubes at 30°C for 20 minutes.  Measure the OD600 again.  It should be 
~5% of the starting value.  If not, add more enzyme and continue to incubate the 
cells until it reaches this value.  RECORD the final OD600 value obtained.   
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 Spin at 6000rpm for 5 minutes.  Pour off the supernatant. 
 
10.  Wash the cells in spheroplasting buffer at 10 OD/mL.  Spin at 6000rpm for 5 
minutes.  Pour off supernatant. 
    
  Spheroplasting Buffer = 1M Sorbitol + 20mM Tris-Cl, pH 7.5 + 10mM Na Azide 
    
   12.5mL  4M Sorbitol     Total volume: 50mL 
   1mL  1M Tris-Cl, pH 7.5 
   500µL  1M Na Azide 
   36mL  ddH2O 
    
* Turn on the ultracentrifuge at this time and allow the vacuum to cool it down to 4°C.  Place the 
Ti270 rotor in the refrigerator to cool.  
 
11.  Resuspend the cells in cell lysis buffer at 15-20 OD/mL.  Resuspend the pellet 
completely.  Incubate the cells, on ice, for 15 minutes.  Dounce homogenize using 10 
– 15 strokes. 
    
  Cell Lysis Buffer = 0.1M Sorbitol + 10mM TEA, pH 7.5 + 1mM EDTA + 1mM YPIC 
+ 1mM PMSF       
    
   1.25mL  4M Sorbitol     Total volume: 50mL 
   2mL  250mM TEA, pH 7.5 
   500µL  500mM EDTA 
   300 – 400µL  Yeast Protease Inhibitor Cocktail (YPIC) 
   100µL  500mM PMSF (Prepare this in DMSO) 
   ~46.8mL  ddH2O 
    
 * Use approximately 20mL of cell lysis buffer per strain.  The excess can be used to top off the 
centrifuge tubes in step 13.  
 
12.  Pour the cells into 50mL centrifuge tubes and centrifuge the lysate at 2800rpm (1000 
x g) for 6 minutes in order to clear unbroken cells (Sorvall SS-34 rotor).  
 
13.  Transfer the supernatant into an ultracentrifuge tube.  Spin, in the ultracentrifuge, at 
40,500rpm (130,000 x g) for 1 hour at 4°C (T1270 rotor).  
 
14.  Carefully remove the supernatant from the ultracentrifuge tubes after the spin.  
Don’t disturb the pellet.  Resuspend the pellet in 200 – 400µL gradient buffer.  Use a 
mini dounce homogenizer to resuspend the membrane pellet well, then add enough 
60% sucrose to bring the volume up to 2mL. 
 
  Gradient Buffer = 10mM Hepes, pH 7.5 + 1mM Na Azide  
    
   500µL  1M Hepes, pH 7.5    Total volume: 50mL 
   50µL  1M Na Azide 
   ~49.5mL  ddH2O 
    
  All sucrose solutions are prepared weight/weight in Gradient Buffer. 
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15.  Layer a sucrose step gradient above the sample (in 60% sucrose) consisting of: 
    
  47.5% sucrose   1.5mL 
  45% sucrose   1.0mL 
  42% sucrose   2.0mL 
  40% sucrose   2.0mL 
  38% sucrose   1.0mL 
  36% sucrose   1.0mL 
  32% sucrose   1.5mL    
 
16.  Spin the tubes in the Beckman SW41Ti (or Sorvall TH-641) swinging bucket rotor at 
31,000 rpm for 17 hours at 4°C. 
 
17.  Collect sucrose fractions (1mL each) starting from the top. 
    
* The top layer is considered fraction 1. There will be approximately 12 fractions total (for each 
strain). 
 
18.  Measure the refractive index of each fraction.  Measure the Kex2 activity and 
GDPase activity of each of the fractions.  Also, measure the amount of protein in 
each fraction using the BCA Assay (Sigma kit). 
 
19.  Combine the peak Kex2 fractions for late Golgi membranes.  Combine the peak 
GDPase fractions which is early Golgi membranes.  
    
 * To determine the peak Kex2 fractions, calculate the following for each fraction: Kex2 activity 
divided by protein concentration (from BCA Assay) -- Kex2/[protein].  Combine the two 
fractions (per strain) that have the highest value after this calculation. 
 
20.  Mix the two fractions as well as 3 volumes of H-Buffer and transfer into 
ultracentrifuge tubes.  Spin, in the ultracentrifuge, at 40,500rpm (130,000 x g) for 1 
hour at 4°C (T1270 rotor).  
    
  H-Buffer = 10mM Hepes, pH 7.5 + 150mM NaCl  
 
   500µL  1M Hepes, pH 7.5    Total volume: 50mL 
   1.5mL  5M NaCl 
   48mL  ddH2O 
    
 
21.  Resuspend the pellet in 300µL of H-Buffer + 20% glycerol and measure the protein 
concentration of 5µL of the membranes using the BCA Assay.  
    
 * Use 5µL of the resulting solution to determine the total amount of protein collected. 
 * Use H-Buffer + 20% glycerol as a blank for this step. Prepare ddH2O blank as a control. 
 
22.  Dilute the membranes to a final concentration of 0.5mg/mL using H-Buffer + 20% 
glycerol.  Aliquot 100µL into sterile eppendorf tubes and store in a box in the –80°C 
freezer.    
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Cytosol preparation 
 
* This protocol was modified from the method described for “Preparation of Cytosolic Extracts” 
from In Vitro Reconstitution of Intercompartmental Protein Transport to the Yeast Vacuole, by 
Thomas A. Vida, Todd R. Graham, and Scott D. Emr. 
 
 
1.   Inoculate the appropriate amount of cells into 1000mL of YPD and allow it to grow, 
overnight at 30°C (or 27°C for ts-strains), to an OD600 of 2.0 – 5.0 OD/mL.  RECORD 
the OD600 of the culture in the morning. 
 
2.   Harvest the cells by centrifugation at 6000rpm for 10 minutes (Sorvall GS-3 rotor).  
 
3.    Wash the cells with ice–cold H-Buffer.  Spin at 6000rpm for 10 minutes (Sorvall GS-
3 rotor).  Pour off supernatant. 
    
  H-Buffer = 10mM Hepes, pH 7.5 + 150mM NaCl  
    
   500µL  1M Hepes, pH 7.5    Total volume: 50mL 
   1.5mL  5M NaCl 
   48mL  ddH2O 
 
4.   Resuspend the cells in H-Buffer + YPIC + PMSF at 200 OD/mL.   Filter the cells 
through cheesecloth.  Passage the cells 6 times through the Emulsiflex to ensure 
efficient lysis. 
    
 * Do not exceed 30,000psi on the Emulsiflex!  Do not pass less than 10mL in the Emulsiflex! 
 
5.   Pour the cells into 50mL centrifuge tubes and centrifuge the lysate at 12,000rpm 
(17,000 x g) for 15 minutes in order to clear unbroken cells (Sorvall SS-34 rotor). 
 
6.    Transfer the supernatant into an ultracentrifuge tube.  Spin, in the ultracentrifuge, 
at 42,000rpm (162,000 x g) for 1 hour at 4°C (T1270 rotor).  
 
7.   Aliquot the resulting supernatant into sterile eppendorf tubes and store in a box in 
the –80°C freezer.  
 
8.   Do a BCA Assay to determine the concentration of protein in the cytosol. 
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PROTOCOLS FOR PURIFICATION, RECONSTITUTION AND ASSESSING   
ACTIVITY OF Drs2p 
 
 
The protocols in this section include those involved in the purification of Drs2p using 
C12E9, which was previously published by the Graham lab.  Modifications to that 
protocol, including the use of C12E8 as a detergent, or a new protocol using CHAPS and 
n-octyl-β-D-glucopyranoside have also been included.  The ATPase, Coomassie, Pre-
quenching, Flotation and Flippase Assays that have been used within Chapter 3 of this 
thesis have also been outlined.  
 
 
Yeast Strains used 
Information about strain backgrounds can be found in the following paper 
 (Zhou & Graham, 2009): 
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Single-step purification of TAPN-Drs2p with C12E9 
* Adapted from Zhou and Graham (2009) 
 
Lysis buffer (LB) 
 10mL total (⎧L) Final (mM) 
1M Tris, pH 7.5 400 40 
5M NaCl 1mL 500 
0.5M EDTA 10 0.5 
1M Imidazole, pH 8 400 40 
0.1M PMSF 100X (EtOH) 100 1 (1X) 
100X pPIC (EtOH) 100 1X 
dH2O 7.99mL  
 
1K OD/1mL LB (20mL minimum); EF-C3, 25K psi, 6 pass (lysis efficiency > 95%); 
15K X g for 12 min at 4°C; Keep supernatant (S15); 
 
Wash buffer (WB) 
 10mL total (µL) Final (mM) 
1M Tris, pH 7.5 400 40 
5M NaCl 1mL 500 
1M Imidazole, pH 8 400 40 
10% C12E9 100 0.1% 
dH2O 8.1mL  
 
Pre-wash Ni-NTA-beads w/ 10mL WB at 4°C and transfer into S15; 
Add in 1/9 vol of total S15 of 10% C12E9 (containing 100µL new pPIC & PMSF); 
Rock for 2hr at 4°C; 
Spin down Ni-NTA-beads at 4°C and aspirate off most of supernatant; 
Transfer the rest to column and flow thru at 4°C; 
Wash Ni-NTA-beads w/ 100mL WB at 4°C; 
 
Ni-NTA elution buffer (NEB) 
 1mL total (µL) Final (mM) 
1M Tris, pH 7.5 40 40 
5M NaCl 30 150 
10% C12E9 10 0.1% 
1M Imidazole, pH 8 200 200 
dH2O 720  
 
Incubate protein-Ni-NTA w/ two 0.5mL NEB for 5min at 4°C w/ periodical 
resuspension;  
Elute and combine to 1mL eluate; Reconstitute. 
 
 
 
 147 
Two-step purification of TAPN-Drs2p with C12E9 
* Adapted from Zhou and Graham (2009) 
 
Lysis buffer (LB) 
 10mL total (µL) Final (mM) 
1M Tris, pH 7.5 400 40 
5M NaCl 300 150 
0.5M EDTA 40 2 
50% Glycerol 2mL 10% 
0.1M PMSF 100X (EtOH) 100 1 (1X) 
100X pPIC (EtOH) 100 1X 
dH2O 7.06mL  
 
1K OD/1mL LB (20mL minimum); EF-C3, 25K psi, 6 pass (lysis efficiency > 95%); 
5K X g for 6 min at 4°C; Keep supernatant (S5); 
 
Wash buffer a (WBa) 
 10mL total (µL) Final (mM) 
1M Tris, pH 7.5 400 40 
5M NaCl 300 150 
50% Glycerol 2mL 10% 
10% C12E9 100 0.1% 
dH2O 7.2mL  
 
Pre-wash IgG-beads w/ 10mL WBa at 4°C and transfer into S5; 
Add in 1/9 vol of total S5 of 10% C12E9 (containing 100µL new pPIC & PMSF); 
Rock for 2hr at 4°C; 
Spin down IgG-beads at 4°C and aspirate off most of supernatant; 
Transfer the rest to column and flow thru at 4°C; 
Wash IgG-beads w/ 10mL WBa at 4°C; 
 
TEV cleavage buffer (TCB) 
 1mL total (µL) Final (mM) 
1M Tris, pH 7.5 40 40 
5M NaCl 30 150 
50% Glycerol 200 10% 
10% C12E9 10 0.1% 
100% 2-ME 1.4 20 
0.5M EDTA 1 0.5 
dH2O 717.6  
 
Add in 1mL TCB w/ 100U TEV; Incubate for 2hr at 16°C; 
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Wash buffer b (WBb) 
 10mL total (µL) Final (mM) 
1M Tris, pH 7.5 400 40 
5M NaCl 600 300 
50% Glycerol 2mL 10% 
10% C12E9 100 0.1% 
1M Imidazole, pH 8 200 20 
dH2O 6.7mL  
 
Pre-wash Ni-NTA-beads w/ 10mL WBb at RT; 
 
Ni-NTA binding buffer (NBB) 
 10mL total (µL) Final (mM) 
1M Tris, pH 7.5 400 40 
5M NaCl 600 300 
50% Glycerol 2mL 10% 
10% C12E9 100 0.1% 
1M Imidazole pH 8 200 20 
100% 2-ME 7 10 
dH2O 6.693mL  
 
Elute 1mL TEV action at 4°C to a 15mL conical tube; 
Add in 20µL 1M Imidazole pH 8 and 5µL 1M MgCl2/mL TEV eluate; 
Wash IgG-beads w/ 4mL NBB at 4°C and combine wash with TEV eluate; 
Add eluate in Ni-NTA-beads and incubate in column for 1hr at 4°C; 
Elute and discard flow-thru; 
Wash Ni-NTA beads w/ 2x 10mL WBb at 4°C; 
 
Ni-NTA elution buffer (NEB) 
 1mL total (µL) Final (mM) 
1M Tris, pH 7.5 40 40 
5M NaCl 60 300 
50% Glycerol 200 10% 
10% C12E9 10 0.1% 
1M Imidazole, pH 8 200 200 
dH2O 490  
 
Incubate protein-Ni-NTA w/ 0.5mL NEB for 5min at 4°C w/ periodical resuspension; 
Elute; 
Add in 1vol 80% glycerol in H2O and store at -20°C. 
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Reconstitution of purified TAPN-Drs2p with C12E9 
* Adapted from Zhou and Graham (2009) 
 
1. Prepare lipid mixture as follows in chloroform: 
 2umol egg PC + 20nmol NBD-PS 
  Evaporate organic solvent under N2 stream; 
 
2. Put lipid sample in a vacuum desiccator for 1hr at RT; 
3. Add in 375µL dH2O, 50µL 10X RB and 75µL 10% C12E9; 
4. Gently vortex for 10min at room temp and dissolve lipids completely; 
5. Add in 500µL protein solution and incubate for 10min at 4°C; 
6. Pre-wash BioBeads SM2 w/ 2x 10mL methanol (5min for the first), 3x 10mL water 
and 10mL 1x RB and keep it moist at 4°C; 
7. Add 100mg wet pre-washed SM2 in proteoliposome sample and incubate for 6 hr at 
4°C w/ end-to-end rotating; 
8. Add another 200mg wet pre-washed SM2 in proteoliposome sample and incubate 
overnight at 4°C w/ end-over-end rotating; 
9. Pipette off carefully and keep turbid supernatant;  Store at 4°C. 
 
10X RB: 400mM Tris 7.5 + 1.5M NaCl 
 
1X RB: 40mM Tris 7.5 + 150mM NaCl 
 
 
 
Liposomes were created as follows: 
 
- Instead of adding 500µL protein solution (as indicated in step 5 above), add a 
500µL buffer solution similar to the solution with which your protein will be 
eluted. 
 
- All of the other steps are done exactly as written above. 
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Prequenching a sample 
 
Mix 200 µL of each proteoliposome sample with 10mM dithionite (sodium hydrosulfite). 
Incubate the sample for 5 min on ice. Proceed with flotation protocol. 
 
Flotation and Removal of Fractions 
* Adapted from Zhou and Graham (2009) 
 
On the bottom of the centrifuge tube, place 1:1 sample: 80% glycerol (mixed).   
This should be 400µL in volume. 
 
Above that create a layer of 600µL volume of 10% glycerol. 
 
Spin this sample at 50,000rpm in a TLS55 (spinning bucket) rotor for 3 hours 
at 4°C. 
 
Remove 5 fractions in 200µL aliquots from the top.   
The top fraction is F5 and the bottom is F1.  
 
Time trace for samples 
 
Mix 10µL of proteoliposome sample and 1mL of 1X RB in a disposable cuvette by 
inverting. 
Measure the total fluorescence in the sample for 30 sec. λex = 467nm and λem = 534nm. 
 
Add in 10µL of 1M dithionite and mix by inverting several times. 
Measure the amount of fluorescence quenched for 120 sec. 
 
Add in 50µL of 10% Triton X-100 (from Anatrace) and mix by inverting 3 or 4 times. 
Measure fluorescence for 30 sec. 
 
** 1X RB = 40mM Tris 7.5 + 150mM NaCl 
 
Coomassie Staining of Gels 
 
Life Technologies pre-cast 10% Bis-Tris SDS-PAGE gels were used with MES running 
buffer.  The microwave protocol for Simply Blue SafeStain by Invitrogen was used to 
stain the gels. 
The following BSA Standards were prepared and 10µL each were loaded onto the gels:  
2 ng/µL, 10 ng/µL and 50 ng/µL. 
Gels were scanned using the Odyssey system. 
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ATPase Assay (and colorimetric determination) 
* Adapted from Zhou and Graham (2009) 
 
Setup for Assay: 
 
Master mix: 
      Per sample 
100mM Na-ATP    2µL 
0.5M HEPES, pH 7.5    5µL 
1M NaCl     5µL 
500mM KCl     5µL 
100mM MgCl2     5µL 
dH2O      18µL 
 
Add 40µL of master mix to 10µL of sample (50µL total volume).   
Incubate at 37°C for 60min. 
Add 150µL dH2O to stop the reaction (total vol is now 200µL).  
 
Proceed to colorimetric determination. 
** 5µL of 10% C12E8 (or other detergent) can also be added to the Master mix (decrease 
the amount of water to 13µL) if necessary. 
 
Colorimetric Determination: 
 
Add 150µL of PiA solution and mix; Wait 15s 
Add 150µL of PiB solution and mix; Wait 2min 
Add 500µL of PiC solution and mix; Transfer sample to cuvette 
After 30min, read A625.  
 
PiA solution: 2 vol of 7.8% (v/v) H2SO4 + 1 vol 0.1M Na2MoO4 
 
PiB solution: 37.16mg malachite green in 100mL 1% (w/v) polyvinyl alcohol  
(PVA; dissolves at 80°C); [0.4mM malachite green] 
 
PiC solution: 7.8% (v/v) H2SO4 
 
 
Measure nmol of Pi released against a KH2PO4 (0 nmol to 6 nmol) standard curve. 
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Single-step purification of TAPN-Drs2p with CHAPS, n-octyl-β-D-glucopyronoside 
* Adapted from Coleman, et al, 2009 
 
Lysis buffer (LB) 
 
 10mL total (µL) Final (mM) 
1M HEPES, pH 7.5 500 50 
5M NaCl 300 150 
1M MgCl2 50 5 
1M Imidazole pH 8 400 40 
0.1M DTT 100 1 
0.1M PMSF 100X (EtOH) 100 1X 
100X pPIC (EtOH) 100 1X 
dH2O 8.45mL  
 
1K OD/1mL LB (20mL minimum); EF-C3, 25K psi, 6 pass (lysis efficiency > 95%); 
Spin samples at 15K x g (11,400rpm in SS-34) for 12min at 4°C; Keep supernatant (S15); 
Spin S15 at 23K x g (14,000rpm in SS-34) again for 12min, 4°C; Keep supernatant (S15-2); 
Transfer S23 to ultracentrifuge tube and spin at 130K x g (40,500rpm in T-1270) for 
60min; 
 
Solubilizing buffer (SB) 
 
 5mL total (µL) Final (mM) 
1M HEPES, pH 7.5 250 50 
5M NaCl 150 150 
1M MgCl2 25 5 
0.1M DTT 50 1 
dH2O 4.525mL  
 
Resuspend pellet with 1mL SB + 10µL new pPIC & PMSF and dounce homogenize 
(P130); 
Mix 0.5mg DOPC (20µL) in 4mL SB + 550µL 200mM CHAPS (final:20mM) + 40µL pPIC 
& PMSF;  Add to the resuspended pellet (P130); 
 
Wash buffer a (WBa) 
 
 5mL total (µL) Final (mM) 
1M HEPES, pH 7.5 250 50 
5M NaCl 150 150 
1M MgCl2 25 5 
0.1M DTT 50 1 
200mM CHAPS 250 10 
dH2O 4.275mL  
 
Pre-wash Ni-NTA-beads w/ 5mL WBa at 4°C and transfer beads into P130;  
Rock for 2hr at 4°C; 
Transfer sample to column and flow thru at 4°C; 
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Wash buffer b (WBb) 
 
 5mL total (⎧L) Final (mM) 
1M HEPES, pH 7.5 250 50 
5M NaCl 150 150 
1M MgCl2 25 5 
1M Imidazole pH 8 200 40 
10% n-octyl-β-D-glucopyranoside 375 0.75% 
0.1M DTT 50 1 
dH2O 3.95mL  
 
Wash Ni-NTA-beads 6 times w/ 500µL WBb + 0.5mg/mL egg PC at 4°C; [3mL WBB + 
1.5mg eggPC] 
 
Ni-NTA elution buffer (NEB) 
 
 1mL total (⎧L) Final (mM) 
1M HEPES, pH 7.5 50 50 
5M NaCl 30 150 
1M MgCl2 5 5 
10% n-octyl-β-D-glucopyranoside 75 0.75% 
0.1M DTT 10 1 
1M Imidazole pH 8 200 200 
dH2O 630  
 
Incubate protein-Ni-NTA w/ two 400µL NEB for 10min at 4°C w/ periodical 
resuspension; Combine;  
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Reconstitution of purified protein (Dialysis method) 
 
Reconstitution Buffer (RnB) 
 
 0.5mL total (µL) Final (mM) 
1M HEPES, pH 7.5 25 50 
5M NaCl 15 150 
1M MgCl2 2.5 5 
10% n-octyl-β-D-glucopyranoside 50 1% 
0.1M DTT 5 1 
40% sucrose 125 10% 
dH2O 277.5  
 
Mix the purified protein 1:1 with reconstitution buffer + 5mg/mL egg PC; Rotate for 1h 
at 4°C; 
 
Dialysis Buffer (DB) 
 
 1L total (mL) Final (mM) 
1M HEPES, pH 7.5 50 10 
5M NaCl 30 150 
1M MgCl2 5 5 
0.1M DTT 10 1 
dH2O 905  
 
Dialyze the sample against 1L DB for ~20h with 2 changes to remove the detergent; 
Check seal. 
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Single-step purification of TAPN-Drs2p with C12E9 
* Modified from Coleman, et al, 2009 
 
Lysis buffer (LB) 
 10mL total (µL) Final (mM) 
1M HEPES, pH 7.5 500 50 
5M NaCl 300 150 
1M MgCl2 50 5 
1M Imidazole pH 8 400 40 
1M DTT 10 1 
0.1M PMSF 100X (EtOH) 100 1X 
100X pPIC (EtOH) 100 1X 
dH2O 8. 45mL  
 
1K OD/1mL LB (20mL minimum); EF-C3, 25K psi, 6 pass (lysis efficiency > 95%); 
Spin samples at 15K x g (11,400rpm in SS-34) for 12min at 4°C; Keep supernatant (S15); 
Spin S15 at 23K x g (14,000rpm in SS-34) again for 12min, 4°C; Keep supernatant (S15-2); 
Transfer S23 to ultracentrifuge tube and spin at 130K x g (40,500rpm in T-1270) for 
60min; 
 
Solubilizing buffer (SB) 
 5mL total (µL) Final (mM) 
1M HEPES, pH 7.5 250 50 
5M NaCl 150 150 
1M MgCl2 25 5 
1M DTT 5 1 
dH2O 4.57mL  
 
Resuspend pellet with 1mL SB + 10µL new pPIC & PMSF and dounce homogenize 
(P130); 
Mix 0.5mg DOPC (20µL) in 4mL SB + 1/9th total vol of 10%C12E9 (final: 1%) + 100µL 
pPIC & PMSF;  
Add to the resuspended pellet (P130); 
 
Wash buffer a (WBa) 
 5mL total (µL) Final (mM) 
1M HEPES, pH 7.5 250 50 
5M NaCl 150 150 
1M MgCl2 25 5 
1M DTT 5 1 
10% C12E9 50 0.1% 
dH2O 4.52mL  
 
Pre-wash Ni-NTA-beads w/ 5mL WBa at 4°C and transfer beads into P130; Rock for 2hr 
at 4°C; 
Transfer sample to column and flow thru at 4°C; 
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Wash buffer b (WBb) 
 10mL total (µL) Final (mM) 
1M HEPES, pH 7.5 500 50 
5M NaCl 300 150 
1M MgCl2 50 5 
1M Imidazole pH 8 400 40 
10% C12E9 100 0.1% 
1M DTT 10 1 
dH2O 8.64mL  
 
Wash Ni-NTA-beads 6 times w/ 500µL WBb + 0.5mg/mL egg PC at 4°C; [3mL WBB + 
1.5mg eggPC] 
 
Ni-NTA elution buffer (NEB) 
 1mL total (µL) Final (mM) 
1M HEPES, pH 7.5 50 50 
5M NaCl 30 150 
1M MgCl2 5 5 
10% C12E9 10 0.1% 
1M DTT 1 1 
1M Imidazole pH 8 200 200 
dH2O 704  
 
Incubate protein-Ni-NTA w/ two 400µL NEB for 10min at 4°C w/ periodical 
resuspension; Combine;  
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Reconstitution of purified protein (Biobeads method) 
 
Reconstitution Buffer (RnB) 
 1mL total (µL) Final (mM) 
1M HEPES, pH 7.5 50 50 
5M NaCl 30 150 
1M MgCl2 5 5 
10% C12E9 150 1.5% 
1M DTT 1 1 
dH2O 764  
 
Mix the purified protein 1:1 with reconstitution buffer + lipids (5mg/mL egg PC);  
Rotate for 30min at 4°C; 
 
Dialysis Buffer (DB) 
 1L total (mL) Final (mM) 
1M HEPES, pH 7.5 50 10 
5M NaCl 30 150 
1M MgCl2 5 5 
0.1M DTT 10 1 
dH2O 905  
 
Dialyze the sample against 1L DB for ~20h with 2 changes to remove the detergent;  
Add 200mg of activated Biobeads per 1L DB; Check seal. 
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Single-step purification of TAPN-Drs2p with C12E8 
* Modified from Zhou, X. et al (2009). 
 
Lysis buffer (LB) 
 
 10mL total (µL) Final (mM) 
1M HEPES, pH 7.5 400 40 
5M NaCl 300 150 
0.5M EDTA 10 0.5 
1M Imidazole, pH 8 400 40 
0.1M PMSF 100X (EtOH) 100 1 (1X) 
100X pPIC (EtOH) 100 1X 
dH2O 8.69mL  
 
1K OD/1mL LB (20mL minimum); EF-C3, 25K psi, 7 pass (lysis efficiency > 95%); 
15K X g for 15 min at 4°C; Keep supernatant (S15); 
 
Wash buffer (WB) 
 
 10mL total (µL) Final (mM) 
1M HEPES, pH 7.5 400 40 
5M NaCl 300 150 
1M Imidazole, pH 8 400 40 
10% C12E8 100 0.1% 
dH2O 8.8mL  
 
Pre-wash Ni-NTA-beads w/ 10mL WB at 4°C and transfer into S15; 
Add in 1/9 vol of total S15 of 10% C12E8 (containing 130µL new pPIC & PMSF); 
Rock for 1hr at 4°C; Pour S15 into large chromatography column; allow the beads to 
settle to the bottom for 15min; flow thru the sample at 4°C; 
Wash Ni-NTA-beads w/ 100mL WB at 4°C -- Split up into 10 washes (10mL each) 
 
Ni-NTA elution buffer (NEB): 
 
 1mL total (µL) Final (mM) 
1M HEPES, pH 7.5 40 40 
5M NaCl 30 150 
10% C12E8 10 0.1% 
1M Imidazole, pH 8 200 200 
dH2O 720  
 
Incubate protein-Ni-NTA w/ three 0.5mL NEB for 10min at 4°C w/ periodical 
resuspension; 
Elute and combine the first two elutions to 1mL eluate;  Save the third eluate separately.  
Store at 4°C or flash freeze and store at -20°C for longer storage. 
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Single-step purification of Drs2p-TAPC with C12E8 
* Modified from Zhou, X. et al (2009). 
 
Lysis buffer (LB) 
 10mL total (µL) Final (mM) 
1M HEPES, pH 7.5 400 40 
5M NaCl 300 150 
0.5M EDTA 10 0.5 
1M Imidazole, pH 8 10 1 
0.1M PMSF 100X (EtOH) 100 1 (1X) 
100X pPIC (EtOH) 100 1X 
dH2O 9.08mL  
 
1K OD/1mL LB (20mL minimum); EF-C3, 25K psi, 6 pass (lysis efficiency > 95%); 
15K X g for 12 min at 4°C; Keep supernatant (S15); 
 
Wash buffer (WB) 
 10mL total (µL) Final (mM) 
1M HEPES, pH 7.5 400 40 
5M NaCl 300 150 
1M Imidazole, pH 8 10 1 
10% C12E8 100 0.1% 
100mM CaCl2 200 2 
dH2O 8.99mL  
 
Pre-wash Ni-NTA-beads w/ 10mL WB at 4°C and transfer into S15; 
Add in 1/9 vol of total S15 of 10% C12E8 (containing 100µL new pPIC & PMSF); 
Rock for 2hr at 4°C; 
Spin down Ni-NTA-beads at 4°C and aspirate off most of supernatant; 
Transfer the rest to column and flow thru at 4°C; 
Wash Ni-NTA-beads w/ 100mL WB at 4°C; 
 
Calmodulin elution buffer (CEB): 
 1mL total (µL) Final (mM) 
1M HEPES, pH 7.5 40 40 
5M NaCl 30 150 
10% C12E8 10 0.1% 
30mM EGTA 200 6 
dH2O 720  
 
Incubate protein-Ni-NTA w/ three 0.5mL NEB for 10min at 4°C w/ periodical 
resuspension; 
Elute and combine the first two elutions to 1mL eluate;  Save the third eluate separately.  
Store at 4°C or flash freeze and store at -20°C for longer storage. 
 
 
 
 160 
Reconstitution of purified TAPN-Drs2p and Drs2p-TAPC (with C12E8) 
* Adapted from Zhou and Graham (2009) 
 
1. Prepare lipid mixture as follows in chloroform: 
2umol egg PC + 20nmol NBD-PS 
Evaporate organic solvent under N2 stream; 
 
2. Put lipid sample in a vacuum desiccator for 1hr 30min at RT; 
3. Add in 375µL dH2O, 50µL 10X RB and 75µL 10% C12E8; 
4. Gently vortex for 10min at RT and dissolve lipids completely; 
5. Add in 500µL protein solution and incubate for 10min at 4°C; 
6. Pre-wash BioBeads SM2 w/ 3x 10mL methanol (5min for the first), 3x 10mL 
water and 20mL 1x RB and keep it moist at 4°C; 
7. Add 150mg wet pre-washed SM2 in proteoliposome sample and incubate for 6 
hr at 4°C w/ end-to-end rotating; 
8. Add another 320mg wet pre-washed SM2 in proteoliposome sample and 
incubate overnight at 4°C w/ end-over-end rotating; 
9. Pipette off carefully and keep turbid supernatant;  Store at 4°C. 
 
10X RB: 400mM Tris 7.5 + 1.5M NaCl 
 
1X RB: 40mM Tris 7.5 + 150mM NaCl 
 
 
 
Liposomes were created as follows: 
 
- Instead of adding 500µL protein solution (as indicated in step 5 above), add a 
500µL buffer solution similar to the solution with which your protein will be 
eluted. 
 
- All of the other steps are done exactly as written above. 
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Flotation and Removal of Fractions 
 
On the bottom of the centrifuge tube, place 1:1 sample: 80% glycerol (mixed).  
This should be 400µL in volume. 
 
Above that create a layer of 600µL volume of 10% glycerol. 
 
Spin this sample at 50,000rpm in a TLS55 (spinning bucket) rotor for 6 hours 
at 4°C. 
 
Remove 5 fractions in 200µL aliquots from the top.  The top fraction is F5 
and the bottom is F1.  
 
Flotations can also be done for half the volume, but spin times must be reduced. 
 
 
 
Flippase Assay 
 
1. For each reading, 40µL proteoliposome is used; 
2. Add in 10µL 1X RB;  
3. Add in 1µL 0.5M Na-ATP and 1µL 1M MgCl2 per sample and incubate at 37°C for 
your designated experimental time  
Final 5mM Na-ATP and 10mM MgCl2; Controls skip MgCl2 and add ATPγS 
4. At time points, take aliquots out and mix w/ 1mL 1X RB; 
I commonly use two time points for my assays – 0min and 40min. I use 20µL 
aliquots. 
5. Total fluorescence (FT) is recorded at ⎣ex=460nm and ⎣em=534nm by time trace for 
stable line (30s); 
6. Add in 10µL 1M dithionite (prepared fresh in 1M Tris, pH 9.4) and mix gently; 
7. Fluorescence after dithionite quenching (FD) is recorded for new stable line (120s); 
8. Add in 50µL of 20% TX100 to completely permeabilize liposome; 
9. Background fluorescence (F0) is read for another 30s. 
 
1X RB: 40mM Tris 7.5 + 150mM NaCl 
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PROTOCOLS FOR ELECTROFORMATION OF GIANT UNILAMELLAR VESICLES 
 
 
Several basic protocols for GUV formation were initially developed by Xiaoming Zhou, 
based on the classic GUV methods paper from the Bassereau lab (Girard et al, 2004), and 
are presented in the beginning of the protocols section.  Charles A. Day, our collaborator 
and a Vanderbilt graduate student in the lab of Anne Kenworthy (Dept. of Molecular 
Physiology and Biophysics) visited the lab of Sarah Veatch (Univ. of Michigan) and 
learned her protocol for the formation of protein-free GUV’s (Veatch, 2007).  
Additionally, our collaboration with the lab of Thomas Günther-Pomorski (Univ. of 
Copenhagen), provided access to their protocols.  The Pomorski lab is working on the 
purification, reconstitution and GUV incorporation of the proton pump.  Therefore, I’ve 
included their protocols for reconstitution and assays. Finally, I’ve included the protocol 
that I developed based on the techniques that I learned, as well as my experiences with 
GUV formation.  
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Formation of GUVs – Protocol #1  
* from Xiaoming Zhou, Graham lab 
 
1. Carefully deposit 2µL of lipids (2mg/ml DOPC), or 4µg of lipids on the conductive 
side of one ITO slide; 
2. Air dry then dry in vacuum for 1hr at RT; 
3. Assemble electroformation chamber (O-ring spacer) and fill w/ 120µL of 
electroformation buffer (EB); 
4. Apply AC field at 1V/10Hz for 2hr at RT; 
5. Apply AC field at 2V/5Hz for 1hr at RT (to detach GUVs from glass); 
6. Collect GUVs w/ a pipetter using large tip opening; 
7. Dilute 10x w/ GUV dilution buffer (GDB); 
8. Store at 4°C. 
 
EB (electroformation buffer):  1mM Tris, pH 7.5 + 100mM sucrose + 1% glycerol 
 
GDB (GUV dilution buffer):  1mM Tris, pH 7.5 + 100mM glucose + 1% glycerol 
 
 
Formation of GUVs – Protocol #2  
* from Xiaoming Zhou, Graham lab 
 
1. Carefully deposit 10µL of proteoliposomes (1mM, 99% DOPC+1% NBD-PS+0.1% 
Rho-PE, 1X RB) on the conductive side of one ITO slide;  
2. Dry in a desiccator for 45min at RT; 
3. Assemble electroformation chamber (O-ring spacer) and fill in w/ 100µL of 
electroformation buffer (EB); 
4. Apply AC field at 1V/12Hz for 4-6hr at RT; 
5. Apply AC field at 2V/4Hz for 30min at RT (to detach GUVs from glass); 
6. Collect GUVs w/ a pipet using large tip opening; 
7. (Optional) Dilute w/ GUV dilution buffer (GDB); 
8. Store at 4°C. 
 
1X RB:  40mM Tris, pH 7.5 + 150mM NaCl 
 
EB (electroformation buffer):  2mM Tris, pH 7.5 + 200mM sucrose + 2% glycerol 
 
GDB (GUV dilution buffer):  2mM Tris, pH 7.5 + 200mM glucose + 2% glycerol 
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Formation of GUVs – Protocol #3  
* from Xiaoming Zhou, Graham lab 
 
1. Carefully deposit 2µL of lipids (DOPC+Rho-DHPE), or 4µg of lipids on the 
conductive side of one ITO slide; 
2. Air dry then dry in vacuum for 1hr at RT; 
3. Assemble electroformation chamber (O-ring spacer) and fill w/ 120µL of 
electroformation buffer (EB); 
4. Apply AC field at 1V/10Hz for 2hr at RT; 
5. Apply AC field at 2V/5Hz for 1hr at RT (to detach GUVs from glass); 
6. Collect GUVs w/ a pipetter using large tip opening; 
7. Dilute 10x w/ GUV dilution buffer (GDB); 
8. Store at 4°C. 
 
EB (electroformation buffer):  2mM Tris, pH 7.5 + 200mM sucrose + 2% glycerol 
 
GDB (GUV dilution buffer):  2mM Tris, pH 7.5 + 200mM glucose + 2% glycerol 
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Electroswelling Procedure for Giant Unilamellar Vesicles  
* from the lab of Sarah Veatch (Univ. of Michigan) 
 
Things to do in preparation for procedure:  
 
1. Take out lipid stocks – let them warm up to room temperature (~45 min – 1 hr). Keep 
them covered in the dark box.  
 
While lipids are equilibrating to room temperature perform steps 2-6  
2. Wash caps with the holes at the top thoroughly with EtOH  
3. Clean microscope slides (indium tin oxide (ITO)-coated microscope slides) with 
ethanol. Wet one kimwipe and wipe slide gently. Get a new kimwipe and wipe the 
cleaned slide dry. Use this kimwipe to clean the next slide. Repeat for all slides.  
4. Use voltmeter and switch to the music note setting. Touch the red and black leads to 
the microscope slide. If the voltmeter, beeps the metal-coated side is up. Mark this 
side with your sample number (e.g. 1A, 1B, 2A, 2B, etc.) to test which side of slide is 
coated.  If the voltmeter is silent, turn the slide over. Test this side to be sure. Mark 
the slide.  
5. Set up vacuum 
6. Turn on temperature block and set to 55 °C. Use the surface thermometer to check 
the temperature. 
 
Mixing lipids: 
 
7. Clean the appropriate Hamilton syringes with chloroform 
8. Clean the screw cap with hole using acetone and chemwipe 
9. Add 140 ml of choloform per sample to a single glass test tube (i.e. 140 ml for 1 
sample, 280 ml for 2, 420 ml for 3 samples, etc.) 
10. To that test tube add the appropriate amount of lipid and probe.  Typically 350 mg of 
total lipid per sample is used.  The probe is not included in the total mass of the lipid.  
11. Place the microscope slides on the heat block at 55°C. Use 250 µl syringe and 
withdraw 80 µl of lipid mixture.  
12. Deposit the lipid mixture in syringe to a microscope slide, near the top 1/3 of the 
slide. 
13. Take the glass pipet and gently spread the liquid onto the slide, keeping to the top 
1/3 of slide. For even coverage hold the pipet just off the slide surface and then pull 
the slide forward and backward.  Try not to rub the pipet against the slide as it may 
damage the slide.  Watch the lipid between the pipet and the slide to make sure that 
the lipid is deposited uniformly from right to left.  Also stop spreading shortly 
before all chloroform has evaporated.  This will prevent streaking.    
14. Repeat on all slides. 
15. When finished place both slides in dessicator.  
 
Vacuum pump:  
Connect the dessicator containing the slides to the vacuum pump. Cover dessicator with 
black cloth. Leave on pump for ~1 hr. While dessicator is on pump, should be able to 
achieve pressure of ~100 torr.  
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Procedures to do when desiccator is on vacuum pump:  
 
16. Take out 100mM sucrose solution from fridge and fill a clean test tube 3/4 full.  
17. Clean rubber o-rings: Clean large viton o-rings with EtOH. Rinse with H2O. (The # of 
large o-rings you need = the number of samples you are making.) Place these in a 
kimwipe and put them on the heating block. Put another heating block over it to 
ensure o-rings are flat.  
 
Count out the number of small buna o-rings that you need. (the number of small o-
rings = 4x the number of samples). Rinse with EtOH. These don’t have to be 
thoroughly cleaned. They only act as spacers.  
 
Sandwiching:  
 
18. Place the large o-ring on slide 1A above the lipid.  Using a spare slide press the o-
ring into the lipid.  This should cause it to adhere to slide 1A and seal it.  If the o-ring 
is not round it can be heated on the heating stage with a heavy object on top to 
flatten it. 
  
19. Take 700 µL of sucrose solution. Have your 
pipet at the ready with one hand and have slide 1B in 
your other hand, with lipid film facing down. Deposit 
the 700 µL sucrose into the large o-ring on 1A and 
quickly place slide 1B on top. Pick up the sandwiched 
slides by sliding the two slides off of the edge of the 
table (move them by sliding the kimwipe). Be sure to 
have a firm grip of both slides (thumb and index finger) 
20. Place alligator clips on the either side of the slides 
21. Take a kimwipe and wipe off excess sucrose by inserting kimwipe tip in between the 
slides.  
22. Slide the sandwiched slides into the metal GUV block. Once it is in, use a binder clip 
to hold together the slides and release your grip.  
 
You have now finished one sample. Repeat for all samples.  
 
Electroswelling: 
 
23. Turn on the pulse/function generator. Make sure oscilloscope is set correctly. 
10 ± 1 Hz, + 1V ;  Sinusoidal function 
24. Connect the slide to the bus bars using alligator clips.  Up to 4 slides can be on each 
bus bar before there is any effect on GUV production.   
25. Connect the leads onto the bus bars.  
26. Check to make sure none of the leads are contacting slides opposite to them.  
27. Apply current for 40 minutes to 2 hours. Remove the samples from the leads and 
then turn off the wave generators. 
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Harvesting and washing GUV’s: 
 
28. Preheat the 100 mM Glucose media to 55°C. 
29. Deposit 2-4 ml of Glucose media in a glass cuvette 
30. Remove the alligator clips 
31. Press the slides between your thumb and pointer finger.  Move your thumb in a 
circular pattern until the seal begins to break. 
32. Place the slide on the table top with slide having the unbroken seal on the bottom.  
Gently slide the top slide off. 
33. Using a 1 ml pipeter (clip the tip), suction up the GUV’s. 
34. Drop the GUV’s in the Glucose in small droplet just above the surface of the glucose 
media 
35. Without making bubbles, gently pipet solution at the bottom and deposit it at the top 
of the liquid.  Repeat 4 more times. 
36. Give 10-20 minutes for the larger vesicles to settle to the bottom of the solution. 
 
Making the Grease chamber: 
 
37. Stick the end of a glass pipet into the vacuum grease.   
38. Being careful not to touch the center of the cover slip, deposit grease around the 
edges of the coverslip using the glass pipet.  
39. Deposit 4 ml of GUV’s suspension on to the center of the glass coverslide using a 
pipet with the tip clipped.  Try to avoid making contact between the grease and the 
GUV’s.  The best GUV’s will be at the very bottom of the test tube.  Therefore for 
checking the GUV’s before the final experiment, take from near the bottom but leave 
the solution at the very bottom of the actual experiment. 
40. Place a second coverslip on top of the first and gently press the two together.  Here 
you are trying to seal the chamber without crushing the GUVs. 	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Reconstitution into small vesicles 
* provided by the lab of Thomas Pomorski, Univ of Copenhagen 
 
 
Reconstitution buffer:  
10 mM Mes/KOH, pH 6.5 + 50 mM K2SO4  + 20% glycerol  
 
• K2SO4 is not stable in 1 M solution, so I add the salt as a powder to the other 
components. 
• Reconstitution buffer is stable for ca. 3 months, but has to be kept in the fridge so one 
can make ca. 500 mL-1 L depending on projected use. 
• Purified proton pump in GMEKD (as at the end of general purification protocol) 
• 30 mg/mL Asolectin in reconstitution buffer or other lipid of choice 
• Detergent: 1 M Octylglucoside (Sigma) (OG) or 10% Deoxycholate (DOC) 
 
 
 
Reconstitution: 
 
Protein/lipid/buffer/detergent mix: 
• 78 µL 30 mg/ml lipids,  
• 11.5 µL of 1M OG/15 µL 10% DOC  
• 12 µg (~115 pmol AHA2) of purified protein or 106 µg of membrane proteins. 
• final volume of 220 µl in reconstitution buffer 
 
 
• Prepare 2 g Sephadex g-50 fine in 50mL Reconst. Buffer (enough for 6-8 
reconstitutions, can be kept in fridge for ca. 1 month) the day before, let swell in 
fridge 
• Insert 2 ml syringes into 15 ml falcon tubes, and put glass wool at the bottom 
• Fill the syringes with gel to the top with a Pasteur pipette; repeat adding gel until the 
syringe is full 
• Centrifuge 5 min at 180g /1200 rpm at RT 
• Transfer the syringes to new 15 ml falcon tubes 
• Make the protein/lipid/buffer mixture; add detergent and vortex for 5 seconds 
• Apply the samples (220 µl) to the top of the columns, and let stand for 5 minutes 
• Centrifuge 7.5 minutes at 180 g at RT 
• Recover the proteoliposomes, and transfer each of them to an Eppendorf tube 
containing 100 mg Biobeads (from BioRad); Shake gently for 30 min at RT 
• Insert Eppendorf tube into spin column, inserted into a second Eppendorf tube. 
Pierce hole in the Eppendorf tube containing the vesicles (this step can also be 
performed without spin column, by simply inserting the Eppendorf tube with the 
sample in another Eppendorf tube and piercing hole). 
• Centrifuge ensemble a few seconds at 1000 rpm, and collect the vesicles in the 
bottom Eppendorf tube. Measure the volume obtained (typically 150 µl). 
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Analysis of Reconstitution – ACMA assay 
* provided by the lab of Thomas Pomorski, Univ of Copenhagen 
 
 
Activity assay (based on quenching of ACMA dye): 
ACMA buffer (20 ml) 
20 mM MOPS-KOH, pH 7.0 (400 µL 1M) 
40 mM K2SO4 (139 mg) 
25 mM KNO3 (0.5 ml 1 M) 
2  mM ATP (80 µL ATP 0.5 M, pH 7.0) 
1  µM ACMA  (2 µl 10 mM in DMSO) 
60 nM Valinomycin (1 µl 1.25 mM in ethanol) 
 
Can be stored without ATP, ACMA, and Valinomycin, up to 6 months 
 
Always run an emission and excitation scan to ensure your settings and buffers are OK: 
ACMA:  Excitation   412 nm scan  350-450 nm 
  Emission   480 nm scan  450-500 nm 
The signal should be around 105-106 
Time scan: Ex 412 nm, Em 480 nm, 1 point/s, 600 s duration  
(all these settings are saved on the fluorometer computer in Gerdi/templates) 
 
Running the assay: 
1. Add 10 µl of reconstituted vesicles to 2 mL of ACMA buffer w ATP 
2. Put cuvette in fluorometer (remember to include the stirring bar). 
3. Let equilibrate for 1-2 min 
4. Start time scan 
5. If signal stable/after ca. 100 s Add MgSO4 to start the reaction (6 µl 1 M) 
6. Optional: Dissipate membrane potential by addition of 2 µl of 5 mM CCCP 
when the flourescence has stabilized.  
ACMA: 9-amino-6-chloro-2-metoxyacridine, in DMSO 
CCCP: m-chlorophenylhydrazon, in Ethanol 
 
Evaluation: 
Upon addition of Mg, there should be a visible drop.  Fluorescence does not have to go 
to 0, but close to and stabilize to a more or less straight line (parallel to the time-axis). 
Depending on the activity, the drop will be steeper or flatter. Upon addition of CCCP, 
the fluorescence should go back (or almost) to the initial level. 
 
* An alternative method used by the Pomorski lab to analyze their reconstitutions is 
an ATPase assay based on the Baginsky method.  
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Labeling of the Proton pump 
* provided by the lab of Thomas Pomorski, Univ of Copenhagen 
 
 
Purified proton pump: 
• Stored in GMEKD supplemented with DDM (GMEKD:  20% Glycerol, 50 mM 
Mes/KOH pH 6.5, 50 mM KCl, 1mM EDTA, 1 mM DTT, ca. 2 µL/mL DDM)  
frozen in liq. Nitrogen, stored at -80 °C 
• Concentration ca. 1-5 mg/mL 
 
 
Labelling of the protein: 
 
Material: 
• Purified proton pump in GMEKD (as at the end of general purification protocol) 
 Dye: Alexa Fluor ® 555 Microscale Protein Labeling Kit (A30007) 
Dialysis of the protein: 
 
• in GMEKD with 2 µL/mL DDM 
• 3 times 1 hr in 200 mL buffer 
 
 
Labelling: Exactly as described in the manual of the dye, except for the changes below 
• pH change when 1M bicarbonate is added does not sufficiently alkalize the 
solution, instead of 1:10 we need 3:10 dilution of the 1 mg/mL protein solution 
(step 1.2) 
Example: to 100 µL dialysed sample, added 1.78 µL reactive dye solution, resulting in 
deg of labeling ca. 1.5 as determined by Nanodrop 
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Preparation of Proteo-GUVs  
* provided by the lab of Thomas Pomorski, Univ of Copenhagen 
 
(adapted from Girard P, et al. (2004). A new method for the reconstitution of membrane proteins into 
giant unilamellar vesicles) 
• 0.8 mg/mL lipid (16 µL BR recon or 6 µL AHA2 recon, 0% Glycerol) in 80 µL, 
diluted with water, addition of 0.25 mM Glucose (according to Poolman 0.1 g 
sugar/1g lipid) 
 
• under vacuum for not more than 5 min, w/o any salt solution or special pressure 
 
• swelling buffer: 0.1 M sucrose, 1 mM Mops-Tris, pH 7, 2 mM KCl, 10 µM 
Pyranine if needed (same buffer for both proteins, evt. change pH 6.5 for 
ATPase)	  	  
• Electroformation conditions:  6 min increment,  20 mV to 1.1 V,  12 Hz,  4-6 h 
 
• Then 2 V, 4 Hz, 30 min 
 
• Observe in microscopy buffer (0.1 M glucose, 5 mM Mops-Tris, pH 7, 5 mM KCl), 
dilution ca. 1:1 
Even better results are obtained when the ready proteoliposomes are harvested by 
ultracentrifugation (40 min, 160 000 g) and resuspended in low ionic strength buffer (5 
mM Mes/KOH, pH 6.5). 
 
Immobilization of GUVs using Streptavidin 
* provided by the lab of Thomas Pomorski, Univ of Copenhagen 
 
Clean glass slides (stored in methanol dried under nitrogen) 
 
Incubate with 50 µl of a 9:1 mix of BSA and BSA-Biotin (each 1g/L), in microscopy 
buffer, 20min 
 
Wash 10 times by addition and removal of 200 µl buﬀer 
 
Add 50 µl 1 g/l streptavidin, incubate 20 min 
 
Wash 10 times 
 
Add around 50 µl of GUVs and 50 µL microscopy buffer 
 
5 minutes incubation to bind to the surface 
 
Optional: wash with microscopy buffer 
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Electroswelling Procedure for Giant Unilamellar Vesicles 
* adapted from the Veatch lab protocol (Univ. of Michigan), by Tessy Sebastian 
 
Delta Technologies: ITO Slides #CG-90IN-S115 
Marco Rubber: O-rings #V1000-016, #B1000-004 
 
Spot your liposome or proteoliposome solution onto the ITO slides in 0.5 – 2μL aliquots.  
Place the ITO slides in a vacuum chamber and dry the drops till they are just dry.  
Clean rubber o-rings  
 
Sandwiching:  
 
1. Place the large o-ring on slide 1A above the lipid.  Using a spare slide press the o-
ring into the lipid.  This should cause it to adhere to slide 1A and seal it.  If the o-ring 
is not round it can be heated on the heating stage with a heavy object on top to 
flatten it. 
 
 
2. Take 700 µL of 100mM sucrose solution. Have 
your pipet at the ready with one hand and have slide 
1B in your other hand, with lipid film facing down. 
Deposit the 700 µL sucrose into the large o-ring on 1A 
and quickly place slide 1B on top. Pick up the 
sandwiched slides by sliding the two slides off of the 
edge of the table (move them by sliding the kimwipe). Be sure to have a firm grip 
of both slides (thumb and index finger) 
 
3. Place alligator clips on the either side of the slides 
4. Take a kimwipe and wipe off excess sucrose by inserting kimwipe tip in between the 
slides.  
5. Use a binder clip to hold together the slides and release your grip.  
 
Electroswelling: 
 
6. Turn on the pulse/function generator. 
10 ± 1 Hz, + 1V ;  Sinusoidal function 
7. Connect the alligator clips and leads to the function generator. 
8. Check to make sure none of the leads are contacting slides opposite to them.  
9. Apply current for 40 minutes to 2 hours. Remove the samples from the leads and 
then turn off the generator. 
 
Harvesting and Washing GUV’s: 
 
10. Remove the alligator clips 
11. Press the slides between your thumb and pointer finger.  Move your thumb in a 
circular pattern until the seal begins to break. 
12. Place the slide on the table top with slide having the unbroken seal on the bottom.  
Gently slide the top slide off. 
13. Using a 1 ml pipeter (clip the tip), suction up the GUV’s. 
14. Store in a microfuge tube at 4°C.  
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